Long Working Hours Kill More Workers Than Injuries 18/09/2021 Kerry Cullinan The biggest killers of working people are strokes and heart disease associated with long working hours – over 55 hours a week. This is according to a joint report from the World Health Organization (WHO) and International Labour Organization (ILO), the first global comparative risk assessment of the work-related burden of disease, which was released on Friday. Diseases associated with long working hours accounted for almost 40% of global deaths in 2016, some 750,000 deaths. People from South East Asia and Western Pacific, men and those over 54 were most at risk. Workplace injuries were the next biggest cause of worker deaths, accounting for 19.4% of deaths (360,000 deaths) – around half the deaths caused by long working hours. Workers most in danger of injuries were those in the construction, transport, manufacturing and agricultural sectors. Workplace exposure to air pollution (particulate matter, gases and fumes) was responsible for 450,000 deaths. Meanwhile, asbestos exposure caused 11.1% deaths, causing a variety of cancers. According to the report, 81% of deaths in 2016 were caused by non-communicable diseases (NCDs), the most common being chronic obstructive pulmonary disease (450,000 deaths); stroke (400,000 deaths) and ischaemic heart disease (350,000 deaths). “It’s shocking to see so many people literally being killed by their jobs,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Our report is a wake-up call to countries and businesses to improve and protect the health and safety of workers by honouring their commitments to provide universal coverage of occupational health and safety services.” Healthy limits This report will enable policymakers to track work-related health loss at country, regional and global levels, according to the two bodies. “These estimates provide important information on the work-related burden of disease, and this information can help to shape policies and practices to create healthier and safer workplaces,” said Guy Ryder, ILO Director-General. Each risk factor has a unique set of preventive actions, which are outlined in the monitoring report to guide governments, in consultation with employers and workers. Preventing long working hours requires agreement on healthy maximum limits on working time, for example. To reduce workplace exposure to air pollution, dust control, ventilation, and personal protective equipment is recommended. “These almost 2 million premature deaths are preventable. Action needs to be taken based on the research available to target the evolving nature of work-related health threats,” said Dr. Maria Neira, Director of the Department of Environment, Climate Change and Health at WHO. The report notes that total work-related burden of disease is likely substantially larger, as health loss from several other occupational risk factors must still be quantified in the future. Moreover, the effects of the COVID-19 pandemic will add another dimension to this burden to be captured in future estimates. COVID-19 Hit HIV, TB and Malaria Programs Hard, But We’re Fighting Back 17/09/2021 Peter Sands A doctor shows Oleg Chutvatov, who receives treatment for tuberculosis at the TB hospital in Kharkiv, an X-ray of his lungs. The Results Report published by the Global Fund to Fight AIDS, Tuberculosis and Malaria last week illustrates how COVID-19 has pushed us off track in significant ways – particularly with respect to access to tuberculosis (TB) and HIV diagnoses and treatment. But at the same time, there is better news with respect to the battle against malaria. And all in all, the picture would be far worse, without the rapid and determined actions that took place across the Global Fund partnership. Devastating impact on TB access and treatment For TB, the new pandemic has been devastating. In 2020, the number of people treated for drug-resistant TB in the countries where the Global Fund invests dropped by 19%, with those on treatment for extensively drug-resistant TB falling by 37%. This means around one million fewer people with TB were treated in 2020 compared with 2019. For HIV, the impact has also been significant. While it is encouraging that the number of HIV-positive people receiving antiretroviral treatment has continued to grow, the declines in prevention services and testing in 2020 were alarming. People reached with HIV prevention programs and services declined by 11%, while HIV tests taken declined by 22% compared with 2019. Because of the disruptions resulting from COVID-19, the people at greatest risk of infection have had less access to the information and tools they need to protect themselves. Malaria services fared better Thus far, interventions to combat malaria appear to have been less disrupted by COVID-19 than the other two diseases. Other than suspected cases of malaria tested – which fell by 4% compared with 2019 – rapid adaptation of malaria services seems to have limited the reverses. However, progress stalled: we did not see the year-on-year growth in provision of malaria services that we need to beat the disease. These numbers are stark confirmation of what we feared might happen when COVID-19 struck. In many countries, COVID-19 has overwhelmed health systems, lockdowns have disrupted service provision, and critical resources have been diverted from the fight against HIV, TB and malaria to fight the new virus. The pandemic has disproportionately impacted the people most affected by existing diseases: the poor, the marginalized, those without access to health care. People avoided going to health centers for treatment out of fear of catching COVID-19 – or of being stigmatized for having COVID-like symptoms such as cough or fever, which could also be treatable malaria or TB. Rapid action prevents worse outcomes Yet it would have been even worse without the rapid and determined actions that took place across the Global Fund partnership to mitigate the impact of COVID-19 on the three diseases. Decades of experience in fighting HIV, TB and malaria with Global Fund support enabled many low- and middle-income countries to respond quickly to COVID-19, using the laboratories, disease surveillance systems, community networks, trained health workers and supply chains put in place to fight HIV, TB and malaria. By the end of 2020, we had invested about US$1 billion to support more than 100 countries fight COVID-19 and mitigate its impact on HIV, TB and malaria. To save lives from both the direct and knock-on impacts of COVID -19, we worked intensively with partners across the world, in countries and through the Access to COVID-19 Tools (ACT) Accelerator. These efforts prevented an even more catastrophic impact on HIV, TB and malaria. Yet the setbacks we have seen mean that infections and deaths will inevitably rise, reversing the positive trajectory we have achieved for many years. Even more worrying is what’s been happening in 2021, with the highly transmissible Delta variant causing havoc in many countries, once again overwhelming health systems and disrupting other disease programs. Because of this we have ramped up our investments in the fight against COVID-19. As of August 2021, we had approved a further US$3.3 billion to support 107 countries and 16 multi-country programs to respond to the pandemic with critical tests, treatments and medical supplies, protect front-line health workers, adapt lifesaving HIV, TB and malaria programs, and reinforce fragile systems for health. COVID-19 as a catalyst But to beat COVID-19 and protect our hard-won gains against HIV, TB and malaria, we must do more. The direct and knock-on death tolls from the COVID-19 pandemic are already staggering, and the longer it continues the deeper will be the scars – in health, the economy and society. T wenty years ago, the Global Fund was created to step up the fight against the three infectious diseases that were then killing most people. Working as partnership, we proved they could be beaten back – and an extraordinary 44 million lives have been saved. Now we must step up again: to arrest the new pandemic, get back on track against HIV, TB and malaria, and build resilient systems for health that can protect everyone, everywhere, from future pathogens. Right now, COVID-19 presents a daunting challenge. But if we have the political will, commit more resources, and continue to innovate and collaborate, we can turn the tide on this virus, as we did with HIV, TB and malaria, and ultimately defeat it. We should seize this moment to make everyone safer from the deadliest infectious diseases, whether COVID-19, the earlier pandemics of HIV, TB and malaria, or future pandemic threats. Let us not just beat this pandemic, but use it as a catalyst to build a better, more equitable and healthier world. Peter Sands is the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. Image Credits: The Global Fund / Evgeny Maloletka, Global Fund to Fight AIDS, Tuberculosis and Malaria. Mothers and Babies’ Lives are Threatened by Fake and Sub-Standard Medicine 17/09/2021 Kawaldip Sehmi Health gains of Afghanistani women and children are in danger. Iconic places across the world will be lit up in orange on World Patient Safety Day on Friday to highlight the global campaign to reduce preventable deaths in childbirth and pregnancy and deliver safe maternal and newborn care. The International Alliance of Patients’ Organisation (IAPO), which I lead, and the alliance we are a member of,Fight the Fakes Alliance (FTF), will actively participate. Afghan women, many already fearing for their lives with the return of the Taliban, may well be watching too. In the two decades of civilian rule since the Taliban were defeated in 2001, infant and child mortality has dropped by some 70% – the fastest reduction among low-income countries. The rate went down from 191 deaths per 1000 live births in 2007 to 49 in 2018, according to Dr Mohammad Razai, an Afghan doctor working in London, What’s more, Razai says, maternal mortality was more than halved, declining from 1100 deaths per 100,000 live births to 396 as access to healthcare and sanitation rose dramatically. All of this is now at serious risk, as is the progress the world made in the same period to combat preventable deaths in pregnancy and childbirth, far too many of them caused by sub-standard and falsified medicines. The COVID-19 pandemic has negatively affected the often-fragile lives of mothers and their babies, and also brought a surge in the purchase and use of falsified medicines and the promotion of fake treatments. Ensuring mothers and babies get high-quality medicine That is why, on this special day, we are urging the global community to back moves to provide mothers and newborns with the extra care and high-quality medicines they need. Every single day, approximately 800 women and 6 700 babies lose their lives around the time of childbirth, according to the World Health Organization (WHO). In addition, nearly 5,400 babies are stillborn daily, with 40% of these deaths occurring in relation to labour and childbirth. Most stillbirths, maternal and newborn deaths and harm can be avoided by safe, respectful and quality care during pregnancy, childbirth and in the first days of a baby’s life. Sub-Saharan Africa and South Asia, two of the epicentres of fake medicines, account for 86% of these deaths. Safe and quality care provided by skilled health professionals working in supportive environments is key. But there are other, smaller things we can do. One is to ensure that patients are safe and secure and, critically, can trust their local health services. Fake and sub-standard medicines to manage hemorrhages, pre-eclampsia, eclampsia and sepsis proliferate in low- and middle-income countries (LMIC), according to a recent article. Almost half the samples of uterotonic medicines to induce or speed up labour failed quality tests. Three-quarters of ergometrine supplies failed, while almost 40% of oxytocin and misoprostol also failed. These drugs are deemed by the WHO to be “the most effective and safest drug of choice for the control, prevention, and management of postpartum haemorrhage — the leading cause of maternal mortality globally.” Fake products undermine patient trust In Nigeria, one of the richest countries in Africa, the likelihood of a woman receiving poor-quality or even fake oxytocin is very high, Devex reported, citing Dr Chimezie Anyakora, chief of party in Nigeria for the Promoting the Quality of Medicines. It also quotes a prominent local gynaecologist who recountedd how he had to go out on a Sunday and find genuine oxytocin after that which he had administered was manifestly not working. Fight the Fakes has also reported on the experiences of Ghanaian patient Victoria Amponsah who first received fake malaria medicine while two months’ pregnant then, at the end of her pregnancy, she was deceived by a fake version of oxytocin in an official-looking package. “Within 30 minutes, Victoria started sweating, shaking, vomiting and bleeding. She was in the hospital for two days, nearly lost her baby and had to return to the hospital every week after the incident for some time,” according to Fight the Fakes. In line with the WHO in its Global Patient Safety Action Plan 2021-2030, we call on the global and local communities to step up their efforts to stamp out unsafe and fake products. To build back better and ensure we have people-centred, accessible, acceptable, affordable, and quality healthcare and universal health coverage, we first must ensure patient safety. Safe care fosters trust in health systems, health professionals and medical products – but products that do not adhere to the highest standards of quality can undermine this trust Addressing fake and sub-standard medicine will require monumental effort on all our parts. But one key lesson from the pandemic is that we are all in this together. Kawaldip Sehmi is the CEO of the International Alliance of Patients’ Organisation (IAPO), a member of the Fight the Fakes Alliance. Kawaldip Sehmi Image Credits: Ahmadi/ UNICEF. Young African Innovators Lack Investment Not Creativity, Awards Ceremony Told 16/09/2021 Madeleine Hoecklin Panelists at the Africa Young Innovators for Health Award Ceremony, held on Thursday. Africa has the highest entrepreneurship rate in the world, yet greater financial resources are needed to ensure that innovation can be implemented to strengthen health systems and the welfare of health workers, said panellists at an innovation award ceremony on Thursday. The Africa Young Innovators for Health Award, co-organised by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Speak Up Africa, launched its first competition this year designed to highlight and support the work of pioneering young African entrepreneurs in the field of health innovations, particularly healthcare solutions to support healthcare workers. Attracting over 300 entries from 33 countries, the winners had developed innovations to assist in cancer diagnosis, health worker development and patient record retrieval. Winner Dr Conrad Tankou, CEO of Global Innovation and Creativity Space in Cameroon, developed GICMED, a suite of medical technologies that helps to screen and diagnose breast and cervical cancer in women. Dr Conrad Tankou, CEO of Global Innovation and Creativity Space, won first place for the Africa Young Innovators for Health Award. Breast and cervical cancer account for 50% of all new cancers in Sub-saharan African women. Healthcare workers can be trained to use the technology to remotely screen women with real-time pathology confirmation and connect them to a point of care for treatment. “It is an honour to receive the first-ever Africa Young Innovators for Health Award,” said Tankou. “With the Award’s financial and business mentorship support, we can upgrade our technologies and start scaling our solution much quicker by investing in manufacturing capabilities and building more local partnerships.” In second place was John Mwangi, CEO of Daktari Media Africa in Kenya, who established Daktari Online, which provides a professional development platform for healthcare workers. John Mwangi, CEO of Daktari Media Africa, won second place for the Africa Young Innovators for Health Award. Currently 13,000 health workers use the platform and it has been accredited by the regulatory bodies for pharmacists, pharmaceutical technologists, and physician assistants. “The practice of medicine requires continuous updating…and that’s what we seek to do,” said Mwangi. “We said why don’t we just democratize [access to information and professional development] and have this accessible to people even from remote areas.” The third-place winner, Dr Imodoye Abioro, CEO of Healthbotics in Nigeria, developed an artificial intelligence (AI) powered electronic medical record system – Mediverse – that utilizes blockchain to help healthcare workers input and retrieve patient records. Dr Imodoye Abioro, CEO of Healthbotics in Nigeria, won third place for the Africa Young Innovators for Health Award. The technology could work on any device and even in places where the internet has not yet reached. “We do not have enough healthcare workers for the disease burden we’re battling,” said Abioro. “The first thought we had was how do we make the healthcare worker more effective, how can he or she see more patients, how can he or she be smarter or faster.” “Mediverse is what we consider to be a solution that will be necessary for us to build a sustainable healthcare infrastructure in Africa upon,” Abioro added. “This could really revolutionize the way that healthcare workers are able to access the data they need about their patients in real time,” said Nicole Kayode, CEO and Founder of Medixus. The winners take home between US$15,000 and US$40,000 and will benefit from a business mentorship program, media exposure, technical training on intellectual property protection, and expert advice from an extensive network of stakeholders working across healthcare mediums. More investment needed Some 22% of Africa’s working-age population are starting businesses, “yet more investment in human capital is needed for this demographic potential to reap the development rewards it should,” said Thomas Cueni, Director-General of IFPMA. “We are confident that the winners of the African Young Innovators for health award will contribute to improving health systems and growing African economies,” added Cueni. “We don’t lack ideas or creativity, that’s not what’s missing,” said Dr Awa Marie Coll-Seck, Senegal’s Minister of State of Senegal and former health minister. “Among innovators, it’s often about the lack of financial resources for research…This is what stops them from concretising their ideas and developing prototypes.” “We need to give [the young innovators] the opportunity to develop ideas and their expertise,” said Coll-Seck. Africa is the youngest continent on the planet. By 2050, Africa’s youth population under the age of 24 will increase by nearly 50%. This presents an opportunity for rapid social and economic transformation, said the panelists. In 2019, sub-Saharan African countries were classified among the hundred best countries in terms of innovation. Africa facing massive shortages in healthcare workforce Africa bears a quarter of the global disease burden but faces a shortage of over two million healthcare professionals. Only 2% of the world’s healthcare workforce are from the continent. “Our world lacks about 18 million health workers globally and…Africa is the place that really suffers the most from it,” said Pape Gaye, President Emeritus of IntraHealth International, addressing the awards ceremony. The shortage of human and financial resources invested in the African healthcare system is putting a strain on healthcare workers and the broader national and regional health infrastructure. “COVID-19 has laid bare the underlying inequities and prejudices in existing healthcare,” said Dr Moredreck Chibi, the World Health Organization’s (WHO) Africa Advisor for Innovation. “Our young people [need to] take the bull by its horn and apply their intellectual capital to address some of these challenges.” Dr Moredreck Chibi, WHO Regional Advisor for Innovation for the Regional Office for Africa. “Only this approach will ensure Africa’s sustainable path for the future of health on the continent,” said Chibi. “As we are all aware, the COVID pandemic has been devastating and exposed the vulnerabilities of health systems across the globe, including in Africa,” said Dr Lindiwe Makubalo, WHO Assistant Regional Director for Africa. “There could be no better time to draw on the rich human capital, especially among young people, to find solutions to the problems that we are facing.” “COVID-19 has been a wake-up call for the continent. It is inevitable that we need to think outside the box to solve these problems,” said Makubalo. Innovation is a central component of public health “Innovation has always been the driving force of progress in public health, from vaccines to penicillin to the mapping of the human genome,” said Cueni. “Innovations have changed the world and this has never been more evident than with the COVID-19 pandemic.” Vaccines and treatments for COVID-19 were developed by pharma companies in record time due to large investments in research and a lot of innovation. “We have seen from smartphones to drones, there’s no doubt that technology and innovation are leapfrogging Africa and future young African entrepreneurs are playing a crucial role by developing creative ideas that can resolve the various health challenges on the continent,” said Cueni. Thomas Cueni, Director General of the IFPMA, at the award ceremony on Thursday. The panelists called on countries to support efforts and innovations of the youth by harnessing domestic resources through advocacy for partner financing and the creation of platforms to showcase initiatives. Partnerships with private sector are essential “We all know that innovation is best when it is tailored to the local context and that we should think about those who need it most when we’re creating them, and how we can create the most impact,” said Yacine Djibo, Founder and Executive Director of Speak Up Africa. Yacine Djibo, Founder and Executive Director of Speak Up Africa. Building science, technology, and innovation capacity, as well as stimulating the existing entrepreneurial culture in Africa should be a priority, said Djibo. Collaboration with the private sector will increase the opportunities for innovation and help the continent build sustainable health systems. “Health system strengthening and the potential of Africa’s private sector are crucially important for unleashing the entrepreneurial power of Africa’s young people,” said Cueni. “This will create innovative and compelling modern businesses, increase the capacity for these businesses to compete regionally and globally, attract both domestic and foreign investment, and diversify investment profiles.” This will contribute to job creation and economic growth across the region. “By leveraging its resources, expertise, networks, infrastructure, and assets, the private sector can focus on innovation for new technologies, systems, and processes, [and] can influence policy and form partnerships that will have continent-wide impact on the populations,” said Cueni. “We are extremely impressed by the quality of the applications we received. These applications are a shining example that young Africans are bursting with creativity and are constantly looking for local-based solutions that work,” said Djibo. With only one-fifth of applications to the innovation award coming from women, the IFPMA and Speak Up Africa have launched the Women Innovators Incubator to address the gaps in female-led innovation. Three female participants will receive financial support, mentorship, media training, expert advice on intellectual property protection, and access to a network of global health experts. Image Credits: Africa Young Innovators for Health Award, Africa Young Innovators for Health Award. Wealthy Countries Urged to Share 2 Billion Excess COVID-19 Doses, as South Africa’s mRNA Hub Prepares to Make ‘Moderna-like’ Vaccine 16/09/2021 Kerry Cullinan The South African mRNA hub aims to make Moderna-like vaccine. Countries with high COVID-19 vaccination rates have pre-purchased over two billion excess vaccine doses, limiting the supplies available for low- and middle-income countries (LMIC). This emerged from a meeting on Thursday between the heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization – the multilateral Task Force – and CEOs of leading vaccine manufacturing companies. Meanwhile, the South African mRNA technology transfer hub set up in July to enable Africa to manufacture its own vaccines is moving ahead with plans to make a “Moderna-like” vaccine – despite a lack of co-operation from either mRNA manufacturer, Moderna or Pfizer-BioNTech. This was confirmed to Health Policy Watch by Dr Marie-Paule Kieny, Chair of the Board of the Medicines Patent Pool in Geneva and President of the French Scientific Committee on COVID-19 vaccines. “The mRNA hub doesn’t need direct transfer of technology from Pfizer/BioNTech or Moderna, as enough information on production process is available publicly and as there are no patent on mRNA vaccines in any African country,” said Kieny, who recently visited South Africa to work with local hub partners. “The hub will therefore work with technical experts to recreate a new ‘Moderna-like’ vaccine,” added Kieny. Appeal to swap doses, deliver to COVAX and AVAT To alleviate COVID vaccine shortages in LMICs, the task force called on wealthy countries to urgently “swap their near-term delivery schedules with COVAX and the African Vaccine Acquisition Task Force (AVAT)”, meet their dose donation pledges with “unearmarked upfront deliveries to COVAX”, and release vaccine companies from options and contracts to enable these doses to be delivered to LMICs. Without these urgent steps, the world is unlikely to meet the WHO’s target of vaccinating 40% of the global population by the end of the year. “Despite adequate total global vaccine production in the aggregate, the doses are not reaching LMICs in sufficient amounts, resulting in a crisis of vaccine inequity,” the task force said. It also appealed for transparency about the supply of vaccines, calling on vaccine manufacturers to share details on month-by-month delivery schedules for all vaccine shipments, especially for COVAX and AVAT. It also called on all countries to urgently address export restrictions, high tariffs and customs bottlenecks on COVID-19 vaccines, raw materials and supplies. The task team welcomed the pharmaceutical CEOs’ willingness to ‘work collectively to end vaccine inequity” and “readiness” to form a joint technical working group with the Task Force to exchange and coordinate information on vaccine production and deliveries. However, the big pharmaceutical companies have been unwilling to work with the mRNA hub. ‘No point’ in mRNA transfer In response to a Health Policy Watch question, Pfizer CEO Albert Bourla said that he didn’t see the point as the tech transfer “would take years”, and that producing mRNA vaccines was what Pfizer did. Kieny confirmed that the Medicines Patent Pool, WHO and others had reached out to the mRNA vaccine manufacturers “but up to this point, the companies have not been interested”. Vaccine manufacturers are apparently wary of new manufacturers competing for raw materials and customers. Shortly after the mRNA hub was announced, Pfizer revealed that it had made a deal with South African pharmaceutical company and hub member Biovac, to “fill and finish” around 100 million vaccines destined for Africa. Kieny described this as “an excellent step forward”, as Biovac will receive technology transfer from Pfizer for the fill-finish part of their mRNA vaccine, “especially as the Pfizer contract does not claim exclusivity”. “Biovac will therefore also become the first African manufacturer with a product resulting from technology transfer of the full production cycle from the hub,” said Kieny. Image Credits: Gavi . Finding Sustainable Solutions to WHO’s Financial Woes 16/09/2021 Pokuaa Oduro-Bonsrah Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health and chair of the WHO Working Group on Sustainable Finance. For a long time, the World Health Organization (WHO) has experienced immense financial stress resulting in numerous debates on how to remedy its economic woes. A working group set up earlier this year has been tasked with finding long-term solutions. Each year the representatives of some 194 countries make demands on what work should be carried out by the WHO, but the money needed to carry out the requests is severely lacking. Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health, and chair of WHO’s Working Group on Sustainable Funding, recalls explaining the situation to his daughter who asks what the money problem is. “The family decides to have breakfast with lots of friends. We need to buy 20 buns from the bakery, and there’s a plan in place because we know our guests want different buns. I send my daughter to the bakery to buy 20 different buns but only give her enough money for two,” he says. Without enough money, Kümmel’s daughter would have to beg for money on the way to the store. Some generous passersby might give her some change, but on the condition that she spends it on specific types of buns. She might be able to bring back home all 20 buns but to a large extent they will not be the ones ordered. “It sounds absurd when we put it this way but the member states of the WHO, in the same way, do not provide the finances to fund their own priorities agreed to by these countries,” Kümmel told Geneva Solutions. Increasingly, individual donors have been providing funding money for these “buns”, but often face criticism for financing projects that personally interest them. Meanwhile, the funds needed to execute the activities of the ever-broadening agenda set by the World Health Assembly (WHA) are lacking. COVID-19 has revealed major discrepancies between the expectations of the WHO and its de facto ability. “The pandemic has shown that we need a strong WHO, now more than ever, and it is clear that it is not strong enough,” Kümmel said. Sustainability lens For years discussions have circled around WHO’s funding, prompting its Director-General, Dr Tedros Adhanom Ghebreyesus, to reflect on how these conversations have “remained rather abstract” in a report delivered to the Executive Board. As a result, the WHO created the Working Group on Sustainable Financing (WGSF), which is tasked with finding long-term solutions to the body’s financial troubles. Kümmel notes that although finances remain a popular topic amongst the organisation’s members, this is the first time a “sustainability” lens is being adopted. He adds that everyone shares the view that a stronger WHO is needed, which requires more stable sources of long-term funding. The alternative, continuing with the status quo, poses a threat to global health security and the achievement of the Sustainable Development Goals. “There needs to be a completely new approach to ensure the WHO has the right finances in place in order to fulfil the world’s expectations,” he says. The WSFG is working on a proposal that will “enable WHO to have the robust structures and capacities needed to fulfil its core functions,” as highlighted in the meeting report. The final report and recommendations will be taken forward to the WHO’s executive board in January 2022. Concluding their third and most recent meeting in June, the group has already explored different financing models, including other global health actors’ funding structures that could help recharge the WHO’s coffers, drawing on lessons from other health actors. Adopting the Global Fund’s so-called replenishment model, for example, would mean raising funds in multi-year cycles. Kümmel says the WHO budget could at least be partially funded this way. Dr Tedros addressing the WHO’s 149th Executive Board meeting Since taking office in 2017, Ghebreyesus has made broadening the WHO’s funding base one of the organisation’s main priorities. In 2019, he announced plans to establish the WHO Foundation to secure funds from the public, individual major donors and corporate partners. The launch of the independent grant-making body came amid controversy over former US President Donald Trump’s decision to halt funding from the US, the WHO’s single largest donor. The move was later reversed by current President Joe Biden but it had already exposed the health organisation’s heavy dependence on a few major donors. Approved for 2020-2021, the budget is $5.8 billion, which reflects a $1.4bn increase from the previous biennium, mostly needed for the Covid-19 response. About 16 per cent of this figure stems from mandatory payments known as assessed contributions, paid by its members, which over the last two decades or so, have remained flat at one billion US dollars. The other way is through voluntary contributions, secured from governments, other UN agencies and the private sector, which make up the majority of the budget. In recent years the top voluntary contributors, in addition to the US, have included the United Kingdom, Germany and the Bill and Melinda Gates Foundation. Yet, private players such as the Gates Foundation have come under fire for having some of the most powerful and influential voices in global health, raising questions about the WHO’s independence. Praise for ‘Big Philanthropy’ donors Kümmel, however, believes “these voluntary generous donors should be praised because they provide the needed funding in the absence of member states”. The vast majority of funds coming from the private sector go to the Polio Eradication Initiative, he points out. “If the WHO didn’t receive these resources, we wouldn’t even be close to an eradication of polio because many member states just don’t put the money on the table,” he adds. In the last 10 years, the UN health agency has depended heavily on voluntary contributions, which can include both flexible funds untied to specified causes as well as money that can only be spent on activities decided by the donor. Still, in 2018/2019, almost 70 % of the overall budget was financed by funds allocated for specific purposes. The working group has considered whether the core mandate of the WHO should be fully funded by “un-earmarked” flexible contributions, which favours the organisation’s aspired ways of working, whilst also exploring the importance of expanding the WHO’s donor base. Following the recommendations of the Independent Panel for Pandemic Preparedness and Response (IPPPR), who share the view that two thirds of assessed contributions should be dues paid by member states, the working group are toying with the idea of whether this figure should be at least 50 per cent, a proposal that has been put forward to the regional committees, which Kümmel expressed had been received constructively and positively. In addition, the group has put forward to the regional committees whether member states would support and agree to the proposal on increasing assessed contributions as well as adopt an incremental implementation schedule at next May’s 75th WHA. Contributions from all member states For Kümmel, all member states should contribute regardless of their economic status. However, he agrees that some countries experience severe financial challenges, thus the current mechanisms in place ensure financial possibilities are accounted for. At the moment each country is assigned a share of the assessed budget through the WHO’s scale of assessments proportional to the size of its economy, but ultimately it is up to member states to fork out the money, particularly if it is un-earmarked funding. Coordinated efforts across regions are vital, especially when faced with health crises such as the Covid-19 pandemic. If paired with the loss of funds from major contributors, the results can be devastating. In 2020, the US fell to the third largest donor position, providing about 8% of the overall budget in the first three quarters. Biden has since restored ties with the body and in February pledged $4bn to the WHO-backed COVAX initiative to boost the equitable distribution of COVID vaccines, however, the full effect of this is yet to be seen. Germany has similarly reinforced its support to WHO’s work and fight against COVID. Earlier this month the WHO launched its new Hub for Pandemic and Epidemic Intelligence in Berlin. Germany has said it will make an initial $100 million investment to prop up the facility. The Hub is said to focus on “collaborative intelligence”, where all 194 member states, scientific institutions and civil society could share information openly. As the coronavirus has demonstrated, the world is not ready to rapidly spot and tackle potential pandemics. The working group believes preparing the health body against such future challenges with the appropriate resources is crucial. “I think that it is quite clear that the strengthening of WHO post-COVID is a key priority for many countries including Germany. Member states who really want to strengthen WHO understand that ensuring sustainable financing to WHO is one of the key pillars of this,” Kümmel urged. “We are very supportive of constructive multilateralism in global health. WHO is the global health forum where everyone sits at the table, all 194 Member States, it has a broad global health mandate, and it is fully inclusive.” This article was first published by Geneva Solutions. Image Credits: WHO/ Violaine Martin, WHO. World Leaders Call on Future German Chancellor to Support TRIPS Waiver 15/09/2021 Kerry Cullinan German Health Minister Jens Spahn and German Chancellor Angela Merkel have staunchly opposed the TRIPS waiver. More than 140 former heads of state and Nobel laureates have called on the three candidates in line to be the next German chancellor to declare themselves in favour of waiving intellectual property on COVID-19 vaccines and transferring vaccine technologies. Germany is leading the European Commission’s refusal to accept the so-called TRIPS waiver proposal put forward by South Africa and India at the World Trade Organisation (WTO). However, German elections on 26 September could unseat Angela Merkel’s ruling Christian Democratic Union Party, which has steadfastly opposed the TRIPS waiver – apparently in support of BioNTech-Pfizer. In the letter, addressed to Annalena Baerbock, Olaf Scholz, and Armin Laschet, sent on Wednesday, the signatories stress that German support for waiving patents is vital to overcoming vaccine monopolies, transferring vaccine technology and scaling up vaccine manufacturing around the world to prevent millions more deaths from COVID-19. Signatories include former French President François Hollande, former UK Prime Minister Gordon Brown, former Colombian President Juan Manuel Santos, former Malawian President Joyce Banda and Helen Clark, New Zealand’s former prime minister. Nobel prize winners include Professor Joseph Stiglitz, Professor Francoise Barre-Sinoussi and Elfriede Jelinek. End the pandemic They express deep concern with Germany’s “continued opposition to a temporary waiver of the World Trade Organization’s (WTO) intellectual property rules”, at a time in which “the artificial restriction on manufacturing and supply is leading to thousands of unnecessary deaths from COVID-19 each day”. Less than 2% of adults are fully vaccinated in low-income countries compared to almost 50 % in high-income countries. The TRIPS waiver on COVID-19 vaccines, proposed by India and South Africa in October 2020, is supported by over 100 countries including the United States and France in doing so. “Having helped create the most successful vaccine technology against COVID-19, by overcoming pharmaceutical monopolies and insisting that the technology be shared, Germany has the ability to help end this pandemic,” according to the letter. It also calls on the next Chancellor to ensure that German pharmaceutical companies openly and rapidly share life-saving mRNA vaccine technology with qualified producers around the world. Commenting on the letter, New Zealand’s Clark stressed: “Germany’s support for a TRIPS waiver in the exceptional circumstances presented by COVID-19 would send a clear signal that all peoples should be able to benefit speedily from available vaccines and therapeutics. Widespread vaccination now and further scaling up of vaccine production will play a significant role in curbing the pandemic.” Extraordinary power Meanwhile, Nobel laureate Joseph Stiglitz, said that the new Chancellor of Germany will “hold extraordinary power to turn the tide on this horrific pandemic”. “Intellectual property rules are today locking out people across the world from the benefits of life-saving science – it is time for Germany to ensure the transfer of vaccine technologies and join the rest of the world in backing a temporary waiver at the WTO,” he added. Earlier in the week, Belgian Green Sarah Matthieu, a Member of the European Parliament, said that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. The letter was coordinated by the People’s Vaccine Alliance, a coalition of more than 70 organizations including Club de Madrid, Global Justice Now and UNAIDS. Image Credits: Clemens Bilan. Much More Needs to be Done About Unhealthy Impact of Meat 15/09/2021 Madeleine Hoecklin To address the climate impacts of livestock production, people need to halve their meat-eating, says the Meat Atlas 2021. Twenty multinational meat and dairy conglomerates emit more greenhouse gases than Germany, Britain, or France, according to the Meat Atlas which was launched recently by Friends of the Earth and the Heinrich Böll Stiftung. A range of health issues associated with meat-heavy diets also require attention in the push toward more sustainable practices, according to the World Health Organization (WHO), ahead of next week’s UN Food Systems Summit scheduled for 23 September and the Glasgow Climate Summit, COP 26, which opens 31 October. Around 840,000 deaths annually are attributable to diets high in processed meats, and some 40,000 deaths are linked to diets high in red meats, according to the WHO’s Dr Maria Neira, Director of the Department of Environment, Climate Change and Health, in an interview with Health Policy Watch. Millions more premature deaths have been associated with people eating diets high in saturated fats from meat, and not eating enough fruits, vegetables, fibre, legumes, and other plant-based foods. The consequences of this are malnutrition, hypertension, heart disease and other chronic disease ailments. “[We need to focus on] reducing the consumption of meat and increasing the consumption of plant-based foods, and at the same time [developing] more sustainable food systems, a better recovery from COVID-19, a strategy to tackle climate change, and promoting health,” Neira told Health Policy Watch. For decades, the WHO has recommended replacing high saturated-fat, high-calorie meats and processed foods with unprocessed foods, fibre-rich foods, fresh fruits and vegetables. Health and climate synergies The health and climate synergies are elaborated on in WHO’s recent Compendium of guidance on health and the environment, which covers issues from air pollution to biodiversity, clean water and sanitation. “Current patterns of food production and consumption use much of the world’s resources on land and water and contribute significantly to climate and ecosystem change through for example deforestation, loss of biodiversity and GHG emissions,” according to the compendium. “This is aggravated by the fact that about one third of food produced for human consumption is wasted,” it adds. “The expansion of industrial agriculture at the expense of nature puts our global health at risk,” according to the Meat Atlas. It calls on countries to “develop an action plan to promote less and better consumption and production of meat, dairy and eggs, to shift away from industrial farming, and to support better animal farming and healthy, plant-rich diets.” Meanwhile, the WHO’s compendium provides over 400 interventions and recommendations for action to address the overconsumption of red and processed meat. Neira argues that the world has to move to decarbonisation ”with a high level of ambition and speed”. This can be done through more regulation of meat producers, raising awareness about the health implications of high meat consumption, and shifting consumption decisions in favor of sustainability and health. Impact on water and land Livestock production produces 14.5% of the world’s greenhouse gas emissions, but also uses vast amounts of water. Agriculture uses some 92% of the global water footprint and 29% of this is used in animal production. Agriculture uses three times as much available fresh water than 50 years ago. Three-quarters of all agricultural land is used to raise livestock and to grow the crops to feed them – but livestock corporations also drive water pollution, deforestation, pesticide use, and biodiversity loss. While climate campaigners push for reducing meat consumption, the demand for meat is forecasted to continue to grow over the next decade, warns the Meat Atlas. To meet this demand, meat production is becoming more industrialised, marginalising smaller meat and milk producers that represent more sustainable food production models. Antimicrobial resistance Industrial livestock production also increases the risk of zoonotic disease transmission and antimicrobial resistance (AMR), through inappropriate and largely unregulated agricultural practices. Some 73% of the antibiotics sold worldwide are used on animals and the proportion of industrial animal agriculture that routinely uses antibiotics is rising. Antibiotics are used as growth stimulants in animals and can compensate for shortcomings in hygiene, management, and the care of animals in livestock production. But the overuse or misuse of antibiotics in food-producing animals can lead to AMR in humans that cause longer illnesses, more frequent hospitalizations, and treatment failures. According to the ‘Meat Atlas’, half the chicken samples from major poultry producers in five European Union countries were contaminated with antibiotic-resistant pathogens. “Antimicrobial resistance linked to the excessive and inappropriate use of antibiotics in animal and human healthcare leads to an estimated 33,000 human deaths in the EU every year,” said the Meat Atlas. Zoonotic diseases Freshly slaughtered animals and processed meat in a market in Wuhan, Hubei, China Certain wild animals – including rodents, bats, carnivores and monkeys – are among those most likely to harbour zoonotic diseases that are harmful to humans, according to the Meat Atlas. The coronavirus, which originates in bat populations, is an example. One of the most favoured hypotheses put forward by the WHO scientists investigating the origins of the SARS-C0V2 virus causing the current pandemic is that it came from wild animals. Approximately 60% of all infectious diseases in humans are zoonotic and almost three-quarters of known zoonoses can be traced to wildlife, for example by people eating the meat of wild animals. The industrialized production of wild animals or domesticated livestock often serve as a bridge for transmission, thus posing a “dire threat to global human health,” said the Meat Atlas. Emerging pathogens are crossing the animal-human barrier with increased frequency or greater impact. The crowded conditions used to house animals in industrialised livestock production systems allow infections to easily mutate and jump to human hosts. In addition, the destruction of ecosystems to cultivate land for agricultural production is bringing people into closer contact with wild animals. As consumption patterns shift towards more meat, the risk of contracting zoonotic diseases will increase. Shifting to plant-based foods Trends in meat production (Meat Atlas 2021) Shifting diets towards plant-based foods could help reduce diet-related non-communicable disease risks and global disease burdens of obesity, cardiovascular disease, and diabetes – and slow the rise in methane emissions associated with livestock production. Plant-based and minimally processed foods “must be made available, accessible, affordable, safe, culturally acceptable and desirable to the whole population including the most vulnerable,” says the WHO’s compendium report. The world will need tailored approaches to curbing meat consumption, said Neira. “For more industrialised countries, we can move into stimulating the reduction of meat consumption and promoting healthy diets…[with] plant-based or unprocessed food,” Neira said. “A policymaker in a developed country…can go with more ambition on promoting [a plant-based diet], while in developing countries…we need to have a holistic view of their protein intake…and ensure that people will have access to foods that meet their protein needs every day,” she said. Interventions from health policymakers will require advocacy campaigns with clear arguments to “promote the importance of reducing meat consumption and increasing consumption of plant-based foods for the health of the people,” said Neira. “WHO will go to COP26 with a very strong report called the ‘Health Argument for Climate Action’ and we will put the focus on the health benefits that can be obtained be mitigating the causes of climate change and promoting a more sustainable food system from the beginning to the end,” said Neira. Image Credits: Friends of the Earth and the Heinrich Böll Stiftung, Arend Kuester/Flickr, Meat Atlas 2021. Pressure Builds on Biden to End TRIPS Waiver Impasse, Enable Equitable Access to COVID Vaccines 15/09/2021 Kerry Cullinan President Joe Biden speaking in Germany after a G7 meeting. Pressure is mounting on US President Joe Biden to provide global leadership to ensure equitable access to COVID-19 vaccines in the face of the European Commission’s refusal to support a waiver on intellectual property rights. Biden is expected to host a global leaders’ summit on COVID-19 alongside the United Nations General Assembly next week, and US officials are lobbying countries to support targets to end the pandemic centred on how to get 70% of people vaccinated by late 2022. African leaders hope that Biden’s COVID-19 summit will lead to more equitable access to vaccines: WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response Negotiations over the suspension of intellectual property rights for COVID-19 vaccines, therapeutics and diagnostics, the TRIPS waiver, have stalled at the World Trade Organization (WTO) in the face of opposition from the European Union. But if the US put forward a text on waiver, this would reinvigorate the talks, appealed South African trade ministry advisor Zane Dangor on Tuesday. South Africa and India are co-sponsors of the waiver. “Action by the US will be particularly potent to shift the needle in the negotiations and make people come around the table and discuss these issues,” said Dangor, one of the key officials involved in the WTO TRIPS waiver negotiations. In May, Biden took the world by surprise when he announced US support for the waiver proposal – although only in relation to COVID-19 vaccines. But the European Commission, particularly Germany, has refused to budget. “The European Union would like to kick the discussions further down the road,” said Dangor, adding that the EU had made it known this week that it was not in favour of a decision on the TRIPS waiver being made at the upcoming WTO Ministerial on 30 November. Zane Dangor, Special Adviser to South Africa’s Trade Minister. “We need commitment on a text from the US that can be tabled and negotiated with South Africa, India and other co-sponsors so that we can have an outcome and move to get to the business of actually ensuring that we get jabs in arms of those who need most and have equitable access,” Dangor told a press briefing organised by Public Citizen. “Not only do we need to get the WTO waiver done, but we require vaccine recipes to be shared via broad tech transfer to speed expansion of COVID medicine supplies,” added Dangor. In July, the World Health Organization (WHO) announced that it had established a “tech transfer hub” in South Africa to enable African companies produce mRNA vaccines – but the mRNA manufacturers, Pfizer-BioNTech and Moderna, have refused to join the hub. Last week, in response to a recent Health Policy Watch question, Pfizer CEO Albert Bourla said: “I’m not sure what is the point of transferring technology that it is going to take years to transfer. And, by the way, this is what we do. I’m not sure I understand what they want, to give it someone else to do?” European Commission counter-proposal is ‘big air’ Belgian Green Sarah Matthieu, a Member of the European Parliament, believes that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. Matthieu said that the German elections on 26 September may shift the power balance it that country and change the position of Germany on the waiver. US Congressman Ro Khanna said that Biden had shown “strong leadership on the TRIPS waiver” but he now had to “convince our European allies, who are often fond of lecturing the United States about moral responsibility, to live up to theirs”. Khanna added that the US had been “instrumental in the development of these vaccines”, including by “funding some of the critical research” and “providing purchase agreements that mitigated the risk for pharmaceutical companies”. Although the US government has indicated it would only support a waiver for vaccines, Khanna told the MSF briefing that this should extend to therapeutics. “More broadly, we need to have a better system for how we incentivize the production and distribution of drugs to the poor and for issues of that really affect large numbers of population,” said Khanna. “A purely for-profit model of developing medicines may lead to an over-investment in acne treatment and an under-investment of treatment on some of the biggest diseases. “Not only do we need a TRIPS waiver, but we need to think about how can we incentivize the development and the production of medicine that actually are affecting the urgent needs of many people in the United States and around the world.” Waiver debate is about pharma profit, says Stiglitz Professor Joseph Stiglitz Nobel laureate and Columbia University economist Professor Joseph Stiglitz described the waiver debate as being about the ability of the drug companies to exercise monopoly power to get substantial profits, rather than a reasonable return on their investment. “Drug companies’ concern is maximising profits. That’s their business model. And maximising profits means restricting supply because by restricting supply, you increase price, and by increasing price you increase profits,” he stressed. Referring to Pfizer’s recent talk about selling its vaccine for $175 a dose, Stiglitz said this was based on the belief that there was going to be a vaccine shortage, which would enable the company to extract a monopoly price. Like Khanna, Stiglitz stressed that the development of the COVID-19 vaccines was an international effort that had involved significant investment from various governments as well as scientists from around the world. “Germany’s particular view on this is especially peculiar because the German company, BioNTech, has already sold its international rights to Pfizer so the waiver is not even going to affect its profits,” he said, describing the EU’s opposition to the waiver as “objectionable” and “unconscionable”. Confusion about TRIPS waiver Stiglitz stressed that there was also confusion about the TRIPS waiver. “First, this is not the abolition of property rights. [Pharmaceutical companies] still get compensated for using their intellectual property rights. So, it’s not taking away their property rights. Its just saying we are in an emergency, and in this emergency, intellectual property rights have to be available more widely,” Stiglitz told the MSF briefing. “Secondly, it’s not even a change in the intellectual framework because, since the beginning of the WTO, we’ve recognised the principle of compulsory licenses. This is effectively just a compulsory license… to lower transaction costs. Lower transaction costs in the midst of the pandemic, where there’s a kind of urgency that we don’t normally have, is absolutely essential,” he added. “We’ve enacted voluntary licenses. The world has debated this. It debated it when the WTO TRIPS initially adopted it. It was really debated that in the context of HIV/AIDS, which reaffirmed the principle of compulsory licenses.” “We are in the midst of what some people call the new cold war. On the one hand, there are authoritarian governments like Russia and China, and then, on the other hand, there are democracies. We would like the democracies to win, but we’re not putting a good face on democracy when we say our democracies put profits over lives. “Russia has been very actively engaged in vaccine diplomacy. It’s made its vaccine available, say in a country like Argentina. But not only has it made its vaccine available, it’s actually actively engaged in transferring technology and enabling countries to build plants to produce the vaccine. And I’m afraid we’re losing this particular battle.” Civil society groups demonstrate outside embassies of countries that oppose a temporary WTO patent waiver on COVID-19 health products. Image Credits: CNBC, Munich Security Conference, Tadeau Andre/MSF . WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response 14/09/2021 Elaine Ruth Fletcher Left-right: Strive Masiyiwa, AU COVID envoy, Dr Tedros Adhanom Ghebreyesus, WHO Director General, Dr John Nkengasong, Africa CDC diector After months of frustrated efforts to unlock global vaccine supplies for the African continent, WHO and African Union leaders are now pinning their hopes on US President Joe Biden’s reported plan to call heads of state to a “Global Pandemic Summit” on the sidelines of the United Nations General Assembly, which opened today, as a way out of the current deadlock. Biden reportedly is circulating a plan to hold the summit on 22 September – with the aim of reaching a joint commitment to the vaccination of 70% of the world’s population by the GA session in September 2022, ensuring that “additional doses and adequate supplies are available to all countries”, according to a set of targets circulating among embassies, and obtained by the Washington Post. To achieve that, the Biden plan for the Global COVID-19 Summit also calls for “expediting delivery of approximately 2.0 billion previous committed doses.. including by converting existing dose sharing pledges into near-term deliveries, swapping delivery dates to secure earlier delivery of doses to LIC/LMICs, and eliminating cross-border bottlenecks in the supply of vaccines and critical inputs.” But speaking at Tuesday’s press conference following two days of meetings in Geneva, African Union and African Centers for Disease officials stressed that the era of “pledges” for vaccine donations to Africa, needs to end and investments in African vaccine manufacturing to begin, as part of any ‘New Deal’ on pandemic response in low- and middle-income (LMICs) countries. “”We, as the African Union, are calling on a permanent structure,” said Masiyiwa, a billionaire entrepreneur and AU Special Envoy for COVID-19, “and this is something that we will be calling on to be put in place at this summit that President Biden is convening. “We strongly believe that the pledge architecture, where countries gathered together and made pledges…. has had its day. Let us now have a permanent structure. Vaccine sharing is good. But we shouldn’t have to be relying on vaccine sharing, when we can come to the table, put structures in place, and then say that we also want to buy.” Calls for new African vaccine facility Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank This should involve the creation of a new, and permanent African vaccine facility, supported by the African Union, World Bank and International Monetary Fund, said Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank. Afreximbank has provided financing for the continent’s purchase of some 400 million Johnson & Johnson vaccines – backed by the World Bank. But Benedict stressed this is only the beginning of a long road that will require the procurement of booster doses as well. And so a more permanent finance mechanism is needed for countries to manufacturer and purchase doses themselves – rather than being solely reliant on goodwill donations. While “thanking” COVAX for the role it has played in facilitating global COVID vaccine supplies, “going forward, we need the IMF to do the vaccine facility – to make it possible for countries to now access these vaccines through the structures put in place,” said Oramah. Those structures should include domestic manufacturing and procurement financed through African mechanisms, such as “Afreximbank, providing the initial financing, and then they refinance it in a way that makes it possible for the current accounts to carry all this – while the World Bank continues to provide institutional structures that are required to effectively administer vaccines.” Africa is region with lowest rates of vaccine coverage in the world Seth Berkley, CEO Gavi, The Vaccine Alliance Among all LMICs, Africa stands out for its particularly low vaccination rates so far – with under 3.5% of its population vaccinated – as compared to 60-70% in some high-income nations, African Union also said, speaking at a WHO press conference in Geneva. Of 5.2 billion doses delivered worldwide, only a tiny fraction have reached Africa, noted WHO Director General Dr Tedros Ahanom Ghebreyesus. And as things stand now, COVAX, the global vaccine facility, only has sufficient doses in the delivery pipeline to vaccinate roughly 20% of the population in the 91 lowest income countries by the end of the year, using some 1.4 billion purchased and donated doses, admitted Gavi CEO Seth Berkley at the WHO press conference. And it would hit 36% coverage by March, 2022. That falls far short of WHO’s target of 40% vaccination by December 2021 and 70% by March 2022. To reach those targets, “the world needs 2.4 billion additional doses to go into low income countries to get us to 40% by the end of this year,” Said Bruce Aylward, a special WHO advisor on the pandemic. “Those doses exist,” he said, citing recent pharma statements to the effect that there are now sufficient doses for everyone to go around – including high- and low-income countries. See related story Massive Increase in COVID-19 Vaccine Production May Mean Dose Surplus by Mid-2022, says IFPMA I think the question we ask is: where are those doses if there are enough for everybody?” Aylward asked. “And [the US Summit] next week is all about making sure there’s a clear path to ensuring they go to where they’re needed.” Barriers that have fouled vaccine access – both countries and manufacturers share blame Strive Masiyiwa, African Union COVID-19 envoy Speaking at the close of a two-day Geneva meeting, which also included Dr John Nkengasong, Africa CDC director and African Regional Director Matshidiso Moeti, the WHO and AU officials said that in they had reviewed in painstaking detail the various obstacles in the way of African vaccine access – and ways to overcome them. The challenges have included export bans, including the interruption of supplies from India in March 2020 when the subcontinent experienced its own COVID surge, but also barriers on the exports of vaccines and their inputs to a complex supply chain, they noted. But the African officials also repeated longstanding complaints against rich countries for vaccine hoarding, as well as against pharma for preferential sales to high income countries of huge vaccine quantities – in excess of actual population needs. “We want to buy from the same manufacturers,” said Masiyiwa. “But to be fair, those manufacturers know very well that they never gave us proper access. They gave access on a very different basis. “When they knew that supplies were restricted at the beginning, there was no production… they [pharma manufacturers] had a moral responsibility to ensure that others also had access,” he said. “And we find this very sad. It’s very sad. We could have addressed this very differently. We as Africa will now address this through setting up our own manufacturing capabilities.” Countries’ export restrictions also holding up distribution But countries’ export restrictions on vaccines as well as the many vaccine manufacturing inputs also continue to foul deliveries – and these are poorly understood, Masiyiwa said. . “My principal job is to negotiate with suppliers, and the suppliers have over the last 8-9 months, made it clear that the biggest challenge that they face are export restrictions, export restrictions are being operated right across the board. So, if those export restrictions aren’t there, where are the vaccines, because the production is happening? “We’re not seeing the vaccines, and we are being told by the suppliers, they are facing export restrictions. He added that without resolving, “this issue around the movement of the various ingredients that drive production… we will not even be able to get manufacturing effectively set up.” “We need to get these restrictions removed, and we had a very constructive discussion around this issue with the WTO yesterday,” he said. AU leaders call on India to remove its ban on AstraZeneca vaccine exports – now that domestic COVID surge has subsided WHO Director General Dr Tedros Adhanom Ghebreyesus Masiyiwa also appealed to India to resume its deliveries of AstraZeneca vaccines, produced by the Serum Institute of India – noting that the countries’ embargo on the export of vaccines, remains the most outstanding example of restrictions fouling distribution plans. The SII vaccines were a centerpiece of COVAX and African countries – until exports were abruptly cancelled in March. “We understood that at the time why they were put in place, it was because there was that massive surge in India, and we were incredibly, incredibly sympathetic. But we do now urge our colleagues to show sympathy to us, because we are the ones facing difficulty now. We need to see some of those vaccines begin to come through.” Finally, both African Union and WHO officials repeated their call to countries to support a waiver on intellectual property on COVID vaccines and therapeutics, currently being negotiated by the World Trade Organization – saying that this would help jump-start more manufacturing in developing regions. “American taxpayers, European taxpayers financed some of this intellectual property, and so it should be for the common good,” said Masiyiwa. “So we ask for this IP to be made available. It was a great miracle to have these vaccines, now let this miracle be available to all mankind”. Added WHO’s Tedros: “If it [a waiver] cannot be used now during this unprecedented condition or situation, then when is there a time when it can be used.” Image Credits: @WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVID-19 Hit HIV, TB and Malaria Programs Hard, But We’re Fighting Back 17/09/2021 Peter Sands A doctor shows Oleg Chutvatov, who receives treatment for tuberculosis at the TB hospital in Kharkiv, an X-ray of his lungs. The Results Report published by the Global Fund to Fight AIDS, Tuberculosis and Malaria last week illustrates how COVID-19 has pushed us off track in significant ways – particularly with respect to access to tuberculosis (TB) and HIV diagnoses and treatment. But at the same time, there is better news with respect to the battle against malaria. And all in all, the picture would be far worse, without the rapid and determined actions that took place across the Global Fund partnership. Devastating impact on TB access and treatment For TB, the new pandemic has been devastating. In 2020, the number of people treated for drug-resistant TB in the countries where the Global Fund invests dropped by 19%, with those on treatment for extensively drug-resistant TB falling by 37%. This means around one million fewer people with TB were treated in 2020 compared with 2019. For HIV, the impact has also been significant. While it is encouraging that the number of HIV-positive people receiving antiretroviral treatment has continued to grow, the declines in prevention services and testing in 2020 were alarming. People reached with HIV prevention programs and services declined by 11%, while HIV tests taken declined by 22% compared with 2019. Because of the disruptions resulting from COVID-19, the people at greatest risk of infection have had less access to the information and tools they need to protect themselves. Malaria services fared better Thus far, interventions to combat malaria appear to have been less disrupted by COVID-19 than the other two diseases. Other than suspected cases of malaria tested – which fell by 4% compared with 2019 – rapid adaptation of malaria services seems to have limited the reverses. However, progress stalled: we did not see the year-on-year growth in provision of malaria services that we need to beat the disease. These numbers are stark confirmation of what we feared might happen when COVID-19 struck. In many countries, COVID-19 has overwhelmed health systems, lockdowns have disrupted service provision, and critical resources have been diverted from the fight against HIV, TB and malaria to fight the new virus. The pandemic has disproportionately impacted the people most affected by existing diseases: the poor, the marginalized, those without access to health care. People avoided going to health centers for treatment out of fear of catching COVID-19 – or of being stigmatized for having COVID-like symptoms such as cough or fever, which could also be treatable malaria or TB. Rapid action prevents worse outcomes Yet it would have been even worse without the rapid and determined actions that took place across the Global Fund partnership to mitigate the impact of COVID-19 on the three diseases. Decades of experience in fighting HIV, TB and malaria with Global Fund support enabled many low- and middle-income countries to respond quickly to COVID-19, using the laboratories, disease surveillance systems, community networks, trained health workers and supply chains put in place to fight HIV, TB and malaria. By the end of 2020, we had invested about US$1 billion to support more than 100 countries fight COVID-19 and mitigate its impact on HIV, TB and malaria. To save lives from both the direct and knock-on impacts of COVID -19, we worked intensively with partners across the world, in countries and through the Access to COVID-19 Tools (ACT) Accelerator. These efforts prevented an even more catastrophic impact on HIV, TB and malaria. Yet the setbacks we have seen mean that infections and deaths will inevitably rise, reversing the positive trajectory we have achieved for many years. Even more worrying is what’s been happening in 2021, with the highly transmissible Delta variant causing havoc in many countries, once again overwhelming health systems and disrupting other disease programs. Because of this we have ramped up our investments in the fight against COVID-19. As of August 2021, we had approved a further US$3.3 billion to support 107 countries and 16 multi-country programs to respond to the pandemic with critical tests, treatments and medical supplies, protect front-line health workers, adapt lifesaving HIV, TB and malaria programs, and reinforce fragile systems for health. COVID-19 as a catalyst But to beat COVID-19 and protect our hard-won gains against HIV, TB and malaria, we must do more. The direct and knock-on death tolls from the COVID-19 pandemic are already staggering, and the longer it continues the deeper will be the scars – in health, the economy and society. T wenty years ago, the Global Fund was created to step up the fight against the three infectious diseases that were then killing most people. Working as partnership, we proved they could be beaten back – and an extraordinary 44 million lives have been saved. Now we must step up again: to arrest the new pandemic, get back on track against HIV, TB and malaria, and build resilient systems for health that can protect everyone, everywhere, from future pathogens. Right now, COVID-19 presents a daunting challenge. But if we have the political will, commit more resources, and continue to innovate and collaborate, we can turn the tide on this virus, as we did with HIV, TB and malaria, and ultimately defeat it. We should seize this moment to make everyone safer from the deadliest infectious diseases, whether COVID-19, the earlier pandemics of HIV, TB and malaria, or future pandemic threats. Let us not just beat this pandemic, but use it as a catalyst to build a better, more equitable and healthier world. Peter Sands is the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. Image Credits: The Global Fund / Evgeny Maloletka, Global Fund to Fight AIDS, Tuberculosis and Malaria. Mothers and Babies’ Lives are Threatened by Fake and Sub-Standard Medicine 17/09/2021 Kawaldip Sehmi Health gains of Afghanistani women and children are in danger. Iconic places across the world will be lit up in orange on World Patient Safety Day on Friday to highlight the global campaign to reduce preventable deaths in childbirth and pregnancy and deliver safe maternal and newborn care. The International Alliance of Patients’ Organisation (IAPO), which I lead, and the alliance we are a member of,Fight the Fakes Alliance (FTF), will actively participate. Afghan women, many already fearing for their lives with the return of the Taliban, may well be watching too. In the two decades of civilian rule since the Taliban were defeated in 2001, infant and child mortality has dropped by some 70% – the fastest reduction among low-income countries. The rate went down from 191 deaths per 1000 live births in 2007 to 49 in 2018, according to Dr Mohammad Razai, an Afghan doctor working in London, What’s more, Razai says, maternal mortality was more than halved, declining from 1100 deaths per 100,000 live births to 396 as access to healthcare and sanitation rose dramatically. All of this is now at serious risk, as is the progress the world made in the same period to combat preventable deaths in pregnancy and childbirth, far too many of them caused by sub-standard and falsified medicines. The COVID-19 pandemic has negatively affected the often-fragile lives of mothers and their babies, and also brought a surge in the purchase and use of falsified medicines and the promotion of fake treatments. Ensuring mothers and babies get high-quality medicine That is why, on this special day, we are urging the global community to back moves to provide mothers and newborns with the extra care and high-quality medicines they need. Every single day, approximately 800 women and 6 700 babies lose their lives around the time of childbirth, according to the World Health Organization (WHO). In addition, nearly 5,400 babies are stillborn daily, with 40% of these deaths occurring in relation to labour and childbirth. Most stillbirths, maternal and newborn deaths and harm can be avoided by safe, respectful and quality care during pregnancy, childbirth and in the first days of a baby’s life. Sub-Saharan Africa and South Asia, two of the epicentres of fake medicines, account for 86% of these deaths. Safe and quality care provided by skilled health professionals working in supportive environments is key. But there are other, smaller things we can do. One is to ensure that patients are safe and secure and, critically, can trust their local health services. Fake and sub-standard medicines to manage hemorrhages, pre-eclampsia, eclampsia and sepsis proliferate in low- and middle-income countries (LMIC), according to a recent article. Almost half the samples of uterotonic medicines to induce or speed up labour failed quality tests. Three-quarters of ergometrine supplies failed, while almost 40% of oxytocin and misoprostol also failed. These drugs are deemed by the WHO to be “the most effective and safest drug of choice for the control, prevention, and management of postpartum haemorrhage — the leading cause of maternal mortality globally.” Fake products undermine patient trust In Nigeria, one of the richest countries in Africa, the likelihood of a woman receiving poor-quality or even fake oxytocin is very high, Devex reported, citing Dr Chimezie Anyakora, chief of party in Nigeria for the Promoting the Quality of Medicines. It also quotes a prominent local gynaecologist who recountedd how he had to go out on a Sunday and find genuine oxytocin after that which he had administered was manifestly not working. Fight the Fakes has also reported on the experiences of Ghanaian patient Victoria Amponsah who first received fake malaria medicine while two months’ pregnant then, at the end of her pregnancy, she was deceived by a fake version of oxytocin in an official-looking package. “Within 30 minutes, Victoria started sweating, shaking, vomiting and bleeding. She was in the hospital for two days, nearly lost her baby and had to return to the hospital every week after the incident for some time,” according to Fight the Fakes. In line with the WHO in its Global Patient Safety Action Plan 2021-2030, we call on the global and local communities to step up their efforts to stamp out unsafe and fake products. To build back better and ensure we have people-centred, accessible, acceptable, affordable, and quality healthcare and universal health coverage, we first must ensure patient safety. Safe care fosters trust in health systems, health professionals and medical products – but products that do not adhere to the highest standards of quality can undermine this trust Addressing fake and sub-standard medicine will require monumental effort on all our parts. But one key lesson from the pandemic is that we are all in this together. Kawaldip Sehmi is the CEO of the International Alliance of Patients’ Organisation (IAPO), a member of the Fight the Fakes Alliance. Kawaldip Sehmi Image Credits: Ahmadi/ UNICEF. Young African Innovators Lack Investment Not Creativity, Awards Ceremony Told 16/09/2021 Madeleine Hoecklin Panelists at the Africa Young Innovators for Health Award Ceremony, held on Thursday. Africa has the highest entrepreneurship rate in the world, yet greater financial resources are needed to ensure that innovation can be implemented to strengthen health systems and the welfare of health workers, said panellists at an innovation award ceremony on Thursday. The Africa Young Innovators for Health Award, co-organised by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Speak Up Africa, launched its first competition this year designed to highlight and support the work of pioneering young African entrepreneurs in the field of health innovations, particularly healthcare solutions to support healthcare workers. Attracting over 300 entries from 33 countries, the winners had developed innovations to assist in cancer diagnosis, health worker development and patient record retrieval. Winner Dr Conrad Tankou, CEO of Global Innovation and Creativity Space in Cameroon, developed GICMED, a suite of medical technologies that helps to screen and diagnose breast and cervical cancer in women. Dr Conrad Tankou, CEO of Global Innovation and Creativity Space, won first place for the Africa Young Innovators for Health Award. Breast and cervical cancer account for 50% of all new cancers in Sub-saharan African women. Healthcare workers can be trained to use the technology to remotely screen women with real-time pathology confirmation and connect them to a point of care for treatment. “It is an honour to receive the first-ever Africa Young Innovators for Health Award,” said Tankou. “With the Award’s financial and business mentorship support, we can upgrade our technologies and start scaling our solution much quicker by investing in manufacturing capabilities and building more local partnerships.” In second place was John Mwangi, CEO of Daktari Media Africa in Kenya, who established Daktari Online, which provides a professional development platform for healthcare workers. John Mwangi, CEO of Daktari Media Africa, won second place for the Africa Young Innovators for Health Award. Currently 13,000 health workers use the platform and it has been accredited by the regulatory bodies for pharmacists, pharmaceutical technologists, and physician assistants. “The practice of medicine requires continuous updating…and that’s what we seek to do,” said Mwangi. “We said why don’t we just democratize [access to information and professional development] and have this accessible to people even from remote areas.” The third-place winner, Dr Imodoye Abioro, CEO of Healthbotics in Nigeria, developed an artificial intelligence (AI) powered electronic medical record system – Mediverse – that utilizes blockchain to help healthcare workers input and retrieve patient records. Dr Imodoye Abioro, CEO of Healthbotics in Nigeria, won third place for the Africa Young Innovators for Health Award. The technology could work on any device and even in places where the internet has not yet reached. “We do not have enough healthcare workers for the disease burden we’re battling,” said Abioro. “The first thought we had was how do we make the healthcare worker more effective, how can he or she see more patients, how can he or she be smarter or faster.” “Mediverse is what we consider to be a solution that will be necessary for us to build a sustainable healthcare infrastructure in Africa upon,” Abioro added. “This could really revolutionize the way that healthcare workers are able to access the data they need about their patients in real time,” said Nicole Kayode, CEO and Founder of Medixus. The winners take home between US$15,000 and US$40,000 and will benefit from a business mentorship program, media exposure, technical training on intellectual property protection, and expert advice from an extensive network of stakeholders working across healthcare mediums. More investment needed Some 22% of Africa’s working-age population are starting businesses, “yet more investment in human capital is needed for this demographic potential to reap the development rewards it should,” said Thomas Cueni, Director-General of IFPMA. “We are confident that the winners of the African Young Innovators for health award will contribute to improving health systems and growing African economies,” added Cueni. “We don’t lack ideas or creativity, that’s not what’s missing,” said Dr Awa Marie Coll-Seck, Senegal’s Minister of State of Senegal and former health minister. “Among innovators, it’s often about the lack of financial resources for research…This is what stops them from concretising their ideas and developing prototypes.” “We need to give [the young innovators] the opportunity to develop ideas and their expertise,” said Coll-Seck. Africa is the youngest continent on the planet. By 2050, Africa’s youth population under the age of 24 will increase by nearly 50%. This presents an opportunity for rapid social and economic transformation, said the panelists. In 2019, sub-Saharan African countries were classified among the hundred best countries in terms of innovation. Africa facing massive shortages in healthcare workforce Africa bears a quarter of the global disease burden but faces a shortage of over two million healthcare professionals. Only 2% of the world’s healthcare workforce are from the continent. “Our world lacks about 18 million health workers globally and…Africa is the place that really suffers the most from it,” said Pape Gaye, President Emeritus of IntraHealth International, addressing the awards ceremony. The shortage of human and financial resources invested in the African healthcare system is putting a strain on healthcare workers and the broader national and regional health infrastructure. “COVID-19 has laid bare the underlying inequities and prejudices in existing healthcare,” said Dr Moredreck Chibi, the World Health Organization’s (WHO) Africa Advisor for Innovation. “Our young people [need to] take the bull by its horn and apply their intellectual capital to address some of these challenges.” Dr Moredreck Chibi, WHO Regional Advisor for Innovation for the Regional Office for Africa. “Only this approach will ensure Africa’s sustainable path for the future of health on the continent,” said Chibi. “As we are all aware, the COVID pandemic has been devastating and exposed the vulnerabilities of health systems across the globe, including in Africa,” said Dr Lindiwe Makubalo, WHO Assistant Regional Director for Africa. “There could be no better time to draw on the rich human capital, especially among young people, to find solutions to the problems that we are facing.” “COVID-19 has been a wake-up call for the continent. It is inevitable that we need to think outside the box to solve these problems,” said Makubalo. Innovation is a central component of public health “Innovation has always been the driving force of progress in public health, from vaccines to penicillin to the mapping of the human genome,” said Cueni. “Innovations have changed the world and this has never been more evident than with the COVID-19 pandemic.” Vaccines and treatments for COVID-19 were developed by pharma companies in record time due to large investments in research and a lot of innovation. “We have seen from smartphones to drones, there’s no doubt that technology and innovation are leapfrogging Africa and future young African entrepreneurs are playing a crucial role by developing creative ideas that can resolve the various health challenges on the continent,” said Cueni. Thomas Cueni, Director General of the IFPMA, at the award ceremony on Thursday. The panelists called on countries to support efforts and innovations of the youth by harnessing domestic resources through advocacy for partner financing and the creation of platforms to showcase initiatives. Partnerships with private sector are essential “We all know that innovation is best when it is tailored to the local context and that we should think about those who need it most when we’re creating them, and how we can create the most impact,” said Yacine Djibo, Founder and Executive Director of Speak Up Africa. Yacine Djibo, Founder and Executive Director of Speak Up Africa. Building science, technology, and innovation capacity, as well as stimulating the existing entrepreneurial culture in Africa should be a priority, said Djibo. Collaboration with the private sector will increase the opportunities for innovation and help the continent build sustainable health systems. “Health system strengthening and the potential of Africa’s private sector are crucially important for unleashing the entrepreneurial power of Africa’s young people,” said Cueni. “This will create innovative and compelling modern businesses, increase the capacity for these businesses to compete regionally and globally, attract both domestic and foreign investment, and diversify investment profiles.” This will contribute to job creation and economic growth across the region. “By leveraging its resources, expertise, networks, infrastructure, and assets, the private sector can focus on innovation for new technologies, systems, and processes, [and] can influence policy and form partnerships that will have continent-wide impact on the populations,” said Cueni. “We are extremely impressed by the quality of the applications we received. These applications are a shining example that young Africans are bursting with creativity and are constantly looking for local-based solutions that work,” said Djibo. With only one-fifth of applications to the innovation award coming from women, the IFPMA and Speak Up Africa have launched the Women Innovators Incubator to address the gaps in female-led innovation. Three female participants will receive financial support, mentorship, media training, expert advice on intellectual property protection, and access to a network of global health experts. Image Credits: Africa Young Innovators for Health Award, Africa Young Innovators for Health Award. Wealthy Countries Urged to Share 2 Billion Excess COVID-19 Doses, as South Africa’s mRNA Hub Prepares to Make ‘Moderna-like’ Vaccine 16/09/2021 Kerry Cullinan The South African mRNA hub aims to make Moderna-like vaccine. Countries with high COVID-19 vaccination rates have pre-purchased over two billion excess vaccine doses, limiting the supplies available for low- and middle-income countries (LMIC). This emerged from a meeting on Thursday between the heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization – the multilateral Task Force – and CEOs of leading vaccine manufacturing companies. Meanwhile, the South African mRNA technology transfer hub set up in July to enable Africa to manufacture its own vaccines is moving ahead with plans to make a “Moderna-like” vaccine – despite a lack of co-operation from either mRNA manufacturer, Moderna or Pfizer-BioNTech. This was confirmed to Health Policy Watch by Dr Marie-Paule Kieny, Chair of the Board of the Medicines Patent Pool in Geneva and President of the French Scientific Committee on COVID-19 vaccines. “The mRNA hub doesn’t need direct transfer of technology from Pfizer/BioNTech or Moderna, as enough information on production process is available publicly and as there are no patent on mRNA vaccines in any African country,” said Kieny, who recently visited South Africa to work with local hub partners. “The hub will therefore work with technical experts to recreate a new ‘Moderna-like’ vaccine,” added Kieny. Appeal to swap doses, deliver to COVAX and AVAT To alleviate COVID vaccine shortages in LMICs, the task force called on wealthy countries to urgently “swap their near-term delivery schedules with COVAX and the African Vaccine Acquisition Task Force (AVAT)”, meet their dose donation pledges with “unearmarked upfront deliveries to COVAX”, and release vaccine companies from options and contracts to enable these doses to be delivered to LMICs. Without these urgent steps, the world is unlikely to meet the WHO’s target of vaccinating 40% of the global population by the end of the year. “Despite adequate total global vaccine production in the aggregate, the doses are not reaching LMICs in sufficient amounts, resulting in a crisis of vaccine inequity,” the task force said. It also appealed for transparency about the supply of vaccines, calling on vaccine manufacturers to share details on month-by-month delivery schedules for all vaccine shipments, especially for COVAX and AVAT. It also called on all countries to urgently address export restrictions, high tariffs and customs bottlenecks on COVID-19 vaccines, raw materials and supplies. The task team welcomed the pharmaceutical CEOs’ willingness to ‘work collectively to end vaccine inequity” and “readiness” to form a joint technical working group with the Task Force to exchange and coordinate information on vaccine production and deliveries. However, the big pharmaceutical companies have been unwilling to work with the mRNA hub. ‘No point’ in mRNA transfer In response to a Health Policy Watch question, Pfizer CEO Albert Bourla said that he didn’t see the point as the tech transfer “would take years”, and that producing mRNA vaccines was what Pfizer did. Kieny confirmed that the Medicines Patent Pool, WHO and others had reached out to the mRNA vaccine manufacturers “but up to this point, the companies have not been interested”. Vaccine manufacturers are apparently wary of new manufacturers competing for raw materials and customers. Shortly after the mRNA hub was announced, Pfizer revealed that it had made a deal with South African pharmaceutical company and hub member Biovac, to “fill and finish” around 100 million vaccines destined for Africa. Kieny described this as “an excellent step forward”, as Biovac will receive technology transfer from Pfizer for the fill-finish part of their mRNA vaccine, “especially as the Pfizer contract does not claim exclusivity”. “Biovac will therefore also become the first African manufacturer with a product resulting from technology transfer of the full production cycle from the hub,” said Kieny. Image Credits: Gavi . Finding Sustainable Solutions to WHO’s Financial Woes 16/09/2021 Pokuaa Oduro-Bonsrah Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health and chair of the WHO Working Group on Sustainable Finance. For a long time, the World Health Organization (WHO) has experienced immense financial stress resulting in numerous debates on how to remedy its economic woes. A working group set up earlier this year has been tasked with finding long-term solutions. Each year the representatives of some 194 countries make demands on what work should be carried out by the WHO, but the money needed to carry out the requests is severely lacking. Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health, and chair of WHO’s Working Group on Sustainable Funding, recalls explaining the situation to his daughter who asks what the money problem is. “The family decides to have breakfast with lots of friends. We need to buy 20 buns from the bakery, and there’s a plan in place because we know our guests want different buns. I send my daughter to the bakery to buy 20 different buns but only give her enough money for two,” he says. Without enough money, Kümmel’s daughter would have to beg for money on the way to the store. Some generous passersby might give her some change, but on the condition that she spends it on specific types of buns. She might be able to bring back home all 20 buns but to a large extent they will not be the ones ordered. “It sounds absurd when we put it this way but the member states of the WHO, in the same way, do not provide the finances to fund their own priorities agreed to by these countries,” Kümmel told Geneva Solutions. Increasingly, individual donors have been providing funding money for these “buns”, but often face criticism for financing projects that personally interest them. Meanwhile, the funds needed to execute the activities of the ever-broadening agenda set by the World Health Assembly (WHA) are lacking. COVID-19 has revealed major discrepancies between the expectations of the WHO and its de facto ability. “The pandemic has shown that we need a strong WHO, now more than ever, and it is clear that it is not strong enough,” Kümmel said. Sustainability lens For years discussions have circled around WHO’s funding, prompting its Director-General, Dr Tedros Adhanom Ghebreyesus, to reflect on how these conversations have “remained rather abstract” in a report delivered to the Executive Board. As a result, the WHO created the Working Group on Sustainable Financing (WGSF), which is tasked with finding long-term solutions to the body’s financial troubles. Kümmel notes that although finances remain a popular topic amongst the organisation’s members, this is the first time a “sustainability” lens is being adopted. He adds that everyone shares the view that a stronger WHO is needed, which requires more stable sources of long-term funding. The alternative, continuing with the status quo, poses a threat to global health security and the achievement of the Sustainable Development Goals. “There needs to be a completely new approach to ensure the WHO has the right finances in place in order to fulfil the world’s expectations,” he says. The WSFG is working on a proposal that will “enable WHO to have the robust structures and capacities needed to fulfil its core functions,” as highlighted in the meeting report. The final report and recommendations will be taken forward to the WHO’s executive board in January 2022. Concluding their third and most recent meeting in June, the group has already explored different financing models, including other global health actors’ funding structures that could help recharge the WHO’s coffers, drawing on lessons from other health actors. Adopting the Global Fund’s so-called replenishment model, for example, would mean raising funds in multi-year cycles. Kümmel says the WHO budget could at least be partially funded this way. Dr Tedros addressing the WHO’s 149th Executive Board meeting Since taking office in 2017, Ghebreyesus has made broadening the WHO’s funding base one of the organisation’s main priorities. In 2019, he announced plans to establish the WHO Foundation to secure funds from the public, individual major donors and corporate partners. The launch of the independent grant-making body came amid controversy over former US President Donald Trump’s decision to halt funding from the US, the WHO’s single largest donor. The move was later reversed by current President Joe Biden but it had already exposed the health organisation’s heavy dependence on a few major donors. Approved for 2020-2021, the budget is $5.8 billion, which reflects a $1.4bn increase from the previous biennium, mostly needed for the Covid-19 response. About 16 per cent of this figure stems from mandatory payments known as assessed contributions, paid by its members, which over the last two decades or so, have remained flat at one billion US dollars. The other way is through voluntary contributions, secured from governments, other UN agencies and the private sector, which make up the majority of the budget. In recent years the top voluntary contributors, in addition to the US, have included the United Kingdom, Germany and the Bill and Melinda Gates Foundation. Yet, private players such as the Gates Foundation have come under fire for having some of the most powerful and influential voices in global health, raising questions about the WHO’s independence. Praise for ‘Big Philanthropy’ donors Kümmel, however, believes “these voluntary generous donors should be praised because they provide the needed funding in the absence of member states”. The vast majority of funds coming from the private sector go to the Polio Eradication Initiative, he points out. “If the WHO didn’t receive these resources, we wouldn’t even be close to an eradication of polio because many member states just don’t put the money on the table,” he adds. In the last 10 years, the UN health agency has depended heavily on voluntary contributions, which can include both flexible funds untied to specified causes as well as money that can only be spent on activities decided by the donor. Still, in 2018/2019, almost 70 % of the overall budget was financed by funds allocated for specific purposes. The working group has considered whether the core mandate of the WHO should be fully funded by “un-earmarked” flexible contributions, which favours the organisation’s aspired ways of working, whilst also exploring the importance of expanding the WHO’s donor base. Following the recommendations of the Independent Panel for Pandemic Preparedness and Response (IPPPR), who share the view that two thirds of assessed contributions should be dues paid by member states, the working group are toying with the idea of whether this figure should be at least 50 per cent, a proposal that has been put forward to the regional committees, which Kümmel expressed had been received constructively and positively. In addition, the group has put forward to the regional committees whether member states would support and agree to the proposal on increasing assessed contributions as well as adopt an incremental implementation schedule at next May’s 75th WHA. Contributions from all member states For Kümmel, all member states should contribute regardless of their economic status. However, he agrees that some countries experience severe financial challenges, thus the current mechanisms in place ensure financial possibilities are accounted for. At the moment each country is assigned a share of the assessed budget through the WHO’s scale of assessments proportional to the size of its economy, but ultimately it is up to member states to fork out the money, particularly if it is un-earmarked funding. Coordinated efforts across regions are vital, especially when faced with health crises such as the Covid-19 pandemic. If paired with the loss of funds from major contributors, the results can be devastating. In 2020, the US fell to the third largest donor position, providing about 8% of the overall budget in the first three quarters. Biden has since restored ties with the body and in February pledged $4bn to the WHO-backed COVAX initiative to boost the equitable distribution of COVID vaccines, however, the full effect of this is yet to be seen. Germany has similarly reinforced its support to WHO’s work and fight against COVID. Earlier this month the WHO launched its new Hub for Pandemic and Epidemic Intelligence in Berlin. Germany has said it will make an initial $100 million investment to prop up the facility. The Hub is said to focus on “collaborative intelligence”, where all 194 member states, scientific institutions and civil society could share information openly. As the coronavirus has demonstrated, the world is not ready to rapidly spot and tackle potential pandemics. The working group believes preparing the health body against such future challenges with the appropriate resources is crucial. “I think that it is quite clear that the strengthening of WHO post-COVID is a key priority for many countries including Germany. Member states who really want to strengthen WHO understand that ensuring sustainable financing to WHO is one of the key pillars of this,” Kümmel urged. “We are very supportive of constructive multilateralism in global health. WHO is the global health forum where everyone sits at the table, all 194 Member States, it has a broad global health mandate, and it is fully inclusive.” This article was first published by Geneva Solutions. Image Credits: WHO/ Violaine Martin, WHO. World Leaders Call on Future German Chancellor to Support TRIPS Waiver 15/09/2021 Kerry Cullinan German Health Minister Jens Spahn and German Chancellor Angela Merkel have staunchly opposed the TRIPS waiver. More than 140 former heads of state and Nobel laureates have called on the three candidates in line to be the next German chancellor to declare themselves in favour of waiving intellectual property on COVID-19 vaccines and transferring vaccine technologies. Germany is leading the European Commission’s refusal to accept the so-called TRIPS waiver proposal put forward by South Africa and India at the World Trade Organisation (WTO). However, German elections on 26 September could unseat Angela Merkel’s ruling Christian Democratic Union Party, which has steadfastly opposed the TRIPS waiver – apparently in support of BioNTech-Pfizer. In the letter, addressed to Annalena Baerbock, Olaf Scholz, and Armin Laschet, sent on Wednesday, the signatories stress that German support for waiving patents is vital to overcoming vaccine monopolies, transferring vaccine technology and scaling up vaccine manufacturing around the world to prevent millions more deaths from COVID-19. Signatories include former French President François Hollande, former UK Prime Minister Gordon Brown, former Colombian President Juan Manuel Santos, former Malawian President Joyce Banda and Helen Clark, New Zealand’s former prime minister. Nobel prize winners include Professor Joseph Stiglitz, Professor Francoise Barre-Sinoussi and Elfriede Jelinek. End the pandemic They express deep concern with Germany’s “continued opposition to a temporary waiver of the World Trade Organization’s (WTO) intellectual property rules”, at a time in which “the artificial restriction on manufacturing and supply is leading to thousands of unnecessary deaths from COVID-19 each day”. Less than 2% of adults are fully vaccinated in low-income countries compared to almost 50 % in high-income countries. The TRIPS waiver on COVID-19 vaccines, proposed by India and South Africa in October 2020, is supported by over 100 countries including the United States and France in doing so. “Having helped create the most successful vaccine technology against COVID-19, by overcoming pharmaceutical monopolies and insisting that the technology be shared, Germany has the ability to help end this pandemic,” according to the letter. It also calls on the next Chancellor to ensure that German pharmaceutical companies openly and rapidly share life-saving mRNA vaccine technology with qualified producers around the world. Commenting on the letter, New Zealand’s Clark stressed: “Germany’s support for a TRIPS waiver in the exceptional circumstances presented by COVID-19 would send a clear signal that all peoples should be able to benefit speedily from available vaccines and therapeutics. Widespread vaccination now and further scaling up of vaccine production will play a significant role in curbing the pandemic.” Extraordinary power Meanwhile, Nobel laureate Joseph Stiglitz, said that the new Chancellor of Germany will “hold extraordinary power to turn the tide on this horrific pandemic”. “Intellectual property rules are today locking out people across the world from the benefits of life-saving science – it is time for Germany to ensure the transfer of vaccine technologies and join the rest of the world in backing a temporary waiver at the WTO,” he added. Earlier in the week, Belgian Green Sarah Matthieu, a Member of the European Parliament, said that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. The letter was coordinated by the People’s Vaccine Alliance, a coalition of more than 70 organizations including Club de Madrid, Global Justice Now and UNAIDS. Image Credits: Clemens Bilan. Much More Needs to be Done About Unhealthy Impact of Meat 15/09/2021 Madeleine Hoecklin To address the climate impacts of livestock production, people need to halve their meat-eating, says the Meat Atlas 2021. Twenty multinational meat and dairy conglomerates emit more greenhouse gases than Germany, Britain, or France, according to the Meat Atlas which was launched recently by Friends of the Earth and the Heinrich Böll Stiftung. A range of health issues associated with meat-heavy diets also require attention in the push toward more sustainable practices, according to the World Health Organization (WHO), ahead of next week’s UN Food Systems Summit scheduled for 23 September and the Glasgow Climate Summit, COP 26, which opens 31 October. Around 840,000 deaths annually are attributable to diets high in processed meats, and some 40,000 deaths are linked to diets high in red meats, according to the WHO’s Dr Maria Neira, Director of the Department of Environment, Climate Change and Health, in an interview with Health Policy Watch. Millions more premature deaths have been associated with people eating diets high in saturated fats from meat, and not eating enough fruits, vegetables, fibre, legumes, and other plant-based foods. The consequences of this are malnutrition, hypertension, heart disease and other chronic disease ailments. “[We need to focus on] reducing the consumption of meat and increasing the consumption of plant-based foods, and at the same time [developing] more sustainable food systems, a better recovery from COVID-19, a strategy to tackle climate change, and promoting health,” Neira told Health Policy Watch. For decades, the WHO has recommended replacing high saturated-fat, high-calorie meats and processed foods with unprocessed foods, fibre-rich foods, fresh fruits and vegetables. Health and climate synergies The health and climate synergies are elaborated on in WHO’s recent Compendium of guidance on health and the environment, which covers issues from air pollution to biodiversity, clean water and sanitation. “Current patterns of food production and consumption use much of the world’s resources on land and water and contribute significantly to climate and ecosystem change through for example deforestation, loss of biodiversity and GHG emissions,” according to the compendium. “This is aggravated by the fact that about one third of food produced for human consumption is wasted,” it adds. “The expansion of industrial agriculture at the expense of nature puts our global health at risk,” according to the Meat Atlas. It calls on countries to “develop an action plan to promote less and better consumption and production of meat, dairy and eggs, to shift away from industrial farming, and to support better animal farming and healthy, plant-rich diets.” Meanwhile, the WHO’s compendium provides over 400 interventions and recommendations for action to address the overconsumption of red and processed meat. Neira argues that the world has to move to decarbonisation ”with a high level of ambition and speed”. This can be done through more regulation of meat producers, raising awareness about the health implications of high meat consumption, and shifting consumption decisions in favor of sustainability and health. Impact on water and land Livestock production produces 14.5% of the world’s greenhouse gas emissions, but also uses vast amounts of water. Agriculture uses some 92% of the global water footprint and 29% of this is used in animal production. Agriculture uses three times as much available fresh water than 50 years ago. Three-quarters of all agricultural land is used to raise livestock and to grow the crops to feed them – but livestock corporations also drive water pollution, deforestation, pesticide use, and biodiversity loss. While climate campaigners push for reducing meat consumption, the demand for meat is forecasted to continue to grow over the next decade, warns the Meat Atlas. To meet this demand, meat production is becoming more industrialised, marginalising smaller meat and milk producers that represent more sustainable food production models. Antimicrobial resistance Industrial livestock production also increases the risk of zoonotic disease transmission and antimicrobial resistance (AMR), through inappropriate and largely unregulated agricultural practices. Some 73% of the antibiotics sold worldwide are used on animals and the proportion of industrial animal agriculture that routinely uses antibiotics is rising. Antibiotics are used as growth stimulants in animals and can compensate for shortcomings in hygiene, management, and the care of animals in livestock production. But the overuse or misuse of antibiotics in food-producing animals can lead to AMR in humans that cause longer illnesses, more frequent hospitalizations, and treatment failures. According to the ‘Meat Atlas’, half the chicken samples from major poultry producers in five European Union countries were contaminated with antibiotic-resistant pathogens. “Antimicrobial resistance linked to the excessive and inappropriate use of antibiotics in animal and human healthcare leads to an estimated 33,000 human deaths in the EU every year,” said the Meat Atlas. Zoonotic diseases Freshly slaughtered animals and processed meat in a market in Wuhan, Hubei, China Certain wild animals – including rodents, bats, carnivores and monkeys – are among those most likely to harbour zoonotic diseases that are harmful to humans, according to the Meat Atlas. The coronavirus, which originates in bat populations, is an example. One of the most favoured hypotheses put forward by the WHO scientists investigating the origins of the SARS-C0V2 virus causing the current pandemic is that it came from wild animals. Approximately 60% of all infectious diseases in humans are zoonotic and almost three-quarters of known zoonoses can be traced to wildlife, for example by people eating the meat of wild animals. The industrialized production of wild animals or domesticated livestock often serve as a bridge for transmission, thus posing a “dire threat to global human health,” said the Meat Atlas. Emerging pathogens are crossing the animal-human barrier with increased frequency or greater impact. The crowded conditions used to house animals in industrialised livestock production systems allow infections to easily mutate and jump to human hosts. In addition, the destruction of ecosystems to cultivate land for agricultural production is bringing people into closer contact with wild animals. As consumption patterns shift towards more meat, the risk of contracting zoonotic diseases will increase. Shifting to plant-based foods Trends in meat production (Meat Atlas 2021) Shifting diets towards plant-based foods could help reduce diet-related non-communicable disease risks and global disease burdens of obesity, cardiovascular disease, and diabetes – and slow the rise in methane emissions associated with livestock production. Plant-based and minimally processed foods “must be made available, accessible, affordable, safe, culturally acceptable and desirable to the whole population including the most vulnerable,” says the WHO’s compendium report. The world will need tailored approaches to curbing meat consumption, said Neira. “For more industrialised countries, we can move into stimulating the reduction of meat consumption and promoting healthy diets…[with] plant-based or unprocessed food,” Neira said. “A policymaker in a developed country…can go with more ambition on promoting [a plant-based diet], while in developing countries…we need to have a holistic view of their protein intake…and ensure that people will have access to foods that meet their protein needs every day,” she said. Interventions from health policymakers will require advocacy campaigns with clear arguments to “promote the importance of reducing meat consumption and increasing consumption of plant-based foods for the health of the people,” said Neira. “WHO will go to COP26 with a very strong report called the ‘Health Argument for Climate Action’ and we will put the focus on the health benefits that can be obtained be mitigating the causes of climate change and promoting a more sustainable food system from the beginning to the end,” said Neira. Image Credits: Friends of the Earth and the Heinrich Böll Stiftung, Arend Kuester/Flickr, Meat Atlas 2021. Pressure Builds on Biden to End TRIPS Waiver Impasse, Enable Equitable Access to COVID Vaccines 15/09/2021 Kerry Cullinan President Joe Biden speaking in Germany after a G7 meeting. Pressure is mounting on US President Joe Biden to provide global leadership to ensure equitable access to COVID-19 vaccines in the face of the European Commission’s refusal to support a waiver on intellectual property rights. Biden is expected to host a global leaders’ summit on COVID-19 alongside the United Nations General Assembly next week, and US officials are lobbying countries to support targets to end the pandemic centred on how to get 70% of people vaccinated by late 2022. African leaders hope that Biden’s COVID-19 summit will lead to more equitable access to vaccines: WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response Negotiations over the suspension of intellectual property rights for COVID-19 vaccines, therapeutics and diagnostics, the TRIPS waiver, have stalled at the World Trade Organization (WTO) in the face of opposition from the European Union. But if the US put forward a text on waiver, this would reinvigorate the talks, appealed South African trade ministry advisor Zane Dangor on Tuesday. South Africa and India are co-sponsors of the waiver. “Action by the US will be particularly potent to shift the needle in the negotiations and make people come around the table and discuss these issues,” said Dangor, one of the key officials involved in the WTO TRIPS waiver negotiations. In May, Biden took the world by surprise when he announced US support for the waiver proposal – although only in relation to COVID-19 vaccines. But the European Commission, particularly Germany, has refused to budget. “The European Union would like to kick the discussions further down the road,” said Dangor, adding that the EU had made it known this week that it was not in favour of a decision on the TRIPS waiver being made at the upcoming WTO Ministerial on 30 November. Zane Dangor, Special Adviser to South Africa’s Trade Minister. “We need commitment on a text from the US that can be tabled and negotiated with South Africa, India and other co-sponsors so that we can have an outcome and move to get to the business of actually ensuring that we get jabs in arms of those who need most and have equitable access,” Dangor told a press briefing organised by Public Citizen. “Not only do we need to get the WTO waiver done, but we require vaccine recipes to be shared via broad tech transfer to speed expansion of COVID medicine supplies,” added Dangor. In July, the World Health Organization (WHO) announced that it had established a “tech transfer hub” in South Africa to enable African companies produce mRNA vaccines – but the mRNA manufacturers, Pfizer-BioNTech and Moderna, have refused to join the hub. Last week, in response to a recent Health Policy Watch question, Pfizer CEO Albert Bourla said: “I’m not sure what is the point of transferring technology that it is going to take years to transfer. And, by the way, this is what we do. I’m not sure I understand what they want, to give it someone else to do?” European Commission counter-proposal is ‘big air’ Belgian Green Sarah Matthieu, a Member of the European Parliament, believes that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. Matthieu said that the German elections on 26 September may shift the power balance it that country and change the position of Germany on the waiver. US Congressman Ro Khanna said that Biden had shown “strong leadership on the TRIPS waiver” but he now had to “convince our European allies, who are often fond of lecturing the United States about moral responsibility, to live up to theirs”. Khanna added that the US had been “instrumental in the development of these vaccines”, including by “funding some of the critical research” and “providing purchase agreements that mitigated the risk for pharmaceutical companies”. Although the US government has indicated it would only support a waiver for vaccines, Khanna told the MSF briefing that this should extend to therapeutics. “More broadly, we need to have a better system for how we incentivize the production and distribution of drugs to the poor and for issues of that really affect large numbers of population,” said Khanna. “A purely for-profit model of developing medicines may lead to an over-investment in acne treatment and an under-investment of treatment on some of the biggest diseases. “Not only do we need a TRIPS waiver, but we need to think about how can we incentivize the development and the production of medicine that actually are affecting the urgent needs of many people in the United States and around the world.” Waiver debate is about pharma profit, says Stiglitz Professor Joseph Stiglitz Nobel laureate and Columbia University economist Professor Joseph Stiglitz described the waiver debate as being about the ability of the drug companies to exercise monopoly power to get substantial profits, rather than a reasonable return on their investment. “Drug companies’ concern is maximising profits. That’s their business model. And maximising profits means restricting supply because by restricting supply, you increase price, and by increasing price you increase profits,” he stressed. Referring to Pfizer’s recent talk about selling its vaccine for $175 a dose, Stiglitz said this was based on the belief that there was going to be a vaccine shortage, which would enable the company to extract a monopoly price. Like Khanna, Stiglitz stressed that the development of the COVID-19 vaccines was an international effort that had involved significant investment from various governments as well as scientists from around the world. “Germany’s particular view on this is especially peculiar because the German company, BioNTech, has already sold its international rights to Pfizer so the waiver is not even going to affect its profits,” he said, describing the EU’s opposition to the waiver as “objectionable” and “unconscionable”. Confusion about TRIPS waiver Stiglitz stressed that there was also confusion about the TRIPS waiver. “First, this is not the abolition of property rights. [Pharmaceutical companies] still get compensated for using their intellectual property rights. So, it’s not taking away their property rights. Its just saying we are in an emergency, and in this emergency, intellectual property rights have to be available more widely,” Stiglitz told the MSF briefing. “Secondly, it’s not even a change in the intellectual framework because, since the beginning of the WTO, we’ve recognised the principle of compulsory licenses. This is effectively just a compulsory license… to lower transaction costs. Lower transaction costs in the midst of the pandemic, where there’s a kind of urgency that we don’t normally have, is absolutely essential,” he added. “We’ve enacted voluntary licenses. The world has debated this. It debated it when the WTO TRIPS initially adopted it. It was really debated that in the context of HIV/AIDS, which reaffirmed the principle of compulsory licenses.” “We are in the midst of what some people call the new cold war. On the one hand, there are authoritarian governments like Russia and China, and then, on the other hand, there are democracies. We would like the democracies to win, but we’re not putting a good face on democracy when we say our democracies put profits over lives. “Russia has been very actively engaged in vaccine diplomacy. It’s made its vaccine available, say in a country like Argentina. But not only has it made its vaccine available, it’s actually actively engaged in transferring technology and enabling countries to build plants to produce the vaccine. And I’m afraid we’re losing this particular battle.” Civil society groups demonstrate outside embassies of countries that oppose a temporary WTO patent waiver on COVID-19 health products. Image Credits: CNBC, Munich Security Conference, Tadeau Andre/MSF . WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response 14/09/2021 Elaine Ruth Fletcher Left-right: Strive Masiyiwa, AU COVID envoy, Dr Tedros Adhanom Ghebreyesus, WHO Director General, Dr John Nkengasong, Africa CDC diector After months of frustrated efforts to unlock global vaccine supplies for the African continent, WHO and African Union leaders are now pinning their hopes on US President Joe Biden’s reported plan to call heads of state to a “Global Pandemic Summit” on the sidelines of the United Nations General Assembly, which opened today, as a way out of the current deadlock. Biden reportedly is circulating a plan to hold the summit on 22 September – with the aim of reaching a joint commitment to the vaccination of 70% of the world’s population by the GA session in September 2022, ensuring that “additional doses and adequate supplies are available to all countries”, according to a set of targets circulating among embassies, and obtained by the Washington Post. To achieve that, the Biden plan for the Global COVID-19 Summit also calls for “expediting delivery of approximately 2.0 billion previous committed doses.. including by converting existing dose sharing pledges into near-term deliveries, swapping delivery dates to secure earlier delivery of doses to LIC/LMICs, and eliminating cross-border bottlenecks in the supply of vaccines and critical inputs.” But speaking at Tuesday’s press conference following two days of meetings in Geneva, African Union and African Centers for Disease officials stressed that the era of “pledges” for vaccine donations to Africa, needs to end and investments in African vaccine manufacturing to begin, as part of any ‘New Deal’ on pandemic response in low- and middle-income (LMICs) countries. “”We, as the African Union, are calling on a permanent structure,” said Masiyiwa, a billionaire entrepreneur and AU Special Envoy for COVID-19, “and this is something that we will be calling on to be put in place at this summit that President Biden is convening. “We strongly believe that the pledge architecture, where countries gathered together and made pledges…. has had its day. Let us now have a permanent structure. Vaccine sharing is good. But we shouldn’t have to be relying on vaccine sharing, when we can come to the table, put structures in place, and then say that we also want to buy.” Calls for new African vaccine facility Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank This should involve the creation of a new, and permanent African vaccine facility, supported by the African Union, World Bank and International Monetary Fund, said Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank. Afreximbank has provided financing for the continent’s purchase of some 400 million Johnson & Johnson vaccines – backed by the World Bank. But Benedict stressed this is only the beginning of a long road that will require the procurement of booster doses as well. And so a more permanent finance mechanism is needed for countries to manufacturer and purchase doses themselves – rather than being solely reliant on goodwill donations. While “thanking” COVAX for the role it has played in facilitating global COVID vaccine supplies, “going forward, we need the IMF to do the vaccine facility – to make it possible for countries to now access these vaccines through the structures put in place,” said Oramah. Those structures should include domestic manufacturing and procurement financed through African mechanisms, such as “Afreximbank, providing the initial financing, and then they refinance it in a way that makes it possible for the current accounts to carry all this – while the World Bank continues to provide institutional structures that are required to effectively administer vaccines.” Africa is region with lowest rates of vaccine coverage in the world Seth Berkley, CEO Gavi, The Vaccine Alliance Among all LMICs, Africa stands out for its particularly low vaccination rates so far – with under 3.5% of its population vaccinated – as compared to 60-70% in some high-income nations, African Union also said, speaking at a WHO press conference in Geneva. Of 5.2 billion doses delivered worldwide, only a tiny fraction have reached Africa, noted WHO Director General Dr Tedros Ahanom Ghebreyesus. And as things stand now, COVAX, the global vaccine facility, only has sufficient doses in the delivery pipeline to vaccinate roughly 20% of the population in the 91 lowest income countries by the end of the year, using some 1.4 billion purchased and donated doses, admitted Gavi CEO Seth Berkley at the WHO press conference. And it would hit 36% coverage by March, 2022. That falls far short of WHO’s target of 40% vaccination by December 2021 and 70% by March 2022. To reach those targets, “the world needs 2.4 billion additional doses to go into low income countries to get us to 40% by the end of this year,” Said Bruce Aylward, a special WHO advisor on the pandemic. “Those doses exist,” he said, citing recent pharma statements to the effect that there are now sufficient doses for everyone to go around – including high- and low-income countries. See related story Massive Increase in COVID-19 Vaccine Production May Mean Dose Surplus by Mid-2022, says IFPMA I think the question we ask is: where are those doses if there are enough for everybody?” Aylward asked. “And [the US Summit] next week is all about making sure there’s a clear path to ensuring they go to where they’re needed.” Barriers that have fouled vaccine access – both countries and manufacturers share blame Strive Masiyiwa, African Union COVID-19 envoy Speaking at the close of a two-day Geneva meeting, which also included Dr John Nkengasong, Africa CDC director and African Regional Director Matshidiso Moeti, the WHO and AU officials said that in they had reviewed in painstaking detail the various obstacles in the way of African vaccine access – and ways to overcome them. The challenges have included export bans, including the interruption of supplies from India in March 2020 when the subcontinent experienced its own COVID surge, but also barriers on the exports of vaccines and their inputs to a complex supply chain, they noted. But the African officials also repeated longstanding complaints against rich countries for vaccine hoarding, as well as against pharma for preferential sales to high income countries of huge vaccine quantities – in excess of actual population needs. “We want to buy from the same manufacturers,” said Masiyiwa. “But to be fair, those manufacturers know very well that they never gave us proper access. They gave access on a very different basis. “When they knew that supplies were restricted at the beginning, there was no production… they [pharma manufacturers] had a moral responsibility to ensure that others also had access,” he said. “And we find this very sad. It’s very sad. We could have addressed this very differently. We as Africa will now address this through setting up our own manufacturing capabilities.” Countries’ export restrictions also holding up distribution But countries’ export restrictions on vaccines as well as the many vaccine manufacturing inputs also continue to foul deliveries – and these are poorly understood, Masiyiwa said. . “My principal job is to negotiate with suppliers, and the suppliers have over the last 8-9 months, made it clear that the biggest challenge that they face are export restrictions, export restrictions are being operated right across the board. So, if those export restrictions aren’t there, where are the vaccines, because the production is happening? “We’re not seeing the vaccines, and we are being told by the suppliers, they are facing export restrictions. He added that without resolving, “this issue around the movement of the various ingredients that drive production… we will not even be able to get manufacturing effectively set up.” “We need to get these restrictions removed, and we had a very constructive discussion around this issue with the WTO yesterday,” he said. AU leaders call on India to remove its ban on AstraZeneca vaccine exports – now that domestic COVID surge has subsided WHO Director General Dr Tedros Adhanom Ghebreyesus Masiyiwa also appealed to India to resume its deliveries of AstraZeneca vaccines, produced by the Serum Institute of India – noting that the countries’ embargo on the export of vaccines, remains the most outstanding example of restrictions fouling distribution plans. The SII vaccines were a centerpiece of COVAX and African countries – until exports were abruptly cancelled in March. “We understood that at the time why they were put in place, it was because there was that massive surge in India, and we were incredibly, incredibly sympathetic. But we do now urge our colleagues to show sympathy to us, because we are the ones facing difficulty now. We need to see some of those vaccines begin to come through.” Finally, both African Union and WHO officials repeated their call to countries to support a waiver on intellectual property on COVID vaccines and therapeutics, currently being negotiated by the World Trade Organization – saying that this would help jump-start more manufacturing in developing regions. “American taxpayers, European taxpayers financed some of this intellectual property, and so it should be for the common good,” said Masiyiwa. “So we ask for this IP to be made available. It was a great miracle to have these vaccines, now let this miracle be available to all mankind”. Added WHO’s Tedros: “If it [a waiver] cannot be used now during this unprecedented condition or situation, then when is there a time when it can be used.” Image Credits: @WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Mothers and Babies’ Lives are Threatened by Fake and Sub-Standard Medicine 17/09/2021 Kawaldip Sehmi Health gains of Afghanistani women and children are in danger. Iconic places across the world will be lit up in orange on World Patient Safety Day on Friday to highlight the global campaign to reduce preventable deaths in childbirth and pregnancy and deliver safe maternal and newborn care. The International Alliance of Patients’ Organisation (IAPO), which I lead, and the alliance we are a member of,Fight the Fakes Alliance (FTF), will actively participate. Afghan women, many already fearing for their lives with the return of the Taliban, may well be watching too. In the two decades of civilian rule since the Taliban were defeated in 2001, infant and child mortality has dropped by some 70% – the fastest reduction among low-income countries. The rate went down from 191 deaths per 1000 live births in 2007 to 49 in 2018, according to Dr Mohammad Razai, an Afghan doctor working in London, What’s more, Razai says, maternal mortality was more than halved, declining from 1100 deaths per 100,000 live births to 396 as access to healthcare and sanitation rose dramatically. All of this is now at serious risk, as is the progress the world made in the same period to combat preventable deaths in pregnancy and childbirth, far too many of them caused by sub-standard and falsified medicines. The COVID-19 pandemic has negatively affected the often-fragile lives of mothers and their babies, and also brought a surge in the purchase and use of falsified medicines and the promotion of fake treatments. Ensuring mothers and babies get high-quality medicine That is why, on this special day, we are urging the global community to back moves to provide mothers and newborns with the extra care and high-quality medicines they need. Every single day, approximately 800 women and 6 700 babies lose their lives around the time of childbirth, according to the World Health Organization (WHO). In addition, nearly 5,400 babies are stillborn daily, with 40% of these deaths occurring in relation to labour and childbirth. Most stillbirths, maternal and newborn deaths and harm can be avoided by safe, respectful and quality care during pregnancy, childbirth and in the first days of a baby’s life. Sub-Saharan Africa and South Asia, two of the epicentres of fake medicines, account for 86% of these deaths. Safe and quality care provided by skilled health professionals working in supportive environments is key. But there are other, smaller things we can do. One is to ensure that patients are safe and secure and, critically, can trust their local health services. Fake and sub-standard medicines to manage hemorrhages, pre-eclampsia, eclampsia and sepsis proliferate in low- and middle-income countries (LMIC), according to a recent article. Almost half the samples of uterotonic medicines to induce or speed up labour failed quality tests. Three-quarters of ergometrine supplies failed, while almost 40% of oxytocin and misoprostol also failed. These drugs are deemed by the WHO to be “the most effective and safest drug of choice for the control, prevention, and management of postpartum haemorrhage — the leading cause of maternal mortality globally.” Fake products undermine patient trust In Nigeria, one of the richest countries in Africa, the likelihood of a woman receiving poor-quality or even fake oxytocin is very high, Devex reported, citing Dr Chimezie Anyakora, chief of party in Nigeria for the Promoting the Quality of Medicines. It also quotes a prominent local gynaecologist who recountedd how he had to go out on a Sunday and find genuine oxytocin after that which he had administered was manifestly not working. Fight the Fakes has also reported on the experiences of Ghanaian patient Victoria Amponsah who first received fake malaria medicine while two months’ pregnant then, at the end of her pregnancy, she was deceived by a fake version of oxytocin in an official-looking package. “Within 30 minutes, Victoria started sweating, shaking, vomiting and bleeding. She was in the hospital for two days, nearly lost her baby and had to return to the hospital every week after the incident for some time,” according to Fight the Fakes. In line with the WHO in its Global Patient Safety Action Plan 2021-2030, we call on the global and local communities to step up their efforts to stamp out unsafe and fake products. To build back better and ensure we have people-centred, accessible, acceptable, affordable, and quality healthcare and universal health coverage, we first must ensure patient safety. Safe care fosters trust in health systems, health professionals and medical products – but products that do not adhere to the highest standards of quality can undermine this trust Addressing fake and sub-standard medicine will require monumental effort on all our parts. But one key lesson from the pandemic is that we are all in this together. Kawaldip Sehmi is the CEO of the International Alliance of Patients’ Organisation (IAPO), a member of the Fight the Fakes Alliance. Kawaldip Sehmi Image Credits: Ahmadi/ UNICEF. Young African Innovators Lack Investment Not Creativity, Awards Ceremony Told 16/09/2021 Madeleine Hoecklin Panelists at the Africa Young Innovators for Health Award Ceremony, held on Thursday. Africa has the highest entrepreneurship rate in the world, yet greater financial resources are needed to ensure that innovation can be implemented to strengthen health systems and the welfare of health workers, said panellists at an innovation award ceremony on Thursday. The Africa Young Innovators for Health Award, co-organised by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Speak Up Africa, launched its first competition this year designed to highlight and support the work of pioneering young African entrepreneurs in the field of health innovations, particularly healthcare solutions to support healthcare workers. Attracting over 300 entries from 33 countries, the winners had developed innovations to assist in cancer diagnosis, health worker development and patient record retrieval. Winner Dr Conrad Tankou, CEO of Global Innovation and Creativity Space in Cameroon, developed GICMED, a suite of medical technologies that helps to screen and diagnose breast and cervical cancer in women. Dr Conrad Tankou, CEO of Global Innovation and Creativity Space, won first place for the Africa Young Innovators for Health Award. Breast and cervical cancer account for 50% of all new cancers in Sub-saharan African women. Healthcare workers can be trained to use the technology to remotely screen women with real-time pathology confirmation and connect them to a point of care for treatment. “It is an honour to receive the first-ever Africa Young Innovators for Health Award,” said Tankou. “With the Award’s financial and business mentorship support, we can upgrade our technologies and start scaling our solution much quicker by investing in manufacturing capabilities and building more local partnerships.” In second place was John Mwangi, CEO of Daktari Media Africa in Kenya, who established Daktari Online, which provides a professional development platform for healthcare workers. John Mwangi, CEO of Daktari Media Africa, won second place for the Africa Young Innovators for Health Award. Currently 13,000 health workers use the platform and it has been accredited by the regulatory bodies for pharmacists, pharmaceutical technologists, and physician assistants. “The practice of medicine requires continuous updating…and that’s what we seek to do,” said Mwangi. “We said why don’t we just democratize [access to information and professional development] and have this accessible to people even from remote areas.” The third-place winner, Dr Imodoye Abioro, CEO of Healthbotics in Nigeria, developed an artificial intelligence (AI) powered electronic medical record system – Mediverse – that utilizes blockchain to help healthcare workers input and retrieve patient records. Dr Imodoye Abioro, CEO of Healthbotics in Nigeria, won third place for the Africa Young Innovators for Health Award. The technology could work on any device and even in places where the internet has not yet reached. “We do not have enough healthcare workers for the disease burden we’re battling,” said Abioro. “The first thought we had was how do we make the healthcare worker more effective, how can he or she see more patients, how can he or she be smarter or faster.” “Mediverse is what we consider to be a solution that will be necessary for us to build a sustainable healthcare infrastructure in Africa upon,” Abioro added. “This could really revolutionize the way that healthcare workers are able to access the data they need about their patients in real time,” said Nicole Kayode, CEO and Founder of Medixus. The winners take home between US$15,000 and US$40,000 and will benefit from a business mentorship program, media exposure, technical training on intellectual property protection, and expert advice from an extensive network of stakeholders working across healthcare mediums. More investment needed Some 22% of Africa’s working-age population are starting businesses, “yet more investment in human capital is needed for this demographic potential to reap the development rewards it should,” said Thomas Cueni, Director-General of IFPMA. “We are confident that the winners of the African Young Innovators for health award will contribute to improving health systems and growing African economies,” added Cueni. “We don’t lack ideas or creativity, that’s not what’s missing,” said Dr Awa Marie Coll-Seck, Senegal’s Minister of State of Senegal and former health minister. “Among innovators, it’s often about the lack of financial resources for research…This is what stops them from concretising their ideas and developing prototypes.” “We need to give [the young innovators] the opportunity to develop ideas and their expertise,” said Coll-Seck. Africa is the youngest continent on the planet. By 2050, Africa’s youth population under the age of 24 will increase by nearly 50%. This presents an opportunity for rapid social and economic transformation, said the panelists. In 2019, sub-Saharan African countries were classified among the hundred best countries in terms of innovation. Africa facing massive shortages in healthcare workforce Africa bears a quarter of the global disease burden but faces a shortage of over two million healthcare professionals. Only 2% of the world’s healthcare workforce are from the continent. “Our world lacks about 18 million health workers globally and…Africa is the place that really suffers the most from it,” said Pape Gaye, President Emeritus of IntraHealth International, addressing the awards ceremony. The shortage of human and financial resources invested in the African healthcare system is putting a strain on healthcare workers and the broader national and regional health infrastructure. “COVID-19 has laid bare the underlying inequities and prejudices in existing healthcare,” said Dr Moredreck Chibi, the World Health Organization’s (WHO) Africa Advisor for Innovation. “Our young people [need to] take the bull by its horn and apply their intellectual capital to address some of these challenges.” Dr Moredreck Chibi, WHO Regional Advisor for Innovation for the Regional Office for Africa. “Only this approach will ensure Africa’s sustainable path for the future of health on the continent,” said Chibi. “As we are all aware, the COVID pandemic has been devastating and exposed the vulnerabilities of health systems across the globe, including in Africa,” said Dr Lindiwe Makubalo, WHO Assistant Regional Director for Africa. “There could be no better time to draw on the rich human capital, especially among young people, to find solutions to the problems that we are facing.” “COVID-19 has been a wake-up call for the continent. It is inevitable that we need to think outside the box to solve these problems,” said Makubalo. Innovation is a central component of public health “Innovation has always been the driving force of progress in public health, from vaccines to penicillin to the mapping of the human genome,” said Cueni. “Innovations have changed the world and this has never been more evident than with the COVID-19 pandemic.” Vaccines and treatments for COVID-19 were developed by pharma companies in record time due to large investments in research and a lot of innovation. “We have seen from smartphones to drones, there’s no doubt that technology and innovation are leapfrogging Africa and future young African entrepreneurs are playing a crucial role by developing creative ideas that can resolve the various health challenges on the continent,” said Cueni. Thomas Cueni, Director General of the IFPMA, at the award ceremony on Thursday. The panelists called on countries to support efforts and innovations of the youth by harnessing domestic resources through advocacy for partner financing and the creation of platforms to showcase initiatives. Partnerships with private sector are essential “We all know that innovation is best when it is tailored to the local context and that we should think about those who need it most when we’re creating them, and how we can create the most impact,” said Yacine Djibo, Founder and Executive Director of Speak Up Africa. Yacine Djibo, Founder and Executive Director of Speak Up Africa. Building science, technology, and innovation capacity, as well as stimulating the existing entrepreneurial culture in Africa should be a priority, said Djibo. Collaboration with the private sector will increase the opportunities for innovation and help the continent build sustainable health systems. “Health system strengthening and the potential of Africa’s private sector are crucially important for unleashing the entrepreneurial power of Africa’s young people,” said Cueni. “This will create innovative and compelling modern businesses, increase the capacity for these businesses to compete regionally and globally, attract both domestic and foreign investment, and diversify investment profiles.” This will contribute to job creation and economic growth across the region. “By leveraging its resources, expertise, networks, infrastructure, and assets, the private sector can focus on innovation for new technologies, systems, and processes, [and] can influence policy and form partnerships that will have continent-wide impact on the populations,” said Cueni. “We are extremely impressed by the quality of the applications we received. These applications are a shining example that young Africans are bursting with creativity and are constantly looking for local-based solutions that work,” said Djibo. With only one-fifth of applications to the innovation award coming from women, the IFPMA and Speak Up Africa have launched the Women Innovators Incubator to address the gaps in female-led innovation. Three female participants will receive financial support, mentorship, media training, expert advice on intellectual property protection, and access to a network of global health experts. Image Credits: Africa Young Innovators for Health Award, Africa Young Innovators for Health Award. Wealthy Countries Urged to Share 2 Billion Excess COVID-19 Doses, as South Africa’s mRNA Hub Prepares to Make ‘Moderna-like’ Vaccine 16/09/2021 Kerry Cullinan The South African mRNA hub aims to make Moderna-like vaccine. Countries with high COVID-19 vaccination rates have pre-purchased over two billion excess vaccine doses, limiting the supplies available for low- and middle-income countries (LMIC). This emerged from a meeting on Thursday between the heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization – the multilateral Task Force – and CEOs of leading vaccine manufacturing companies. Meanwhile, the South African mRNA technology transfer hub set up in July to enable Africa to manufacture its own vaccines is moving ahead with plans to make a “Moderna-like” vaccine – despite a lack of co-operation from either mRNA manufacturer, Moderna or Pfizer-BioNTech. This was confirmed to Health Policy Watch by Dr Marie-Paule Kieny, Chair of the Board of the Medicines Patent Pool in Geneva and President of the French Scientific Committee on COVID-19 vaccines. “The mRNA hub doesn’t need direct transfer of technology from Pfizer/BioNTech or Moderna, as enough information on production process is available publicly and as there are no patent on mRNA vaccines in any African country,” said Kieny, who recently visited South Africa to work with local hub partners. “The hub will therefore work with technical experts to recreate a new ‘Moderna-like’ vaccine,” added Kieny. Appeal to swap doses, deliver to COVAX and AVAT To alleviate COVID vaccine shortages in LMICs, the task force called on wealthy countries to urgently “swap their near-term delivery schedules with COVAX and the African Vaccine Acquisition Task Force (AVAT)”, meet their dose donation pledges with “unearmarked upfront deliveries to COVAX”, and release vaccine companies from options and contracts to enable these doses to be delivered to LMICs. Without these urgent steps, the world is unlikely to meet the WHO’s target of vaccinating 40% of the global population by the end of the year. “Despite adequate total global vaccine production in the aggregate, the doses are not reaching LMICs in sufficient amounts, resulting in a crisis of vaccine inequity,” the task force said. It also appealed for transparency about the supply of vaccines, calling on vaccine manufacturers to share details on month-by-month delivery schedules for all vaccine shipments, especially for COVAX and AVAT. It also called on all countries to urgently address export restrictions, high tariffs and customs bottlenecks on COVID-19 vaccines, raw materials and supplies. The task team welcomed the pharmaceutical CEOs’ willingness to ‘work collectively to end vaccine inequity” and “readiness” to form a joint technical working group with the Task Force to exchange and coordinate information on vaccine production and deliveries. However, the big pharmaceutical companies have been unwilling to work with the mRNA hub. ‘No point’ in mRNA transfer In response to a Health Policy Watch question, Pfizer CEO Albert Bourla said that he didn’t see the point as the tech transfer “would take years”, and that producing mRNA vaccines was what Pfizer did. Kieny confirmed that the Medicines Patent Pool, WHO and others had reached out to the mRNA vaccine manufacturers “but up to this point, the companies have not been interested”. Vaccine manufacturers are apparently wary of new manufacturers competing for raw materials and customers. Shortly after the mRNA hub was announced, Pfizer revealed that it had made a deal with South African pharmaceutical company and hub member Biovac, to “fill and finish” around 100 million vaccines destined for Africa. Kieny described this as “an excellent step forward”, as Biovac will receive technology transfer from Pfizer for the fill-finish part of their mRNA vaccine, “especially as the Pfizer contract does not claim exclusivity”. “Biovac will therefore also become the first African manufacturer with a product resulting from technology transfer of the full production cycle from the hub,” said Kieny. Image Credits: Gavi . Finding Sustainable Solutions to WHO’s Financial Woes 16/09/2021 Pokuaa Oduro-Bonsrah Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health and chair of the WHO Working Group on Sustainable Finance. For a long time, the World Health Organization (WHO) has experienced immense financial stress resulting in numerous debates on how to remedy its economic woes. A working group set up earlier this year has been tasked with finding long-term solutions. Each year the representatives of some 194 countries make demands on what work should be carried out by the WHO, but the money needed to carry out the requests is severely lacking. Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health, and chair of WHO’s Working Group on Sustainable Funding, recalls explaining the situation to his daughter who asks what the money problem is. “The family decides to have breakfast with lots of friends. We need to buy 20 buns from the bakery, and there’s a plan in place because we know our guests want different buns. I send my daughter to the bakery to buy 20 different buns but only give her enough money for two,” he says. Without enough money, Kümmel’s daughter would have to beg for money on the way to the store. Some generous passersby might give her some change, but on the condition that she spends it on specific types of buns. She might be able to bring back home all 20 buns but to a large extent they will not be the ones ordered. “It sounds absurd when we put it this way but the member states of the WHO, in the same way, do not provide the finances to fund their own priorities agreed to by these countries,” Kümmel told Geneva Solutions. Increasingly, individual donors have been providing funding money for these “buns”, but often face criticism for financing projects that personally interest them. Meanwhile, the funds needed to execute the activities of the ever-broadening agenda set by the World Health Assembly (WHA) are lacking. COVID-19 has revealed major discrepancies between the expectations of the WHO and its de facto ability. “The pandemic has shown that we need a strong WHO, now more than ever, and it is clear that it is not strong enough,” Kümmel said. Sustainability lens For years discussions have circled around WHO’s funding, prompting its Director-General, Dr Tedros Adhanom Ghebreyesus, to reflect on how these conversations have “remained rather abstract” in a report delivered to the Executive Board. As a result, the WHO created the Working Group on Sustainable Financing (WGSF), which is tasked with finding long-term solutions to the body’s financial troubles. Kümmel notes that although finances remain a popular topic amongst the organisation’s members, this is the first time a “sustainability” lens is being adopted. He adds that everyone shares the view that a stronger WHO is needed, which requires more stable sources of long-term funding. The alternative, continuing with the status quo, poses a threat to global health security and the achievement of the Sustainable Development Goals. “There needs to be a completely new approach to ensure the WHO has the right finances in place in order to fulfil the world’s expectations,” he says. The WSFG is working on a proposal that will “enable WHO to have the robust structures and capacities needed to fulfil its core functions,” as highlighted in the meeting report. The final report and recommendations will be taken forward to the WHO’s executive board in January 2022. Concluding their third and most recent meeting in June, the group has already explored different financing models, including other global health actors’ funding structures that could help recharge the WHO’s coffers, drawing on lessons from other health actors. Adopting the Global Fund’s so-called replenishment model, for example, would mean raising funds in multi-year cycles. Kümmel says the WHO budget could at least be partially funded this way. Dr Tedros addressing the WHO’s 149th Executive Board meeting Since taking office in 2017, Ghebreyesus has made broadening the WHO’s funding base one of the organisation’s main priorities. In 2019, he announced plans to establish the WHO Foundation to secure funds from the public, individual major donors and corporate partners. The launch of the independent grant-making body came amid controversy over former US President Donald Trump’s decision to halt funding from the US, the WHO’s single largest donor. The move was later reversed by current President Joe Biden but it had already exposed the health organisation’s heavy dependence on a few major donors. Approved for 2020-2021, the budget is $5.8 billion, which reflects a $1.4bn increase from the previous biennium, mostly needed for the Covid-19 response. About 16 per cent of this figure stems from mandatory payments known as assessed contributions, paid by its members, which over the last two decades or so, have remained flat at one billion US dollars. The other way is through voluntary contributions, secured from governments, other UN agencies and the private sector, which make up the majority of the budget. In recent years the top voluntary contributors, in addition to the US, have included the United Kingdom, Germany and the Bill and Melinda Gates Foundation. Yet, private players such as the Gates Foundation have come under fire for having some of the most powerful and influential voices in global health, raising questions about the WHO’s independence. Praise for ‘Big Philanthropy’ donors Kümmel, however, believes “these voluntary generous donors should be praised because they provide the needed funding in the absence of member states”. The vast majority of funds coming from the private sector go to the Polio Eradication Initiative, he points out. “If the WHO didn’t receive these resources, we wouldn’t even be close to an eradication of polio because many member states just don’t put the money on the table,” he adds. In the last 10 years, the UN health agency has depended heavily on voluntary contributions, which can include both flexible funds untied to specified causes as well as money that can only be spent on activities decided by the donor. Still, in 2018/2019, almost 70 % of the overall budget was financed by funds allocated for specific purposes. The working group has considered whether the core mandate of the WHO should be fully funded by “un-earmarked” flexible contributions, which favours the organisation’s aspired ways of working, whilst also exploring the importance of expanding the WHO’s donor base. Following the recommendations of the Independent Panel for Pandemic Preparedness and Response (IPPPR), who share the view that two thirds of assessed contributions should be dues paid by member states, the working group are toying with the idea of whether this figure should be at least 50 per cent, a proposal that has been put forward to the regional committees, which Kümmel expressed had been received constructively and positively. In addition, the group has put forward to the regional committees whether member states would support and agree to the proposal on increasing assessed contributions as well as adopt an incremental implementation schedule at next May’s 75th WHA. Contributions from all member states For Kümmel, all member states should contribute regardless of their economic status. However, he agrees that some countries experience severe financial challenges, thus the current mechanisms in place ensure financial possibilities are accounted for. At the moment each country is assigned a share of the assessed budget through the WHO’s scale of assessments proportional to the size of its economy, but ultimately it is up to member states to fork out the money, particularly if it is un-earmarked funding. Coordinated efforts across regions are vital, especially when faced with health crises such as the Covid-19 pandemic. If paired with the loss of funds from major contributors, the results can be devastating. In 2020, the US fell to the third largest donor position, providing about 8% of the overall budget in the first three quarters. Biden has since restored ties with the body and in February pledged $4bn to the WHO-backed COVAX initiative to boost the equitable distribution of COVID vaccines, however, the full effect of this is yet to be seen. Germany has similarly reinforced its support to WHO’s work and fight against COVID. Earlier this month the WHO launched its new Hub for Pandemic and Epidemic Intelligence in Berlin. Germany has said it will make an initial $100 million investment to prop up the facility. The Hub is said to focus on “collaborative intelligence”, where all 194 member states, scientific institutions and civil society could share information openly. As the coronavirus has demonstrated, the world is not ready to rapidly spot and tackle potential pandemics. The working group believes preparing the health body against such future challenges with the appropriate resources is crucial. “I think that it is quite clear that the strengthening of WHO post-COVID is a key priority for many countries including Germany. Member states who really want to strengthen WHO understand that ensuring sustainable financing to WHO is one of the key pillars of this,” Kümmel urged. “We are very supportive of constructive multilateralism in global health. WHO is the global health forum where everyone sits at the table, all 194 Member States, it has a broad global health mandate, and it is fully inclusive.” This article was first published by Geneva Solutions. Image Credits: WHO/ Violaine Martin, WHO. World Leaders Call on Future German Chancellor to Support TRIPS Waiver 15/09/2021 Kerry Cullinan German Health Minister Jens Spahn and German Chancellor Angela Merkel have staunchly opposed the TRIPS waiver. More than 140 former heads of state and Nobel laureates have called on the three candidates in line to be the next German chancellor to declare themselves in favour of waiving intellectual property on COVID-19 vaccines and transferring vaccine technologies. Germany is leading the European Commission’s refusal to accept the so-called TRIPS waiver proposal put forward by South Africa and India at the World Trade Organisation (WTO). However, German elections on 26 September could unseat Angela Merkel’s ruling Christian Democratic Union Party, which has steadfastly opposed the TRIPS waiver – apparently in support of BioNTech-Pfizer. In the letter, addressed to Annalena Baerbock, Olaf Scholz, and Armin Laschet, sent on Wednesday, the signatories stress that German support for waiving patents is vital to overcoming vaccine monopolies, transferring vaccine technology and scaling up vaccine manufacturing around the world to prevent millions more deaths from COVID-19. Signatories include former French President François Hollande, former UK Prime Minister Gordon Brown, former Colombian President Juan Manuel Santos, former Malawian President Joyce Banda and Helen Clark, New Zealand’s former prime minister. Nobel prize winners include Professor Joseph Stiglitz, Professor Francoise Barre-Sinoussi and Elfriede Jelinek. End the pandemic They express deep concern with Germany’s “continued opposition to a temporary waiver of the World Trade Organization’s (WTO) intellectual property rules”, at a time in which “the artificial restriction on manufacturing and supply is leading to thousands of unnecessary deaths from COVID-19 each day”. Less than 2% of adults are fully vaccinated in low-income countries compared to almost 50 % in high-income countries. The TRIPS waiver on COVID-19 vaccines, proposed by India and South Africa in October 2020, is supported by over 100 countries including the United States and France in doing so. “Having helped create the most successful vaccine technology against COVID-19, by overcoming pharmaceutical monopolies and insisting that the technology be shared, Germany has the ability to help end this pandemic,” according to the letter. It also calls on the next Chancellor to ensure that German pharmaceutical companies openly and rapidly share life-saving mRNA vaccine technology with qualified producers around the world. Commenting on the letter, New Zealand’s Clark stressed: “Germany’s support for a TRIPS waiver in the exceptional circumstances presented by COVID-19 would send a clear signal that all peoples should be able to benefit speedily from available vaccines and therapeutics. Widespread vaccination now and further scaling up of vaccine production will play a significant role in curbing the pandemic.” Extraordinary power Meanwhile, Nobel laureate Joseph Stiglitz, said that the new Chancellor of Germany will “hold extraordinary power to turn the tide on this horrific pandemic”. “Intellectual property rules are today locking out people across the world from the benefits of life-saving science – it is time for Germany to ensure the transfer of vaccine technologies and join the rest of the world in backing a temporary waiver at the WTO,” he added. Earlier in the week, Belgian Green Sarah Matthieu, a Member of the European Parliament, said that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. The letter was coordinated by the People’s Vaccine Alliance, a coalition of more than 70 organizations including Club de Madrid, Global Justice Now and UNAIDS. Image Credits: Clemens Bilan. Much More Needs to be Done About Unhealthy Impact of Meat 15/09/2021 Madeleine Hoecklin To address the climate impacts of livestock production, people need to halve their meat-eating, says the Meat Atlas 2021. Twenty multinational meat and dairy conglomerates emit more greenhouse gases than Germany, Britain, or France, according to the Meat Atlas which was launched recently by Friends of the Earth and the Heinrich Böll Stiftung. A range of health issues associated with meat-heavy diets also require attention in the push toward more sustainable practices, according to the World Health Organization (WHO), ahead of next week’s UN Food Systems Summit scheduled for 23 September and the Glasgow Climate Summit, COP 26, which opens 31 October. Around 840,000 deaths annually are attributable to diets high in processed meats, and some 40,000 deaths are linked to diets high in red meats, according to the WHO’s Dr Maria Neira, Director of the Department of Environment, Climate Change and Health, in an interview with Health Policy Watch. Millions more premature deaths have been associated with people eating diets high in saturated fats from meat, and not eating enough fruits, vegetables, fibre, legumes, and other plant-based foods. The consequences of this are malnutrition, hypertension, heart disease and other chronic disease ailments. “[We need to focus on] reducing the consumption of meat and increasing the consumption of plant-based foods, and at the same time [developing] more sustainable food systems, a better recovery from COVID-19, a strategy to tackle climate change, and promoting health,” Neira told Health Policy Watch. For decades, the WHO has recommended replacing high saturated-fat, high-calorie meats and processed foods with unprocessed foods, fibre-rich foods, fresh fruits and vegetables. Health and climate synergies The health and climate synergies are elaborated on in WHO’s recent Compendium of guidance on health and the environment, which covers issues from air pollution to biodiversity, clean water and sanitation. “Current patterns of food production and consumption use much of the world’s resources on land and water and contribute significantly to climate and ecosystem change through for example deforestation, loss of biodiversity and GHG emissions,” according to the compendium. “This is aggravated by the fact that about one third of food produced for human consumption is wasted,” it adds. “The expansion of industrial agriculture at the expense of nature puts our global health at risk,” according to the Meat Atlas. It calls on countries to “develop an action plan to promote less and better consumption and production of meat, dairy and eggs, to shift away from industrial farming, and to support better animal farming and healthy, plant-rich diets.” Meanwhile, the WHO’s compendium provides over 400 interventions and recommendations for action to address the overconsumption of red and processed meat. Neira argues that the world has to move to decarbonisation ”with a high level of ambition and speed”. This can be done through more regulation of meat producers, raising awareness about the health implications of high meat consumption, and shifting consumption decisions in favor of sustainability and health. Impact on water and land Livestock production produces 14.5% of the world’s greenhouse gas emissions, but also uses vast amounts of water. Agriculture uses some 92% of the global water footprint and 29% of this is used in animal production. Agriculture uses three times as much available fresh water than 50 years ago. Three-quarters of all agricultural land is used to raise livestock and to grow the crops to feed them – but livestock corporations also drive water pollution, deforestation, pesticide use, and biodiversity loss. While climate campaigners push for reducing meat consumption, the demand for meat is forecasted to continue to grow over the next decade, warns the Meat Atlas. To meet this demand, meat production is becoming more industrialised, marginalising smaller meat and milk producers that represent more sustainable food production models. Antimicrobial resistance Industrial livestock production also increases the risk of zoonotic disease transmission and antimicrobial resistance (AMR), through inappropriate and largely unregulated agricultural practices. Some 73% of the antibiotics sold worldwide are used on animals and the proportion of industrial animal agriculture that routinely uses antibiotics is rising. Antibiotics are used as growth stimulants in animals and can compensate for shortcomings in hygiene, management, and the care of animals in livestock production. But the overuse or misuse of antibiotics in food-producing animals can lead to AMR in humans that cause longer illnesses, more frequent hospitalizations, and treatment failures. According to the ‘Meat Atlas’, half the chicken samples from major poultry producers in five European Union countries were contaminated with antibiotic-resistant pathogens. “Antimicrobial resistance linked to the excessive and inappropriate use of antibiotics in animal and human healthcare leads to an estimated 33,000 human deaths in the EU every year,” said the Meat Atlas. Zoonotic diseases Freshly slaughtered animals and processed meat in a market in Wuhan, Hubei, China Certain wild animals – including rodents, bats, carnivores and monkeys – are among those most likely to harbour zoonotic diseases that are harmful to humans, according to the Meat Atlas. The coronavirus, which originates in bat populations, is an example. One of the most favoured hypotheses put forward by the WHO scientists investigating the origins of the SARS-C0V2 virus causing the current pandemic is that it came from wild animals. Approximately 60% of all infectious diseases in humans are zoonotic and almost three-quarters of known zoonoses can be traced to wildlife, for example by people eating the meat of wild animals. The industrialized production of wild animals or domesticated livestock often serve as a bridge for transmission, thus posing a “dire threat to global human health,” said the Meat Atlas. Emerging pathogens are crossing the animal-human barrier with increased frequency or greater impact. The crowded conditions used to house animals in industrialised livestock production systems allow infections to easily mutate and jump to human hosts. In addition, the destruction of ecosystems to cultivate land for agricultural production is bringing people into closer contact with wild animals. As consumption patterns shift towards more meat, the risk of contracting zoonotic diseases will increase. Shifting to plant-based foods Trends in meat production (Meat Atlas 2021) Shifting diets towards plant-based foods could help reduce diet-related non-communicable disease risks and global disease burdens of obesity, cardiovascular disease, and diabetes – and slow the rise in methane emissions associated with livestock production. Plant-based and minimally processed foods “must be made available, accessible, affordable, safe, culturally acceptable and desirable to the whole population including the most vulnerable,” says the WHO’s compendium report. The world will need tailored approaches to curbing meat consumption, said Neira. “For more industrialised countries, we can move into stimulating the reduction of meat consumption and promoting healthy diets…[with] plant-based or unprocessed food,” Neira said. “A policymaker in a developed country…can go with more ambition on promoting [a plant-based diet], while in developing countries…we need to have a holistic view of their protein intake…and ensure that people will have access to foods that meet their protein needs every day,” she said. Interventions from health policymakers will require advocacy campaigns with clear arguments to “promote the importance of reducing meat consumption and increasing consumption of plant-based foods for the health of the people,” said Neira. “WHO will go to COP26 with a very strong report called the ‘Health Argument for Climate Action’ and we will put the focus on the health benefits that can be obtained be mitigating the causes of climate change and promoting a more sustainable food system from the beginning to the end,” said Neira. Image Credits: Friends of the Earth and the Heinrich Böll Stiftung, Arend Kuester/Flickr, Meat Atlas 2021. Pressure Builds on Biden to End TRIPS Waiver Impasse, Enable Equitable Access to COVID Vaccines 15/09/2021 Kerry Cullinan President Joe Biden speaking in Germany after a G7 meeting. Pressure is mounting on US President Joe Biden to provide global leadership to ensure equitable access to COVID-19 vaccines in the face of the European Commission’s refusal to support a waiver on intellectual property rights. Biden is expected to host a global leaders’ summit on COVID-19 alongside the United Nations General Assembly next week, and US officials are lobbying countries to support targets to end the pandemic centred on how to get 70% of people vaccinated by late 2022. African leaders hope that Biden’s COVID-19 summit will lead to more equitable access to vaccines: WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response Negotiations over the suspension of intellectual property rights for COVID-19 vaccines, therapeutics and diagnostics, the TRIPS waiver, have stalled at the World Trade Organization (WTO) in the face of opposition from the European Union. But if the US put forward a text on waiver, this would reinvigorate the talks, appealed South African trade ministry advisor Zane Dangor on Tuesday. South Africa and India are co-sponsors of the waiver. “Action by the US will be particularly potent to shift the needle in the negotiations and make people come around the table and discuss these issues,” said Dangor, one of the key officials involved in the WTO TRIPS waiver negotiations. In May, Biden took the world by surprise when he announced US support for the waiver proposal – although only in relation to COVID-19 vaccines. But the European Commission, particularly Germany, has refused to budget. “The European Union would like to kick the discussions further down the road,” said Dangor, adding that the EU had made it known this week that it was not in favour of a decision on the TRIPS waiver being made at the upcoming WTO Ministerial on 30 November. Zane Dangor, Special Adviser to South Africa’s Trade Minister. “We need commitment on a text from the US that can be tabled and negotiated with South Africa, India and other co-sponsors so that we can have an outcome and move to get to the business of actually ensuring that we get jabs in arms of those who need most and have equitable access,” Dangor told a press briefing organised by Public Citizen. “Not only do we need to get the WTO waiver done, but we require vaccine recipes to be shared via broad tech transfer to speed expansion of COVID medicine supplies,” added Dangor. In July, the World Health Organization (WHO) announced that it had established a “tech transfer hub” in South Africa to enable African companies produce mRNA vaccines – but the mRNA manufacturers, Pfizer-BioNTech and Moderna, have refused to join the hub. Last week, in response to a recent Health Policy Watch question, Pfizer CEO Albert Bourla said: “I’m not sure what is the point of transferring technology that it is going to take years to transfer. And, by the way, this is what we do. I’m not sure I understand what they want, to give it someone else to do?” European Commission counter-proposal is ‘big air’ Belgian Green Sarah Matthieu, a Member of the European Parliament, believes that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. Matthieu said that the German elections on 26 September may shift the power balance it that country and change the position of Germany on the waiver. US Congressman Ro Khanna said that Biden had shown “strong leadership on the TRIPS waiver” but he now had to “convince our European allies, who are often fond of lecturing the United States about moral responsibility, to live up to theirs”. Khanna added that the US had been “instrumental in the development of these vaccines”, including by “funding some of the critical research” and “providing purchase agreements that mitigated the risk for pharmaceutical companies”. Although the US government has indicated it would only support a waiver for vaccines, Khanna told the MSF briefing that this should extend to therapeutics. “More broadly, we need to have a better system for how we incentivize the production and distribution of drugs to the poor and for issues of that really affect large numbers of population,” said Khanna. “A purely for-profit model of developing medicines may lead to an over-investment in acne treatment and an under-investment of treatment on some of the biggest diseases. “Not only do we need a TRIPS waiver, but we need to think about how can we incentivize the development and the production of medicine that actually are affecting the urgent needs of many people in the United States and around the world.” Waiver debate is about pharma profit, says Stiglitz Professor Joseph Stiglitz Nobel laureate and Columbia University economist Professor Joseph Stiglitz described the waiver debate as being about the ability of the drug companies to exercise monopoly power to get substantial profits, rather than a reasonable return on their investment. “Drug companies’ concern is maximising profits. That’s their business model. And maximising profits means restricting supply because by restricting supply, you increase price, and by increasing price you increase profits,” he stressed. Referring to Pfizer’s recent talk about selling its vaccine for $175 a dose, Stiglitz said this was based on the belief that there was going to be a vaccine shortage, which would enable the company to extract a monopoly price. Like Khanna, Stiglitz stressed that the development of the COVID-19 vaccines was an international effort that had involved significant investment from various governments as well as scientists from around the world. “Germany’s particular view on this is especially peculiar because the German company, BioNTech, has already sold its international rights to Pfizer so the waiver is not even going to affect its profits,” he said, describing the EU’s opposition to the waiver as “objectionable” and “unconscionable”. Confusion about TRIPS waiver Stiglitz stressed that there was also confusion about the TRIPS waiver. “First, this is not the abolition of property rights. [Pharmaceutical companies] still get compensated for using their intellectual property rights. So, it’s not taking away their property rights. Its just saying we are in an emergency, and in this emergency, intellectual property rights have to be available more widely,” Stiglitz told the MSF briefing. “Secondly, it’s not even a change in the intellectual framework because, since the beginning of the WTO, we’ve recognised the principle of compulsory licenses. This is effectively just a compulsory license… to lower transaction costs. Lower transaction costs in the midst of the pandemic, where there’s a kind of urgency that we don’t normally have, is absolutely essential,” he added. “We’ve enacted voluntary licenses. The world has debated this. It debated it when the WTO TRIPS initially adopted it. It was really debated that in the context of HIV/AIDS, which reaffirmed the principle of compulsory licenses.” “We are in the midst of what some people call the new cold war. On the one hand, there are authoritarian governments like Russia and China, and then, on the other hand, there are democracies. We would like the democracies to win, but we’re not putting a good face on democracy when we say our democracies put profits over lives. “Russia has been very actively engaged in vaccine diplomacy. It’s made its vaccine available, say in a country like Argentina. But not only has it made its vaccine available, it’s actually actively engaged in transferring technology and enabling countries to build plants to produce the vaccine. And I’m afraid we’re losing this particular battle.” Civil society groups demonstrate outside embassies of countries that oppose a temporary WTO patent waiver on COVID-19 health products. Image Credits: CNBC, Munich Security Conference, Tadeau Andre/MSF . WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response 14/09/2021 Elaine Ruth Fletcher Left-right: Strive Masiyiwa, AU COVID envoy, Dr Tedros Adhanom Ghebreyesus, WHO Director General, Dr John Nkengasong, Africa CDC diector After months of frustrated efforts to unlock global vaccine supplies for the African continent, WHO and African Union leaders are now pinning their hopes on US President Joe Biden’s reported plan to call heads of state to a “Global Pandemic Summit” on the sidelines of the United Nations General Assembly, which opened today, as a way out of the current deadlock. Biden reportedly is circulating a plan to hold the summit on 22 September – with the aim of reaching a joint commitment to the vaccination of 70% of the world’s population by the GA session in September 2022, ensuring that “additional doses and adequate supplies are available to all countries”, according to a set of targets circulating among embassies, and obtained by the Washington Post. To achieve that, the Biden plan for the Global COVID-19 Summit also calls for “expediting delivery of approximately 2.0 billion previous committed doses.. including by converting existing dose sharing pledges into near-term deliveries, swapping delivery dates to secure earlier delivery of doses to LIC/LMICs, and eliminating cross-border bottlenecks in the supply of vaccines and critical inputs.” But speaking at Tuesday’s press conference following two days of meetings in Geneva, African Union and African Centers for Disease officials stressed that the era of “pledges” for vaccine donations to Africa, needs to end and investments in African vaccine manufacturing to begin, as part of any ‘New Deal’ on pandemic response in low- and middle-income (LMICs) countries. “”We, as the African Union, are calling on a permanent structure,” said Masiyiwa, a billionaire entrepreneur and AU Special Envoy for COVID-19, “and this is something that we will be calling on to be put in place at this summit that President Biden is convening. “We strongly believe that the pledge architecture, where countries gathered together and made pledges…. has had its day. Let us now have a permanent structure. Vaccine sharing is good. But we shouldn’t have to be relying on vaccine sharing, when we can come to the table, put structures in place, and then say that we also want to buy.” Calls for new African vaccine facility Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank This should involve the creation of a new, and permanent African vaccine facility, supported by the African Union, World Bank and International Monetary Fund, said Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank. Afreximbank has provided financing for the continent’s purchase of some 400 million Johnson & Johnson vaccines – backed by the World Bank. But Benedict stressed this is only the beginning of a long road that will require the procurement of booster doses as well. And so a more permanent finance mechanism is needed for countries to manufacturer and purchase doses themselves – rather than being solely reliant on goodwill donations. While “thanking” COVAX for the role it has played in facilitating global COVID vaccine supplies, “going forward, we need the IMF to do the vaccine facility – to make it possible for countries to now access these vaccines through the structures put in place,” said Oramah. Those structures should include domestic manufacturing and procurement financed through African mechanisms, such as “Afreximbank, providing the initial financing, and then they refinance it in a way that makes it possible for the current accounts to carry all this – while the World Bank continues to provide institutional structures that are required to effectively administer vaccines.” Africa is region with lowest rates of vaccine coverage in the world Seth Berkley, CEO Gavi, The Vaccine Alliance Among all LMICs, Africa stands out for its particularly low vaccination rates so far – with under 3.5% of its population vaccinated – as compared to 60-70% in some high-income nations, African Union also said, speaking at a WHO press conference in Geneva. Of 5.2 billion doses delivered worldwide, only a tiny fraction have reached Africa, noted WHO Director General Dr Tedros Ahanom Ghebreyesus. And as things stand now, COVAX, the global vaccine facility, only has sufficient doses in the delivery pipeline to vaccinate roughly 20% of the population in the 91 lowest income countries by the end of the year, using some 1.4 billion purchased and donated doses, admitted Gavi CEO Seth Berkley at the WHO press conference. And it would hit 36% coverage by March, 2022. That falls far short of WHO’s target of 40% vaccination by December 2021 and 70% by March 2022. To reach those targets, “the world needs 2.4 billion additional doses to go into low income countries to get us to 40% by the end of this year,” Said Bruce Aylward, a special WHO advisor on the pandemic. “Those doses exist,” he said, citing recent pharma statements to the effect that there are now sufficient doses for everyone to go around – including high- and low-income countries. See related story Massive Increase in COVID-19 Vaccine Production May Mean Dose Surplus by Mid-2022, says IFPMA I think the question we ask is: where are those doses if there are enough for everybody?” Aylward asked. “And [the US Summit] next week is all about making sure there’s a clear path to ensuring they go to where they’re needed.” Barriers that have fouled vaccine access – both countries and manufacturers share blame Strive Masiyiwa, African Union COVID-19 envoy Speaking at the close of a two-day Geneva meeting, which also included Dr John Nkengasong, Africa CDC director and African Regional Director Matshidiso Moeti, the WHO and AU officials said that in they had reviewed in painstaking detail the various obstacles in the way of African vaccine access – and ways to overcome them. The challenges have included export bans, including the interruption of supplies from India in March 2020 when the subcontinent experienced its own COVID surge, but also barriers on the exports of vaccines and their inputs to a complex supply chain, they noted. But the African officials also repeated longstanding complaints against rich countries for vaccine hoarding, as well as against pharma for preferential sales to high income countries of huge vaccine quantities – in excess of actual population needs. “We want to buy from the same manufacturers,” said Masiyiwa. “But to be fair, those manufacturers know very well that they never gave us proper access. They gave access on a very different basis. “When they knew that supplies were restricted at the beginning, there was no production… they [pharma manufacturers] had a moral responsibility to ensure that others also had access,” he said. “And we find this very sad. It’s very sad. We could have addressed this very differently. We as Africa will now address this through setting up our own manufacturing capabilities.” Countries’ export restrictions also holding up distribution But countries’ export restrictions on vaccines as well as the many vaccine manufacturing inputs also continue to foul deliveries – and these are poorly understood, Masiyiwa said. . “My principal job is to negotiate with suppliers, and the suppliers have over the last 8-9 months, made it clear that the biggest challenge that they face are export restrictions, export restrictions are being operated right across the board. So, if those export restrictions aren’t there, where are the vaccines, because the production is happening? “We’re not seeing the vaccines, and we are being told by the suppliers, they are facing export restrictions. He added that without resolving, “this issue around the movement of the various ingredients that drive production… we will not even be able to get manufacturing effectively set up.” “We need to get these restrictions removed, and we had a very constructive discussion around this issue with the WTO yesterday,” he said. AU leaders call on India to remove its ban on AstraZeneca vaccine exports – now that domestic COVID surge has subsided WHO Director General Dr Tedros Adhanom Ghebreyesus Masiyiwa also appealed to India to resume its deliveries of AstraZeneca vaccines, produced by the Serum Institute of India – noting that the countries’ embargo on the export of vaccines, remains the most outstanding example of restrictions fouling distribution plans. The SII vaccines were a centerpiece of COVAX and African countries – until exports were abruptly cancelled in March. “We understood that at the time why they were put in place, it was because there was that massive surge in India, and we were incredibly, incredibly sympathetic. But we do now urge our colleagues to show sympathy to us, because we are the ones facing difficulty now. We need to see some of those vaccines begin to come through.” Finally, both African Union and WHO officials repeated their call to countries to support a waiver on intellectual property on COVID vaccines and therapeutics, currently being negotiated by the World Trade Organization – saying that this would help jump-start more manufacturing in developing regions. “American taxpayers, European taxpayers financed some of this intellectual property, and so it should be for the common good,” said Masiyiwa. “So we ask for this IP to be made available. It was a great miracle to have these vaccines, now let this miracle be available to all mankind”. Added WHO’s Tedros: “If it [a waiver] cannot be used now during this unprecedented condition or situation, then when is there a time when it can be used.” Image Credits: @WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Young African Innovators Lack Investment Not Creativity, Awards Ceremony Told 16/09/2021 Madeleine Hoecklin Panelists at the Africa Young Innovators for Health Award Ceremony, held on Thursday. Africa has the highest entrepreneurship rate in the world, yet greater financial resources are needed to ensure that innovation can be implemented to strengthen health systems and the welfare of health workers, said panellists at an innovation award ceremony on Thursday. The Africa Young Innovators for Health Award, co-organised by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Speak Up Africa, launched its first competition this year designed to highlight and support the work of pioneering young African entrepreneurs in the field of health innovations, particularly healthcare solutions to support healthcare workers. Attracting over 300 entries from 33 countries, the winners had developed innovations to assist in cancer diagnosis, health worker development and patient record retrieval. Winner Dr Conrad Tankou, CEO of Global Innovation and Creativity Space in Cameroon, developed GICMED, a suite of medical technologies that helps to screen and diagnose breast and cervical cancer in women. Dr Conrad Tankou, CEO of Global Innovation and Creativity Space, won first place for the Africa Young Innovators for Health Award. Breast and cervical cancer account for 50% of all new cancers in Sub-saharan African women. Healthcare workers can be trained to use the technology to remotely screen women with real-time pathology confirmation and connect them to a point of care for treatment. “It is an honour to receive the first-ever Africa Young Innovators for Health Award,” said Tankou. “With the Award’s financial and business mentorship support, we can upgrade our technologies and start scaling our solution much quicker by investing in manufacturing capabilities and building more local partnerships.” In second place was John Mwangi, CEO of Daktari Media Africa in Kenya, who established Daktari Online, which provides a professional development platform for healthcare workers. John Mwangi, CEO of Daktari Media Africa, won second place for the Africa Young Innovators for Health Award. Currently 13,000 health workers use the platform and it has been accredited by the regulatory bodies for pharmacists, pharmaceutical technologists, and physician assistants. “The practice of medicine requires continuous updating…and that’s what we seek to do,” said Mwangi. “We said why don’t we just democratize [access to information and professional development] and have this accessible to people even from remote areas.” The third-place winner, Dr Imodoye Abioro, CEO of Healthbotics in Nigeria, developed an artificial intelligence (AI) powered electronic medical record system – Mediverse – that utilizes blockchain to help healthcare workers input and retrieve patient records. Dr Imodoye Abioro, CEO of Healthbotics in Nigeria, won third place for the Africa Young Innovators for Health Award. The technology could work on any device and even in places where the internet has not yet reached. “We do not have enough healthcare workers for the disease burden we’re battling,” said Abioro. “The first thought we had was how do we make the healthcare worker more effective, how can he or she see more patients, how can he or she be smarter or faster.” “Mediverse is what we consider to be a solution that will be necessary for us to build a sustainable healthcare infrastructure in Africa upon,” Abioro added. “This could really revolutionize the way that healthcare workers are able to access the data they need about their patients in real time,” said Nicole Kayode, CEO and Founder of Medixus. The winners take home between US$15,000 and US$40,000 and will benefit from a business mentorship program, media exposure, technical training on intellectual property protection, and expert advice from an extensive network of stakeholders working across healthcare mediums. More investment needed Some 22% of Africa’s working-age population are starting businesses, “yet more investment in human capital is needed for this demographic potential to reap the development rewards it should,” said Thomas Cueni, Director-General of IFPMA. “We are confident that the winners of the African Young Innovators for health award will contribute to improving health systems and growing African economies,” added Cueni. “We don’t lack ideas or creativity, that’s not what’s missing,” said Dr Awa Marie Coll-Seck, Senegal’s Minister of State of Senegal and former health minister. “Among innovators, it’s often about the lack of financial resources for research…This is what stops them from concretising their ideas and developing prototypes.” “We need to give [the young innovators] the opportunity to develop ideas and their expertise,” said Coll-Seck. Africa is the youngest continent on the planet. By 2050, Africa’s youth population under the age of 24 will increase by nearly 50%. This presents an opportunity for rapid social and economic transformation, said the panelists. In 2019, sub-Saharan African countries were classified among the hundred best countries in terms of innovation. Africa facing massive shortages in healthcare workforce Africa bears a quarter of the global disease burden but faces a shortage of over two million healthcare professionals. Only 2% of the world’s healthcare workforce are from the continent. “Our world lacks about 18 million health workers globally and…Africa is the place that really suffers the most from it,” said Pape Gaye, President Emeritus of IntraHealth International, addressing the awards ceremony. The shortage of human and financial resources invested in the African healthcare system is putting a strain on healthcare workers and the broader national and regional health infrastructure. “COVID-19 has laid bare the underlying inequities and prejudices in existing healthcare,” said Dr Moredreck Chibi, the World Health Organization’s (WHO) Africa Advisor for Innovation. “Our young people [need to] take the bull by its horn and apply their intellectual capital to address some of these challenges.” Dr Moredreck Chibi, WHO Regional Advisor for Innovation for the Regional Office for Africa. “Only this approach will ensure Africa’s sustainable path for the future of health on the continent,” said Chibi. “As we are all aware, the COVID pandemic has been devastating and exposed the vulnerabilities of health systems across the globe, including in Africa,” said Dr Lindiwe Makubalo, WHO Assistant Regional Director for Africa. “There could be no better time to draw on the rich human capital, especially among young people, to find solutions to the problems that we are facing.” “COVID-19 has been a wake-up call for the continent. It is inevitable that we need to think outside the box to solve these problems,” said Makubalo. Innovation is a central component of public health “Innovation has always been the driving force of progress in public health, from vaccines to penicillin to the mapping of the human genome,” said Cueni. “Innovations have changed the world and this has never been more evident than with the COVID-19 pandemic.” Vaccines and treatments for COVID-19 were developed by pharma companies in record time due to large investments in research and a lot of innovation. “We have seen from smartphones to drones, there’s no doubt that technology and innovation are leapfrogging Africa and future young African entrepreneurs are playing a crucial role by developing creative ideas that can resolve the various health challenges on the continent,” said Cueni. Thomas Cueni, Director General of the IFPMA, at the award ceremony on Thursday. The panelists called on countries to support efforts and innovations of the youth by harnessing domestic resources through advocacy for partner financing and the creation of platforms to showcase initiatives. Partnerships with private sector are essential “We all know that innovation is best when it is tailored to the local context and that we should think about those who need it most when we’re creating them, and how we can create the most impact,” said Yacine Djibo, Founder and Executive Director of Speak Up Africa. Yacine Djibo, Founder and Executive Director of Speak Up Africa. Building science, technology, and innovation capacity, as well as stimulating the existing entrepreneurial culture in Africa should be a priority, said Djibo. Collaboration with the private sector will increase the opportunities for innovation and help the continent build sustainable health systems. “Health system strengthening and the potential of Africa’s private sector are crucially important for unleashing the entrepreneurial power of Africa’s young people,” said Cueni. “This will create innovative and compelling modern businesses, increase the capacity for these businesses to compete regionally and globally, attract both domestic and foreign investment, and diversify investment profiles.” This will contribute to job creation and economic growth across the region. “By leveraging its resources, expertise, networks, infrastructure, and assets, the private sector can focus on innovation for new technologies, systems, and processes, [and] can influence policy and form partnerships that will have continent-wide impact on the populations,” said Cueni. “We are extremely impressed by the quality of the applications we received. These applications are a shining example that young Africans are bursting with creativity and are constantly looking for local-based solutions that work,” said Djibo. With only one-fifth of applications to the innovation award coming from women, the IFPMA and Speak Up Africa have launched the Women Innovators Incubator to address the gaps in female-led innovation. Three female participants will receive financial support, mentorship, media training, expert advice on intellectual property protection, and access to a network of global health experts. Image Credits: Africa Young Innovators for Health Award, Africa Young Innovators for Health Award. Wealthy Countries Urged to Share 2 Billion Excess COVID-19 Doses, as South Africa’s mRNA Hub Prepares to Make ‘Moderna-like’ Vaccine 16/09/2021 Kerry Cullinan The South African mRNA hub aims to make Moderna-like vaccine. Countries with high COVID-19 vaccination rates have pre-purchased over two billion excess vaccine doses, limiting the supplies available for low- and middle-income countries (LMIC). This emerged from a meeting on Thursday between the heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization – the multilateral Task Force – and CEOs of leading vaccine manufacturing companies. Meanwhile, the South African mRNA technology transfer hub set up in July to enable Africa to manufacture its own vaccines is moving ahead with plans to make a “Moderna-like” vaccine – despite a lack of co-operation from either mRNA manufacturer, Moderna or Pfizer-BioNTech. This was confirmed to Health Policy Watch by Dr Marie-Paule Kieny, Chair of the Board of the Medicines Patent Pool in Geneva and President of the French Scientific Committee on COVID-19 vaccines. “The mRNA hub doesn’t need direct transfer of technology from Pfizer/BioNTech or Moderna, as enough information on production process is available publicly and as there are no patent on mRNA vaccines in any African country,” said Kieny, who recently visited South Africa to work with local hub partners. “The hub will therefore work with technical experts to recreate a new ‘Moderna-like’ vaccine,” added Kieny. Appeal to swap doses, deliver to COVAX and AVAT To alleviate COVID vaccine shortages in LMICs, the task force called on wealthy countries to urgently “swap their near-term delivery schedules with COVAX and the African Vaccine Acquisition Task Force (AVAT)”, meet their dose donation pledges with “unearmarked upfront deliveries to COVAX”, and release vaccine companies from options and contracts to enable these doses to be delivered to LMICs. Without these urgent steps, the world is unlikely to meet the WHO’s target of vaccinating 40% of the global population by the end of the year. “Despite adequate total global vaccine production in the aggregate, the doses are not reaching LMICs in sufficient amounts, resulting in a crisis of vaccine inequity,” the task force said. It also appealed for transparency about the supply of vaccines, calling on vaccine manufacturers to share details on month-by-month delivery schedules for all vaccine shipments, especially for COVAX and AVAT. It also called on all countries to urgently address export restrictions, high tariffs and customs bottlenecks on COVID-19 vaccines, raw materials and supplies. The task team welcomed the pharmaceutical CEOs’ willingness to ‘work collectively to end vaccine inequity” and “readiness” to form a joint technical working group with the Task Force to exchange and coordinate information on vaccine production and deliveries. However, the big pharmaceutical companies have been unwilling to work with the mRNA hub. ‘No point’ in mRNA transfer In response to a Health Policy Watch question, Pfizer CEO Albert Bourla said that he didn’t see the point as the tech transfer “would take years”, and that producing mRNA vaccines was what Pfizer did. Kieny confirmed that the Medicines Patent Pool, WHO and others had reached out to the mRNA vaccine manufacturers “but up to this point, the companies have not been interested”. Vaccine manufacturers are apparently wary of new manufacturers competing for raw materials and customers. Shortly after the mRNA hub was announced, Pfizer revealed that it had made a deal with South African pharmaceutical company and hub member Biovac, to “fill and finish” around 100 million vaccines destined for Africa. Kieny described this as “an excellent step forward”, as Biovac will receive technology transfer from Pfizer for the fill-finish part of their mRNA vaccine, “especially as the Pfizer contract does not claim exclusivity”. “Biovac will therefore also become the first African manufacturer with a product resulting from technology transfer of the full production cycle from the hub,” said Kieny. Image Credits: Gavi . Finding Sustainable Solutions to WHO’s Financial Woes 16/09/2021 Pokuaa Oduro-Bonsrah Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health and chair of the WHO Working Group on Sustainable Finance. For a long time, the World Health Organization (WHO) has experienced immense financial stress resulting in numerous debates on how to remedy its economic woes. A working group set up earlier this year has been tasked with finding long-term solutions. Each year the representatives of some 194 countries make demands on what work should be carried out by the WHO, but the money needed to carry out the requests is severely lacking. Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health, and chair of WHO’s Working Group on Sustainable Funding, recalls explaining the situation to his daughter who asks what the money problem is. “The family decides to have breakfast with lots of friends. We need to buy 20 buns from the bakery, and there’s a plan in place because we know our guests want different buns. I send my daughter to the bakery to buy 20 different buns but only give her enough money for two,” he says. Without enough money, Kümmel’s daughter would have to beg for money on the way to the store. Some generous passersby might give her some change, but on the condition that she spends it on specific types of buns. She might be able to bring back home all 20 buns but to a large extent they will not be the ones ordered. “It sounds absurd when we put it this way but the member states of the WHO, in the same way, do not provide the finances to fund their own priorities agreed to by these countries,” Kümmel told Geneva Solutions. Increasingly, individual donors have been providing funding money for these “buns”, but often face criticism for financing projects that personally interest them. Meanwhile, the funds needed to execute the activities of the ever-broadening agenda set by the World Health Assembly (WHA) are lacking. COVID-19 has revealed major discrepancies between the expectations of the WHO and its de facto ability. “The pandemic has shown that we need a strong WHO, now more than ever, and it is clear that it is not strong enough,” Kümmel said. Sustainability lens For years discussions have circled around WHO’s funding, prompting its Director-General, Dr Tedros Adhanom Ghebreyesus, to reflect on how these conversations have “remained rather abstract” in a report delivered to the Executive Board. As a result, the WHO created the Working Group on Sustainable Financing (WGSF), which is tasked with finding long-term solutions to the body’s financial troubles. Kümmel notes that although finances remain a popular topic amongst the organisation’s members, this is the first time a “sustainability” lens is being adopted. He adds that everyone shares the view that a stronger WHO is needed, which requires more stable sources of long-term funding. The alternative, continuing with the status quo, poses a threat to global health security and the achievement of the Sustainable Development Goals. “There needs to be a completely new approach to ensure the WHO has the right finances in place in order to fulfil the world’s expectations,” he says. The WSFG is working on a proposal that will “enable WHO to have the robust structures and capacities needed to fulfil its core functions,” as highlighted in the meeting report. The final report and recommendations will be taken forward to the WHO’s executive board in January 2022. Concluding their third and most recent meeting in June, the group has already explored different financing models, including other global health actors’ funding structures that could help recharge the WHO’s coffers, drawing on lessons from other health actors. Adopting the Global Fund’s so-called replenishment model, for example, would mean raising funds in multi-year cycles. Kümmel says the WHO budget could at least be partially funded this way. Dr Tedros addressing the WHO’s 149th Executive Board meeting Since taking office in 2017, Ghebreyesus has made broadening the WHO’s funding base one of the organisation’s main priorities. In 2019, he announced plans to establish the WHO Foundation to secure funds from the public, individual major donors and corporate partners. The launch of the independent grant-making body came amid controversy over former US President Donald Trump’s decision to halt funding from the US, the WHO’s single largest donor. The move was later reversed by current President Joe Biden but it had already exposed the health organisation’s heavy dependence on a few major donors. Approved for 2020-2021, the budget is $5.8 billion, which reflects a $1.4bn increase from the previous biennium, mostly needed for the Covid-19 response. About 16 per cent of this figure stems from mandatory payments known as assessed contributions, paid by its members, which over the last two decades or so, have remained flat at one billion US dollars. The other way is through voluntary contributions, secured from governments, other UN agencies and the private sector, which make up the majority of the budget. In recent years the top voluntary contributors, in addition to the US, have included the United Kingdom, Germany and the Bill and Melinda Gates Foundation. Yet, private players such as the Gates Foundation have come under fire for having some of the most powerful and influential voices in global health, raising questions about the WHO’s independence. Praise for ‘Big Philanthropy’ donors Kümmel, however, believes “these voluntary generous donors should be praised because they provide the needed funding in the absence of member states”. The vast majority of funds coming from the private sector go to the Polio Eradication Initiative, he points out. “If the WHO didn’t receive these resources, we wouldn’t even be close to an eradication of polio because many member states just don’t put the money on the table,” he adds. In the last 10 years, the UN health agency has depended heavily on voluntary contributions, which can include both flexible funds untied to specified causes as well as money that can only be spent on activities decided by the donor. Still, in 2018/2019, almost 70 % of the overall budget was financed by funds allocated for specific purposes. The working group has considered whether the core mandate of the WHO should be fully funded by “un-earmarked” flexible contributions, which favours the organisation’s aspired ways of working, whilst also exploring the importance of expanding the WHO’s donor base. Following the recommendations of the Independent Panel for Pandemic Preparedness and Response (IPPPR), who share the view that two thirds of assessed contributions should be dues paid by member states, the working group are toying with the idea of whether this figure should be at least 50 per cent, a proposal that has been put forward to the regional committees, which Kümmel expressed had been received constructively and positively. In addition, the group has put forward to the regional committees whether member states would support and agree to the proposal on increasing assessed contributions as well as adopt an incremental implementation schedule at next May’s 75th WHA. Contributions from all member states For Kümmel, all member states should contribute regardless of their economic status. However, he agrees that some countries experience severe financial challenges, thus the current mechanisms in place ensure financial possibilities are accounted for. At the moment each country is assigned a share of the assessed budget through the WHO’s scale of assessments proportional to the size of its economy, but ultimately it is up to member states to fork out the money, particularly if it is un-earmarked funding. Coordinated efforts across regions are vital, especially when faced with health crises such as the Covid-19 pandemic. If paired with the loss of funds from major contributors, the results can be devastating. In 2020, the US fell to the third largest donor position, providing about 8% of the overall budget in the first three quarters. Biden has since restored ties with the body and in February pledged $4bn to the WHO-backed COVAX initiative to boost the equitable distribution of COVID vaccines, however, the full effect of this is yet to be seen. Germany has similarly reinforced its support to WHO’s work and fight against COVID. Earlier this month the WHO launched its new Hub for Pandemic and Epidemic Intelligence in Berlin. Germany has said it will make an initial $100 million investment to prop up the facility. The Hub is said to focus on “collaborative intelligence”, where all 194 member states, scientific institutions and civil society could share information openly. As the coronavirus has demonstrated, the world is not ready to rapidly spot and tackle potential pandemics. The working group believes preparing the health body against such future challenges with the appropriate resources is crucial. “I think that it is quite clear that the strengthening of WHO post-COVID is a key priority for many countries including Germany. Member states who really want to strengthen WHO understand that ensuring sustainable financing to WHO is one of the key pillars of this,” Kümmel urged. “We are very supportive of constructive multilateralism in global health. WHO is the global health forum where everyone sits at the table, all 194 Member States, it has a broad global health mandate, and it is fully inclusive.” This article was first published by Geneva Solutions. Image Credits: WHO/ Violaine Martin, WHO. World Leaders Call on Future German Chancellor to Support TRIPS Waiver 15/09/2021 Kerry Cullinan German Health Minister Jens Spahn and German Chancellor Angela Merkel have staunchly opposed the TRIPS waiver. More than 140 former heads of state and Nobel laureates have called on the three candidates in line to be the next German chancellor to declare themselves in favour of waiving intellectual property on COVID-19 vaccines and transferring vaccine technologies. Germany is leading the European Commission’s refusal to accept the so-called TRIPS waiver proposal put forward by South Africa and India at the World Trade Organisation (WTO). However, German elections on 26 September could unseat Angela Merkel’s ruling Christian Democratic Union Party, which has steadfastly opposed the TRIPS waiver – apparently in support of BioNTech-Pfizer. In the letter, addressed to Annalena Baerbock, Olaf Scholz, and Armin Laschet, sent on Wednesday, the signatories stress that German support for waiving patents is vital to overcoming vaccine monopolies, transferring vaccine technology and scaling up vaccine manufacturing around the world to prevent millions more deaths from COVID-19. Signatories include former French President François Hollande, former UK Prime Minister Gordon Brown, former Colombian President Juan Manuel Santos, former Malawian President Joyce Banda and Helen Clark, New Zealand’s former prime minister. Nobel prize winners include Professor Joseph Stiglitz, Professor Francoise Barre-Sinoussi and Elfriede Jelinek. End the pandemic They express deep concern with Germany’s “continued opposition to a temporary waiver of the World Trade Organization’s (WTO) intellectual property rules”, at a time in which “the artificial restriction on manufacturing and supply is leading to thousands of unnecessary deaths from COVID-19 each day”. Less than 2% of adults are fully vaccinated in low-income countries compared to almost 50 % in high-income countries. The TRIPS waiver on COVID-19 vaccines, proposed by India and South Africa in October 2020, is supported by over 100 countries including the United States and France in doing so. “Having helped create the most successful vaccine technology against COVID-19, by overcoming pharmaceutical monopolies and insisting that the technology be shared, Germany has the ability to help end this pandemic,” according to the letter. It also calls on the next Chancellor to ensure that German pharmaceutical companies openly and rapidly share life-saving mRNA vaccine technology with qualified producers around the world. Commenting on the letter, New Zealand’s Clark stressed: “Germany’s support for a TRIPS waiver in the exceptional circumstances presented by COVID-19 would send a clear signal that all peoples should be able to benefit speedily from available vaccines and therapeutics. Widespread vaccination now and further scaling up of vaccine production will play a significant role in curbing the pandemic.” Extraordinary power Meanwhile, Nobel laureate Joseph Stiglitz, said that the new Chancellor of Germany will “hold extraordinary power to turn the tide on this horrific pandemic”. “Intellectual property rules are today locking out people across the world from the benefits of life-saving science – it is time for Germany to ensure the transfer of vaccine technologies and join the rest of the world in backing a temporary waiver at the WTO,” he added. Earlier in the week, Belgian Green Sarah Matthieu, a Member of the European Parliament, said that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. The letter was coordinated by the People’s Vaccine Alliance, a coalition of more than 70 organizations including Club de Madrid, Global Justice Now and UNAIDS. Image Credits: Clemens Bilan. Much More Needs to be Done About Unhealthy Impact of Meat 15/09/2021 Madeleine Hoecklin To address the climate impacts of livestock production, people need to halve their meat-eating, says the Meat Atlas 2021. Twenty multinational meat and dairy conglomerates emit more greenhouse gases than Germany, Britain, or France, according to the Meat Atlas which was launched recently by Friends of the Earth and the Heinrich Böll Stiftung. A range of health issues associated with meat-heavy diets also require attention in the push toward more sustainable practices, according to the World Health Organization (WHO), ahead of next week’s UN Food Systems Summit scheduled for 23 September and the Glasgow Climate Summit, COP 26, which opens 31 October. Around 840,000 deaths annually are attributable to diets high in processed meats, and some 40,000 deaths are linked to diets high in red meats, according to the WHO’s Dr Maria Neira, Director of the Department of Environment, Climate Change and Health, in an interview with Health Policy Watch. Millions more premature deaths have been associated with people eating diets high in saturated fats from meat, and not eating enough fruits, vegetables, fibre, legumes, and other plant-based foods. The consequences of this are malnutrition, hypertension, heart disease and other chronic disease ailments. “[We need to focus on] reducing the consumption of meat and increasing the consumption of plant-based foods, and at the same time [developing] more sustainable food systems, a better recovery from COVID-19, a strategy to tackle climate change, and promoting health,” Neira told Health Policy Watch. For decades, the WHO has recommended replacing high saturated-fat, high-calorie meats and processed foods with unprocessed foods, fibre-rich foods, fresh fruits and vegetables. Health and climate synergies The health and climate synergies are elaborated on in WHO’s recent Compendium of guidance on health and the environment, which covers issues from air pollution to biodiversity, clean water and sanitation. “Current patterns of food production and consumption use much of the world’s resources on land and water and contribute significantly to climate and ecosystem change through for example deforestation, loss of biodiversity and GHG emissions,” according to the compendium. “This is aggravated by the fact that about one third of food produced for human consumption is wasted,” it adds. “The expansion of industrial agriculture at the expense of nature puts our global health at risk,” according to the Meat Atlas. It calls on countries to “develop an action plan to promote less and better consumption and production of meat, dairy and eggs, to shift away from industrial farming, and to support better animal farming and healthy, plant-rich diets.” Meanwhile, the WHO’s compendium provides over 400 interventions and recommendations for action to address the overconsumption of red and processed meat. Neira argues that the world has to move to decarbonisation ”with a high level of ambition and speed”. This can be done through more regulation of meat producers, raising awareness about the health implications of high meat consumption, and shifting consumption decisions in favor of sustainability and health. Impact on water and land Livestock production produces 14.5% of the world’s greenhouse gas emissions, but also uses vast amounts of water. Agriculture uses some 92% of the global water footprint and 29% of this is used in animal production. Agriculture uses three times as much available fresh water than 50 years ago. Three-quarters of all agricultural land is used to raise livestock and to grow the crops to feed them – but livestock corporations also drive water pollution, deforestation, pesticide use, and biodiversity loss. While climate campaigners push for reducing meat consumption, the demand for meat is forecasted to continue to grow over the next decade, warns the Meat Atlas. To meet this demand, meat production is becoming more industrialised, marginalising smaller meat and milk producers that represent more sustainable food production models. Antimicrobial resistance Industrial livestock production also increases the risk of zoonotic disease transmission and antimicrobial resistance (AMR), through inappropriate and largely unregulated agricultural practices. Some 73% of the antibiotics sold worldwide are used on animals and the proportion of industrial animal agriculture that routinely uses antibiotics is rising. Antibiotics are used as growth stimulants in animals and can compensate for shortcomings in hygiene, management, and the care of animals in livestock production. But the overuse or misuse of antibiotics in food-producing animals can lead to AMR in humans that cause longer illnesses, more frequent hospitalizations, and treatment failures. According to the ‘Meat Atlas’, half the chicken samples from major poultry producers in five European Union countries were contaminated with antibiotic-resistant pathogens. “Antimicrobial resistance linked to the excessive and inappropriate use of antibiotics in animal and human healthcare leads to an estimated 33,000 human deaths in the EU every year,” said the Meat Atlas. Zoonotic diseases Freshly slaughtered animals and processed meat in a market in Wuhan, Hubei, China Certain wild animals – including rodents, bats, carnivores and monkeys – are among those most likely to harbour zoonotic diseases that are harmful to humans, according to the Meat Atlas. The coronavirus, which originates in bat populations, is an example. One of the most favoured hypotheses put forward by the WHO scientists investigating the origins of the SARS-C0V2 virus causing the current pandemic is that it came from wild animals. Approximately 60% of all infectious diseases in humans are zoonotic and almost three-quarters of known zoonoses can be traced to wildlife, for example by people eating the meat of wild animals. The industrialized production of wild animals or domesticated livestock often serve as a bridge for transmission, thus posing a “dire threat to global human health,” said the Meat Atlas. Emerging pathogens are crossing the animal-human barrier with increased frequency or greater impact. The crowded conditions used to house animals in industrialised livestock production systems allow infections to easily mutate and jump to human hosts. In addition, the destruction of ecosystems to cultivate land for agricultural production is bringing people into closer contact with wild animals. As consumption patterns shift towards more meat, the risk of contracting zoonotic diseases will increase. Shifting to plant-based foods Trends in meat production (Meat Atlas 2021) Shifting diets towards plant-based foods could help reduce diet-related non-communicable disease risks and global disease burdens of obesity, cardiovascular disease, and diabetes – and slow the rise in methane emissions associated with livestock production. Plant-based and minimally processed foods “must be made available, accessible, affordable, safe, culturally acceptable and desirable to the whole population including the most vulnerable,” says the WHO’s compendium report. The world will need tailored approaches to curbing meat consumption, said Neira. “For more industrialised countries, we can move into stimulating the reduction of meat consumption and promoting healthy diets…[with] plant-based or unprocessed food,” Neira said. “A policymaker in a developed country…can go with more ambition on promoting [a plant-based diet], while in developing countries…we need to have a holistic view of their protein intake…and ensure that people will have access to foods that meet their protein needs every day,” she said. Interventions from health policymakers will require advocacy campaigns with clear arguments to “promote the importance of reducing meat consumption and increasing consumption of plant-based foods for the health of the people,” said Neira. “WHO will go to COP26 with a very strong report called the ‘Health Argument for Climate Action’ and we will put the focus on the health benefits that can be obtained be mitigating the causes of climate change and promoting a more sustainable food system from the beginning to the end,” said Neira. Image Credits: Friends of the Earth and the Heinrich Böll Stiftung, Arend Kuester/Flickr, Meat Atlas 2021. Pressure Builds on Biden to End TRIPS Waiver Impasse, Enable Equitable Access to COVID Vaccines 15/09/2021 Kerry Cullinan President Joe Biden speaking in Germany after a G7 meeting. Pressure is mounting on US President Joe Biden to provide global leadership to ensure equitable access to COVID-19 vaccines in the face of the European Commission’s refusal to support a waiver on intellectual property rights. Biden is expected to host a global leaders’ summit on COVID-19 alongside the United Nations General Assembly next week, and US officials are lobbying countries to support targets to end the pandemic centred on how to get 70% of people vaccinated by late 2022. African leaders hope that Biden’s COVID-19 summit will lead to more equitable access to vaccines: WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response Negotiations over the suspension of intellectual property rights for COVID-19 vaccines, therapeutics and diagnostics, the TRIPS waiver, have stalled at the World Trade Organization (WTO) in the face of opposition from the European Union. But if the US put forward a text on waiver, this would reinvigorate the talks, appealed South African trade ministry advisor Zane Dangor on Tuesday. South Africa and India are co-sponsors of the waiver. “Action by the US will be particularly potent to shift the needle in the negotiations and make people come around the table and discuss these issues,” said Dangor, one of the key officials involved in the WTO TRIPS waiver negotiations. In May, Biden took the world by surprise when he announced US support for the waiver proposal – although only in relation to COVID-19 vaccines. But the European Commission, particularly Germany, has refused to budget. “The European Union would like to kick the discussions further down the road,” said Dangor, adding that the EU had made it known this week that it was not in favour of a decision on the TRIPS waiver being made at the upcoming WTO Ministerial on 30 November. Zane Dangor, Special Adviser to South Africa’s Trade Minister. “We need commitment on a text from the US that can be tabled and negotiated with South Africa, India and other co-sponsors so that we can have an outcome and move to get to the business of actually ensuring that we get jabs in arms of those who need most and have equitable access,” Dangor told a press briefing organised by Public Citizen. “Not only do we need to get the WTO waiver done, but we require vaccine recipes to be shared via broad tech transfer to speed expansion of COVID medicine supplies,” added Dangor. In July, the World Health Organization (WHO) announced that it had established a “tech transfer hub” in South Africa to enable African companies produce mRNA vaccines – but the mRNA manufacturers, Pfizer-BioNTech and Moderna, have refused to join the hub. Last week, in response to a recent Health Policy Watch question, Pfizer CEO Albert Bourla said: “I’m not sure what is the point of transferring technology that it is going to take years to transfer. And, by the way, this is what we do. I’m not sure I understand what they want, to give it someone else to do?” European Commission counter-proposal is ‘big air’ Belgian Green Sarah Matthieu, a Member of the European Parliament, believes that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. Matthieu said that the German elections on 26 September may shift the power balance it that country and change the position of Germany on the waiver. US Congressman Ro Khanna said that Biden had shown “strong leadership on the TRIPS waiver” but he now had to “convince our European allies, who are often fond of lecturing the United States about moral responsibility, to live up to theirs”. Khanna added that the US had been “instrumental in the development of these vaccines”, including by “funding some of the critical research” and “providing purchase agreements that mitigated the risk for pharmaceutical companies”. Although the US government has indicated it would only support a waiver for vaccines, Khanna told the MSF briefing that this should extend to therapeutics. “More broadly, we need to have a better system for how we incentivize the production and distribution of drugs to the poor and for issues of that really affect large numbers of population,” said Khanna. “A purely for-profit model of developing medicines may lead to an over-investment in acne treatment and an under-investment of treatment on some of the biggest diseases. “Not only do we need a TRIPS waiver, but we need to think about how can we incentivize the development and the production of medicine that actually are affecting the urgent needs of many people in the United States and around the world.” Waiver debate is about pharma profit, says Stiglitz Professor Joseph Stiglitz Nobel laureate and Columbia University economist Professor Joseph Stiglitz described the waiver debate as being about the ability of the drug companies to exercise monopoly power to get substantial profits, rather than a reasonable return on their investment. “Drug companies’ concern is maximising profits. That’s their business model. And maximising profits means restricting supply because by restricting supply, you increase price, and by increasing price you increase profits,” he stressed. Referring to Pfizer’s recent talk about selling its vaccine for $175 a dose, Stiglitz said this was based on the belief that there was going to be a vaccine shortage, which would enable the company to extract a monopoly price. Like Khanna, Stiglitz stressed that the development of the COVID-19 vaccines was an international effort that had involved significant investment from various governments as well as scientists from around the world. “Germany’s particular view on this is especially peculiar because the German company, BioNTech, has already sold its international rights to Pfizer so the waiver is not even going to affect its profits,” he said, describing the EU’s opposition to the waiver as “objectionable” and “unconscionable”. Confusion about TRIPS waiver Stiglitz stressed that there was also confusion about the TRIPS waiver. “First, this is not the abolition of property rights. [Pharmaceutical companies] still get compensated for using their intellectual property rights. So, it’s not taking away their property rights. Its just saying we are in an emergency, and in this emergency, intellectual property rights have to be available more widely,” Stiglitz told the MSF briefing. “Secondly, it’s not even a change in the intellectual framework because, since the beginning of the WTO, we’ve recognised the principle of compulsory licenses. This is effectively just a compulsory license… to lower transaction costs. Lower transaction costs in the midst of the pandemic, where there’s a kind of urgency that we don’t normally have, is absolutely essential,” he added. “We’ve enacted voluntary licenses. The world has debated this. It debated it when the WTO TRIPS initially adopted it. It was really debated that in the context of HIV/AIDS, which reaffirmed the principle of compulsory licenses.” “We are in the midst of what some people call the new cold war. On the one hand, there are authoritarian governments like Russia and China, and then, on the other hand, there are democracies. We would like the democracies to win, but we’re not putting a good face on democracy when we say our democracies put profits over lives. “Russia has been very actively engaged in vaccine diplomacy. It’s made its vaccine available, say in a country like Argentina. But not only has it made its vaccine available, it’s actually actively engaged in transferring technology and enabling countries to build plants to produce the vaccine. And I’m afraid we’re losing this particular battle.” Civil society groups demonstrate outside embassies of countries that oppose a temporary WTO patent waiver on COVID-19 health products. Image Credits: CNBC, Munich Security Conference, Tadeau Andre/MSF . WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response 14/09/2021 Elaine Ruth Fletcher Left-right: Strive Masiyiwa, AU COVID envoy, Dr Tedros Adhanom Ghebreyesus, WHO Director General, Dr John Nkengasong, Africa CDC diector After months of frustrated efforts to unlock global vaccine supplies for the African continent, WHO and African Union leaders are now pinning their hopes on US President Joe Biden’s reported plan to call heads of state to a “Global Pandemic Summit” on the sidelines of the United Nations General Assembly, which opened today, as a way out of the current deadlock. Biden reportedly is circulating a plan to hold the summit on 22 September – with the aim of reaching a joint commitment to the vaccination of 70% of the world’s population by the GA session in September 2022, ensuring that “additional doses and adequate supplies are available to all countries”, according to a set of targets circulating among embassies, and obtained by the Washington Post. To achieve that, the Biden plan for the Global COVID-19 Summit also calls for “expediting delivery of approximately 2.0 billion previous committed doses.. including by converting existing dose sharing pledges into near-term deliveries, swapping delivery dates to secure earlier delivery of doses to LIC/LMICs, and eliminating cross-border bottlenecks in the supply of vaccines and critical inputs.” But speaking at Tuesday’s press conference following two days of meetings in Geneva, African Union and African Centers for Disease officials stressed that the era of “pledges” for vaccine donations to Africa, needs to end and investments in African vaccine manufacturing to begin, as part of any ‘New Deal’ on pandemic response in low- and middle-income (LMICs) countries. “”We, as the African Union, are calling on a permanent structure,” said Masiyiwa, a billionaire entrepreneur and AU Special Envoy for COVID-19, “and this is something that we will be calling on to be put in place at this summit that President Biden is convening. “We strongly believe that the pledge architecture, where countries gathered together and made pledges…. has had its day. Let us now have a permanent structure. Vaccine sharing is good. But we shouldn’t have to be relying on vaccine sharing, when we can come to the table, put structures in place, and then say that we also want to buy.” Calls for new African vaccine facility Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank This should involve the creation of a new, and permanent African vaccine facility, supported by the African Union, World Bank and International Monetary Fund, said Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank. Afreximbank has provided financing for the continent’s purchase of some 400 million Johnson & Johnson vaccines – backed by the World Bank. But Benedict stressed this is only the beginning of a long road that will require the procurement of booster doses as well. And so a more permanent finance mechanism is needed for countries to manufacturer and purchase doses themselves – rather than being solely reliant on goodwill donations. While “thanking” COVAX for the role it has played in facilitating global COVID vaccine supplies, “going forward, we need the IMF to do the vaccine facility – to make it possible for countries to now access these vaccines through the structures put in place,” said Oramah. Those structures should include domestic manufacturing and procurement financed through African mechanisms, such as “Afreximbank, providing the initial financing, and then they refinance it in a way that makes it possible for the current accounts to carry all this – while the World Bank continues to provide institutional structures that are required to effectively administer vaccines.” Africa is region with lowest rates of vaccine coverage in the world Seth Berkley, CEO Gavi, The Vaccine Alliance Among all LMICs, Africa stands out for its particularly low vaccination rates so far – with under 3.5% of its population vaccinated – as compared to 60-70% in some high-income nations, African Union also said, speaking at a WHO press conference in Geneva. Of 5.2 billion doses delivered worldwide, only a tiny fraction have reached Africa, noted WHO Director General Dr Tedros Ahanom Ghebreyesus. And as things stand now, COVAX, the global vaccine facility, only has sufficient doses in the delivery pipeline to vaccinate roughly 20% of the population in the 91 lowest income countries by the end of the year, using some 1.4 billion purchased and donated doses, admitted Gavi CEO Seth Berkley at the WHO press conference. And it would hit 36% coverage by March, 2022. That falls far short of WHO’s target of 40% vaccination by December 2021 and 70% by March 2022. To reach those targets, “the world needs 2.4 billion additional doses to go into low income countries to get us to 40% by the end of this year,” Said Bruce Aylward, a special WHO advisor on the pandemic. “Those doses exist,” he said, citing recent pharma statements to the effect that there are now sufficient doses for everyone to go around – including high- and low-income countries. See related story Massive Increase in COVID-19 Vaccine Production May Mean Dose Surplus by Mid-2022, says IFPMA I think the question we ask is: where are those doses if there are enough for everybody?” Aylward asked. “And [the US Summit] next week is all about making sure there’s a clear path to ensuring they go to where they’re needed.” Barriers that have fouled vaccine access – both countries and manufacturers share blame Strive Masiyiwa, African Union COVID-19 envoy Speaking at the close of a two-day Geneva meeting, which also included Dr John Nkengasong, Africa CDC director and African Regional Director Matshidiso Moeti, the WHO and AU officials said that in they had reviewed in painstaking detail the various obstacles in the way of African vaccine access – and ways to overcome them. The challenges have included export bans, including the interruption of supplies from India in March 2020 when the subcontinent experienced its own COVID surge, but also barriers on the exports of vaccines and their inputs to a complex supply chain, they noted. But the African officials also repeated longstanding complaints against rich countries for vaccine hoarding, as well as against pharma for preferential sales to high income countries of huge vaccine quantities – in excess of actual population needs. “We want to buy from the same manufacturers,” said Masiyiwa. “But to be fair, those manufacturers know very well that they never gave us proper access. They gave access on a very different basis. “When they knew that supplies were restricted at the beginning, there was no production… they [pharma manufacturers] had a moral responsibility to ensure that others also had access,” he said. “And we find this very sad. It’s very sad. We could have addressed this very differently. We as Africa will now address this through setting up our own manufacturing capabilities.” Countries’ export restrictions also holding up distribution But countries’ export restrictions on vaccines as well as the many vaccine manufacturing inputs also continue to foul deliveries – and these are poorly understood, Masiyiwa said. . “My principal job is to negotiate with suppliers, and the suppliers have over the last 8-9 months, made it clear that the biggest challenge that they face are export restrictions, export restrictions are being operated right across the board. So, if those export restrictions aren’t there, where are the vaccines, because the production is happening? “We’re not seeing the vaccines, and we are being told by the suppliers, they are facing export restrictions. He added that without resolving, “this issue around the movement of the various ingredients that drive production… we will not even be able to get manufacturing effectively set up.” “We need to get these restrictions removed, and we had a very constructive discussion around this issue with the WTO yesterday,” he said. AU leaders call on India to remove its ban on AstraZeneca vaccine exports – now that domestic COVID surge has subsided WHO Director General Dr Tedros Adhanom Ghebreyesus Masiyiwa also appealed to India to resume its deliveries of AstraZeneca vaccines, produced by the Serum Institute of India – noting that the countries’ embargo on the export of vaccines, remains the most outstanding example of restrictions fouling distribution plans. The SII vaccines were a centerpiece of COVAX and African countries – until exports were abruptly cancelled in March. “We understood that at the time why they were put in place, it was because there was that massive surge in India, and we were incredibly, incredibly sympathetic. But we do now urge our colleagues to show sympathy to us, because we are the ones facing difficulty now. We need to see some of those vaccines begin to come through.” Finally, both African Union and WHO officials repeated their call to countries to support a waiver on intellectual property on COVID vaccines and therapeutics, currently being negotiated by the World Trade Organization – saying that this would help jump-start more manufacturing in developing regions. “American taxpayers, European taxpayers financed some of this intellectual property, and so it should be for the common good,” said Masiyiwa. “So we ask for this IP to be made available. It was a great miracle to have these vaccines, now let this miracle be available to all mankind”. Added WHO’s Tedros: “If it [a waiver] cannot be used now during this unprecedented condition or situation, then when is there a time when it can be used.” Image Credits: @WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Wealthy Countries Urged to Share 2 Billion Excess COVID-19 Doses, as South Africa’s mRNA Hub Prepares to Make ‘Moderna-like’ Vaccine 16/09/2021 Kerry Cullinan The South African mRNA hub aims to make Moderna-like vaccine. Countries with high COVID-19 vaccination rates have pre-purchased over two billion excess vaccine doses, limiting the supplies available for low- and middle-income countries (LMIC). This emerged from a meeting on Thursday between the heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization – the multilateral Task Force – and CEOs of leading vaccine manufacturing companies. Meanwhile, the South African mRNA technology transfer hub set up in July to enable Africa to manufacture its own vaccines is moving ahead with plans to make a “Moderna-like” vaccine – despite a lack of co-operation from either mRNA manufacturer, Moderna or Pfizer-BioNTech. This was confirmed to Health Policy Watch by Dr Marie-Paule Kieny, Chair of the Board of the Medicines Patent Pool in Geneva and President of the French Scientific Committee on COVID-19 vaccines. “The mRNA hub doesn’t need direct transfer of technology from Pfizer/BioNTech or Moderna, as enough information on production process is available publicly and as there are no patent on mRNA vaccines in any African country,” said Kieny, who recently visited South Africa to work with local hub partners. “The hub will therefore work with technical experts to recreate a new ‘Moderna-like’ vaccine,” added Kieny. Appeal to swap doses, deliver to COVAX and AVAT To alleviate COVID vaccine shortages in LMICs, the task force called on wealthy countries to urgently “swap their near-term delivery schedules with COVAX and the African Vaccine Acquisition Task Force (AVAT)”, meet their dose donation pledges with “unearmarked upfront deliveries to COVAX”, and release vaccine companies from options and contracts to enable these doses to be delivered to LMICs. Without these urgent steps, the world is unlikely to meet the WHO’s target of vaccinating 40% of the global population by the end of the year. “Despite adequate total global vaccine production in the aggregate, the doses are not reaching LMICs in sufficient amounts, resulting in a crisis of vaccine inequity,” the task force said. It also appealed for transparency about the supply of vaccines, calling on vaccine manufacturers to share details on month-by-month delivery schedules for all vaccine shipments, especially for COVAX and AVAT. It also called on all countries to urgently address export restrictions, high tariffs and customs bottlenecks on COVID-19 vaccines, raw materials and supplies. The task team welcomed the pharmaceutical CEOs’ willingness to ‘work collectively to end vaccine inequity” and “readiness” to form a joint technical working group with the Task Force to exchange and coordinate information on vaccine production and deliveries. However, the big pharmaceutical companies have been unwilling to work with the mRNA hub. ‘No point’ in mRNA transfer In response to a Health Policy Watch question, Pfizer CEO Albert Bourla said that he didn’t see the point as the tech transfer “would take years”, and that producing mRNA vaccines was what Pfizer did. Kieny confirmed that the Medicines Patent Pool, WHO and others had reached out to the mRNA vaccine manufacturers “but up to this point, the companies have not been interested”. Vaccine manufacturers are apparently wary of new manufacturers competing for raw materials and customers. Shortly after the mRNA hub was announced, Pfizer revealed that it had made a deal with South African pharmaceutical company and hub member Biovac, to “fill and finish” around 100 million vaccines destined for Africa. Kieny described this as “an excellent step forward”, as Biovac will receive technology transfer from Pfizer for the fill-finish part of their mRNA vaccine, “especially as the Pfizer contract does not claim exclusivity”. “Biovac will therefore also become the first African manufacturer with a product resulting from technology transfer of the full production cycle from the hub,” said Kieny. Image Credits: Gavi . Finding Sustainable Solutions to WHO’s Financial Woes 16/09/2021 Pokuaa Oduro-Bonsrah Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health and chair of the WHO Working Group on Sustainable Finance. For a long time, the World Health Organization (WHO) has experienced immense financial stress resulting in numerous debates on how to remedy its economic woes. A working group set up earlier this year has been tasked with finding long-term solutions. Each year the representatives of some 194 countries make demands on what work should be carried out by the WHO, but the money needed to carry out the requests is severely lacking. Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health, and chair of WHO’s Working Group on Sustainable Funding, recalls explaining the situation to his daughter who asks what the money problem is. “The family decides to have breakfast with lots of friends. We need to buy 20 buns from the bakery, and there’s a plan in place because we know our guests want different buns. I send my daughter to the bakery to buy 20 different buns but only give her enough money for two,” he says. Without enough money, Kümmel’s daughter would have to beg for money on the way to the store. Some generous passersby might give her some change, but on the condition that she spends it on specific types of buns. She might be able to bring back home all 20 buns but to a large extent they will not be the ones ordered. “It sounds absurd when we put it this way but the member states of the WHO, in the same way, do not provide the finances to fund their own priorities agreed to by these countries,” Kümmel told Geneva Solutions. Increasingly, individual donors have been providing funding money for these “buns”, but often face criticism for financing projects that personally interest them. Meanwhile, the funds needed to execute the activities of the ever-broadening agenda set by the World Health Assembly (WHA) are lacking. COVID-19 has revealed major discrepancies between the expectations of the WHO and its de facto ability. “The pandemic has shown that we need a strong WHO, now more than ever, and it is clear that it is not strong enough,” Kümmel said. Sustainability lens For years discussions have circled around WHO’s funding, prompting its Director-General, Dr Tedros Adhanom Ghebreyesus, to reflect on how these conversations have “remained rather abstract” in a report delivered to the Executive Board. As a result, the WHO created the Working Group on Sustainable Financing (WGSF), which is tasked with finding long-term solutions to the body’s financial troubles. Kümmel notes that although finances remain a popular topic amongst the organisation’s members, this is the first time a “sustainability” lens is being adopted. He adds that everyone shares the view that a stronger WHO is needed, which requires more stable sources of long-term funding. The alternative, continuing with the status quo, poses a threat to global health security and the achievement of the Sustainable Development Goals. “There needs to be a completely new approach to ensure the WHO has the right finances in place in order to fulfil the world’s expectations,” he says. The WSFG is working on a proposal that will “enable WHO to have the robust structures and capacities needed to fulfil its core functions,” as highlighted in the meeting report. The final report and recommendations will be taken forward to the WHO’s executive board in January 2022. Concluding their third and most recent meeting in June, the group has already explored different financing models, including other global health actors’ funding structures that could help recharge the WHO’s coffers, drawing on lessons from other health actors. Adopting the Global Fund’s so-called replenishment model, for example, would mean raising funds in multi-year cycles. Kümmel says the WHO budget could at least be partially funded this way. Dr Tedros addressing the WHO’s 149th Executive Board meeting Since taking office in 2017, Ghebreyesus has made broadening the WHO’s funding base one of the organisation’s main priorities. In 2019, he announced plans to establish the WHO Foundation to secure funds from the public, individual major donors and corporate partners. The launch of the independent grant-making body came amid controversy over former US President Donald Trump’s decision to halt funding from the US, the WHO’s single largest donor. The move was later reversed by current President Joe Biden but it had already exposed the health organisation’s heavy dependence on a few major donors. Approved for 2020-2021, the budget is $5.8 billion, which reflects a $1.4bn increase from the previous biennium, mostly needed for the Covid-19 response. About 16 per cent of this figure stems from mandatory payments known as assessed contributions, paid by its members, which over the last two decades or so, have remained flat at one billion US dollars. The other way is through voluntary contributions, secured from governments, other UN agencies and the private sector, which make up the majority of the budget. In recent years the top voluntary contributors, in addition to the US, have included the United Kingdom, Germany and the Bill and Melinda Gates Foundation. Yet, private players such as the Gates Foundation have come under fire for having some of the most powerful and influential voices in global health, raising questions about the WHO’s independence. Praise for ‘Big Philanthropy’ donors Kümmel, however, believes “these voluntary generous donors should be praised because they provide the needed funding in the absence of member states”. The vast majority of funds coming from the private sector go to the Polio Eradication Initiative, he points out. “If the WHO didn’t receive these resources, we wouldn’t even be close to an eradication of polio because many member states just don’t put the money on the table,” he adds. In the last 10 years, the UN health agency has depended heavily on voluntary contributions, which can include both flexible funds untied to specified causes as well as money that can only be spent on activities decided by the donor. Still, in 2018/2019, almost 70 % of the overall budget was financed by funds allocated for specific purposes. The working group has considered whether the core mandate of the WHO should be fully funded by “un-earmarked” flexible contributions, which favours the organisation’s aspired ways of working, whilst also exploring the importance of expanding the WHO’s donor base. Following the recommendations of the Independent Panel for Pandemic Preparedness and Response (IPPPR), who share the view that two thirds of assessed contributions should be dues paid by member states, the working group are toying with the idea of whether this figure should be at least 50 per cent, a proposal that has been put forward to the regional committees, which Kümmel expressed had been received constructively and positively. In addition, the group has put forward to the regional committees whether member states would support and agree to the proposal on increasing assessed contributions as well as adopt an incremental implementation schedule at next May’s 75th WHA. Contributions from all member states For Kümmel, all member states should contribute regardless of their economic status. However, he agrees that some countries experience severe financial challenges, thus the current mechanisms in place ensure financial possibilities are accounted for. At the moment each country is assigned a share of the assessed budget through the WHO’s scale of assessments proportional to the size of its economy, but ultimately it is up to member states to fork out the money, particularly if it is un-earmarked funding. Coordinated efforts across regions are vital, especially when faced with health crises such as the Covid-19 pandemic. If paired with the loss of funds from major contributors, the results can be devastating. In 2020, the US fell to the third largest donor position, providing about 8% of the overall budget in the first three quarters. Biden has since restored ties with the body and in February pledged $4bn to the WHO-backed COVAX initiative to boost the equitable distribution of COVID vaccines, however, the full effect of this is yet to be seen. Germany has similarly reinforced its support to WHO’s work and fight against COVID. Earlier this month the WHO launched its new Hub for Pandemic and Epidemic Intelligence in Berlin. Germany has said it will make an initial $100 million investment to prop up the facility. The Hub is said to focus on “collaborative intelligence”, where all 194 member states, scientific institutions and civil society could share information openly. As the coronavirus has demonstrated, the world is not ready to rapidly spot and tackle potential pandemics. The working group believes preparing the health body against such future challenges with the appropriate resources is crucial. “I think that it is quite clear that the strengthening of WHO post-COVID is a key priority for many countries including Germany. Member states who really want to strengthen WHO understand that ensuring sustainable financing to WHO is one of the key pillars of this,” Kümmel urged. “We are very supportive of constructive multilateralism in global health. WHO is the global health forum where everyone sits at the table, all 194 Member States, it has a broad global health mandate, and it is fully inclusive.” This article was first published by Geneva Solutions. Image Credits: WHO/ Violaine Martin, WHO. World Leaders Call on Future German Chancellor to Support TRIPS Waiver 15/09/2021 Kerry Cullinan German Health Minister Jens Spahn and German Chancellor Angela Merkel have staunchly opposed the TRIPS waiver. More than 140 former heads of state and Nobel laureates have called on the three candidates in line to be the next German chancellor to declare themselves in favour of waiving intellectual property on COVID-19 vaccines and transferring vaccine technologies. Germany is leading the European Commission’s refusal to accept the so-called TRIPS waiver proposal put forward by South Africa and India at the World Trade Organisation (WTO). However, German elections on 26 September could unseat Angela Merkel’s ruling Christian Democratic Union Party, which has steadfastly opposed the TRIPS waiver – apparently in support of BioNTech-Pfizer. In the letter, addressed to Annalena Baerbock, Olaf Scholz, and Armin Laschet, sent on Wednesday, the signatories stress that German support for waiving patents is vital to overcoming vaccine monopolies, transferring vaccine technology and scaling up vaccine manufacturing around the world to prevent millions more deaths from COVID-19. Signatories include former French President François Hollande, former UK Prime Minister Gordon Brown, former Colombian President Juan Manuel Santos, former Malawian President Joyce Banda and Helen Clark, New Zealand’s former prime minister. Nobel prize winners include Professor Joseph Stiglitz, Professor Francoise Barre-Sinoussi and Elfriede Jelinek. End the pandemic They express deep concern with Germany’s “continued opposition to a temporary waiver of the World Trade Organization’s (WTO) intellectual property rules”, at a time in which “the artificial restriction on manufacturing and supply is leading to thousands of unnecessary deaths from COVID-19 each day”. Less than 2% of adults are fully vaccinated in low-income countries compared to almost 50 % in high-income countries. The TRIPS waiver on COVID-19 vaccines, proposed by India and South Africa in October 2020, is supported by over 100 countries including the United States and France in doing so. “Having helped create the most successful vaccine technology against COVID-19, by overcoming pharmaceutical monopolies and insisting that the technology be shared, Germany has the ability to help end this pandemic,” according to the letter. It also calls on the next Chancellor to ensure that German pharmaceutical companies openly and rapidly share life-saving mRNA vaccine technology with qualified producers around the world. Commenting on the letter, New Zealand’s Clark stressed: “Germany’s support for a TRIPS waiver in the exceptional circumstances presented by COVID-19 would send a clear signal that all peoples should be able to benefit speedily from available vaccines and therapeutics. Widespread vaccination now and further scaling up of vaccine production will play a significant role in curbing the pandemic.” Extraordinary power Meanwhile, Nobel laureate Joseph Stiglitz, said that the new Chancellor of Germany will “hold extraordinary power to turn the tide on this horrific pandemic”. “Intellectual property rules are today locking out people across the world from the benefits of life-saving science – it is time for Germany to ensure the transfer of vaccine technologies and join the rest of the world in backing a temporary waiver at the WTO,” he added. Earlier in the week, Belgian Green Sarah Matthieu, a Member of the European Parliament, said that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. The letter was coordinated by the People’s Vaccine Alliance, a coalition of more than 70 organizations including Club de Madrid, Global Justice Now and UNAIDS. Image Credits: Clemens Bilan. Much More Needs to be Done About Unhealthy Impact of Meat 15/09/2021 Madeleine Hoecklin To address the climate impacts of livestock production, people need to halve their meat-eating, says the Meat Atlas 2021. Twenty multinational meat and dairy conglomerates emit more greenhouse gases than Germany, Britain, or France, according to the Meat Atlas which was launched recently by Friends of the Earth and the Heinrich Böll Stiftung. A range of health issues associated with meat-heavy diets also require attention in the push toward more sustainable practices, according to the World Health Organization (WHO), ahead of next week’s UN Food Systems Summit scheduled for 23 September and the Glasgow Climate Summit, COP 26, which opens 31 October. Around 840,000 deaths annually are attributable to diets high in processed meats, and some 40,000 deaths are linked to diets high in red meats, according to the WHO’s Dr Maria Neira, Director of the Department of Environment, Climate Change and Health, in an interview with Health Policy Watch. Millions more premature deaths have been associated with people eating diets high in saturated fats from meat, and not eating enough fruits, vegetables, fibre, legumes, and other plant-based foods. The consequences of this are malnutrition, hypertension, heart disease and other chronic disease ailments. “[We need to focus on] reducing the consumption of meat and increasing the consumption of plant-based foods, and at the same time [developing] more sustainable food systems, a better recovery from COVID-19, a strategy to tackle climate change, and promoting health,” Neira told Health Policy Watch. For decades, the WHO has recommended replacing high saturated-fat, high-calorie meats and processed foods with unprocessed foods, fibre-rich foods, fresh fruits and vegetables. Health and climate synergies The health and climate synergies are elaborated on in WHO’s recent Compendium of guidance on health and the environment, which covers issues from air pollution to biodiversity, clean water and sanitation. “Current patterns of food production and consumption use much of the world’s resources on land and water and contribute significantly to climate and ecosystem change through for example deforestation, loss of biodiversity and GHG emissions,” according to the compendium. “This is aggravated by the fact that about one third of food produced for human consumption is wasted,” it adds. “The expansion of industrial agriculture at the expense of nature puts our global health at risk,” according to the Meat Atlas. It calls on countries to “develop an action plan to promote less and better consumption and production of meat, dairy and eggs, to shift away from industrial farming, and to support better animal farming and healthy, plant-rich diets.” Meanwhile, the WHO’s compendium provides over 400 interventions and recommendations for action to address the overconsumption of red and processed meat. Neira argues that the world has to move to decarbonisation ”with a high level of ambition and speed”. This can be done through more regulation of meat producers, raising awareness about the health implications of high meat consumption, and shifting consumption decisions in favor of sustainability and health. Impact on water and land Livestock production produces 14.5% of the world’s greenhouse gas emissions, but also uses vast amounts of water. Agriculture uses some 92% of the global water footprint and 29% of this is used in animal production. Agriculture uses three times as much available fresh water than 50 years ago. Three-quarters of all agricultural land is used to raise livestock and to grow the crops to feed them – but livestock corporations also drive water pollution, deforestation, pesticide use, and biodiversity loss. While climate campaigners push for reducing meat consumption, the demand for meat is forecasted to continue to grow over the next decade, warns the Meat Atlas. To meet this demand, meat production is becoming more industrialised, marginalising smaller meat and milk producers that represent more sustainable food production models. Antimicrobial resistance Industrial livestock production also increases the risk of zoonotic disease transmission and antimicrobial resistance (AMR), through inappropriate and largely unregulated agricultural practices. Some 73% of the antibiotics sold worldwide are used on animals and the proportion of industrial animal agriculture that routinely uses antibiotics is rising. Antibiotics are used as growth stimulants in animals and can compensate for shortcomings in hygiene, management, and the care of animals in livestock production. But the overuse or misuse of antibiotics in food-producing animals can lead to AMR in humans that cause longer illnesses, more frequent hospitalizations, and treatment failures. According to the ‘Meat Atlas’, half the chicken samples from major poultry producers in five European Union countries were contaminated with antibiotic-resistant pathogens. “Antimicrobial resistance linked to the excessive and inappropriate use of antibiotics in animal and human healthcare leads to an estimated 33,000 human deaths in the EU every year,” said the Meat Atlas. Zoonotic diseases Freshly slaughtered animals and processed meat in a market in Wuhan, Hubei, China Certain wild animals – including rodents, bats, carnivores and monkeys – are among those most likely to harbour zoonotic diseases that are harmful to humans, according to the Meat Atlas. The coronavirus, which originates in bat populations, is an example. One of the most favoured hypotheses put forward by the WHO scientists investigating the origins of the SARS-C0V2 virus causing the current pandemic is that it came from wild animals. Approximately 60% of all infectious diseases in humans are zoonotic and almost three-quarters of known zoonoses can be traced to wildlife, for example by people eating the meat of wild animals. The industrialized production of wild animals or domesticated livestock often serve as a bridge for transmission, thus posing a “dire threat to global human health,” said the Meat Atlas. Emerging pathogens are crossing the animal-human barrier with increased frequency or greater impact. The crowded conditions used to house animals in industrialised livestock production systems allow infections to easily mutate and jump to human hosts. In addition, the destruction of ecosystems to cultivate land for agricultural production is bringing people into closer contact with wild animals. As consumption patterns shift towards more meat, the risk of contracting zoonotic diseases will increase. Shifting to plant-based foods Trends in meat production (Meat Atlas 2021) Shifting diets towards plant-based foods could help reduce diet-related non-communicable disease risks and global disease burdens of obesity, cardiovascular disease, and diabetes – and slow the rise in methane emissions associated with livestock production. Plant-based and minimally processed foods “must be made available, accessible, affordable, safe, culturally acceptable and desirable to the whole population including the most vulnerable,” says the WHO’s compendium report. The world will need tailored approaches to curbing meat consumption, said Neira. “For more industrialised countries, we can move into stimulating the reduction of meat consumption and promoting healthy diets…[with] plant-based or unprocessed food,” Neira said. “A policymaker in a developed country…can go with more ambition on promoting [a plant-based diet], while in developing countries…we need to have a holistic view of their protein intake…and ensure that people will have access to foods that meet their protein needs every day,” she said. Interventions from health policymakers will require advocacy campaigns with clear arguments to “promote the importance of reducing meat consumption and increasing consumption of plant-based foods for the health of the people,” said Neira. “WHO will go to COP26 with a very strong report called the ‘Health Argument for Climate Action’ and we will put the focus on the health benefits that can be obtained be mitigating the causes of climate change and promoting a more sustainable food system from the beginning to the end,” said Neira. Image Credits: Friends of the Earth and the Heinrich Böll Stiftung, Arend Kuester/Flickr, Meat Atlas 2021. Pressure Builds on Biden to End TRIPS Waiver Impasse, Enable Equitable Access to COVID Vaccines 15/09/2021 Kerry Cullinan President Joe Biden speaking in Germany after a G7 meeting. Pressure is mounting on US President Joe Biden to provide global leadership to ensure equitable access to COVID-19 vaccines in the face of the European Commission’s refusal to support a waiver on intellectual property rights. Biden is expected to host a global leaders’ summit on COVID-19 alongside the United Nations General Assembly next week, and US officials are lobbying countries to support targets to end the pandemic centred on how to get 70% of people vaccinated by late 2022. African leaders hope that Biden’s COVID-19 summit will lead to more equitable access to vaccines: WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response Negotiations over the suspension of intellectual property rights for COVID-19 vaccines, therapeutics and diagnostics, the TRIPS waiver, have stalled at the World Trade Organization (WTO) in the face of opposition from the European Union. But if the US put forward a text on waiver, this would reinvigorate the talks, appealed South African trade ministry advisor Zane Dangor on Tuesday. South Africa and India are co-sponsors of the waiver. “Action by the US will be particularly potent to shift the needle in the negotiations and make people come around the table and discuss these issues,” said Dangor, one of the key officials involved in the WTO TRIPS waiver negotiations. In May, Biden took the world by surprise when he announced US support for the waiver proposal – although only in relation to COVID-19 vaccines. But the European Commission, particularly Germany, has refused to budget. “The European Union would like to kick the discussions further down the road,” said Dangor, adding that the EU had made it known this week that it was not in favour of a decision on the TRIPS waiver being made at the upcoming WTO Ministerial on 30 November. Zane Dangor, Special Adviser to South Africa’s Trade Minister. “We need commitment on a text from the US that can be tabled and negotiated with South Africa, India and other co-sponsors so that we can have an outcome and move to get to the business of actually ensuring that we get jabs in arms of those who need most and have equitable access,” Dangor told a press briefing organised by Public Citizen. “Not only do we need to get the WTO waiver done, but we require vaccine recipes to be shared via broad tech transfer to speed expansion of COVID medicine supplies,” added Dangor. In July, the World Health Organization (WHO) announced that it had established a “tech transfer hub” in South Africa to enable African companies produce mRNA vaccines – but the mRNA manufacturers, Pfizer-BioNTech and Moderna, have refused to join the hub. Last week, in response to a recent Health Policy Watch question, Pfizer CEO Albert Bourla said: “I’m not sure what is the point of transferring technology that it is going to take years to transfer. And, by the way, this is what we do. I’m not sure I understand what they want, to give it someone else to do?” European Commission counter-proposal is ‘big air’ Belgian Green Sarah Matthieu, a Member of the European Parliament, believes that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. Matthieu said that the German elections on 26 September may shift the power balance it that country and change the position of Germany on the waiver. US Congressman Ro Khanna said that Biden had shown “strong leadership on the TRIPS waiver” but he now had to “convince our European allies, who are often fond of lecturing the United States about moral responsibility, to live up to theirs”. Khanna added that the US had been “instrumental in the development of these vaccines”, including by “funding some of the critical research” and “providing purchase agreements that mitigated the risk for pharmaceutical companies”. Although the US government has indicated it would only support a waiver for vaccines, Khanna told the MSF briefing that this should extend to therapeutics. “More broadly, we need to have a better system for how we incentivize the production and distribution of drugs to the poor and for issues of that really affect large numbers of population,” said Khanna. “A purely for-profit model of developing medicines may lead to an over-investment in acne treatment and an under-investment of treatment on some of the biggest diseases. “Not only do we need a TRIPS waiver, but we need to think about how can we incentivize the development and the production of medicine that actually are affecting the urgent needs of many people in the United States and around the world.” Waiver debate is about pharma profit, says Stiglitz Professor Joseph Stiglitz Nobel laureate and Columbia University economist Professor Joseph Stiglitz described the waiver debate as being about the ability of the drug companies to exercise monopoly power to get substantial profits, rather than a reasonable return on their investment. “Drug companies’ concern is maximising profits. That’s their business model. And maximising profits means restricting supply because by restricting supply, you increase price, and by increasing price you increase profits,” he stressed. Referring to Pfizer’s recent talk about selling its vaccine for $175 a dose, Stiglitz said this was based on the belief that there was going to be a vaccine shortage, which would enable the company to extract a monopoly price. Like Khanna, Stiglitz stressed that the development of the COVID-19 vaccines was an international effort that had involved significant investment from various governments as well as scientists from around the world. “Germany’s particular view on this is especially peculiar because the German company, BioNTech, has already sold its international rights to Pfizer so the waiver is not even going to affect its profits,” he said, describing the EU’s opposition to the waiver as “objectionable” and “unconscionable”. Confusion about TRIPS waiver Stiglitz stressed that there was also confusion about the TRIPS waiver. “First, this is not the abolition of property rights. [Pharmaceutical companies] still get compensated for using their intellectual property rights. So, it’s not taking away their property rights. Its just saying we are in an emergency, and in this emergency, intellectual property rights have to be available more widely,” Stiglitz told the MSF briefing. “Secondly, it’s not even a change in the intellectual framework because, since the beginning of the WTO, we’ve recognised the principle of compulsory licenses. This is effectively just a compulsory license… to lower transaction costs. Lower transaction costs in the midst of the pandemic, where there’s a kind of urgency that we don’t normally have, is absolutely essential,” he added. “We’ve enacted voluntary licenses. The world has debated this. It debated it when the WTO TRIPS initially adopted it. It was really debated that in the context of HIV/AIDS, which reaffirmed the principle of compulsory licenses.” “We are in the midst of what some people call the new cold war. On the one hand, there are authoritarian governments like Russia and China, and then, on the other hand, there are democracies. We would like the democracies to win, but we’re not putting a good face on democracy when we say our democracies put profits over lives. “Russia has been very actively engaged in vaccine diplomacy. It’s made its vaccine available, say in a country like Argentina. But not only has it made its vaccine available, it’s actually actively engaged in transferring technology and enabling countries to build plants to produce the vaccine. And I’m afraid we’re losing this particular battle.” Civil society groups demonstrate outside embassies of countries that oppose a temporary WTO patent waiver on COVID-19 health products. Image Credits: CNBC, Munich Security Conference, Tadeau Andre/MSF . WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response 14/09/2021 Elaine Ruth Fletcher Left-right: Strive Masiyiwa, AU COVID envoy, Dr Tedros Adhanom Ghebreyesus, WHO Director General, Dr John Nkengasong, Africa CDC diector After months of frustrated efforts to unlock global vaccine supplies for the African continent, WHO and African Union leaders are now pinning their hopes on US President Joe Biden’s reported plan to call heads of state to a “Global Pandemic Summit” on the sidelines of the United Nations General Assembly, which opened today, as a way out of the current deadlock. Biden reportedly is circulating a plan to hold the summit on 22 September – with the aim of reaching a joint commitment to the vaccination of 70% of the world’s population by the GA session in September 2022, ensuring that “additional doses and adequate supplies are available to all countries”, according to a set of targets circulating among embassies, and obtained by the Washington Post. To achieve that, the Biden plan for the Global COVID-19 Summit also calls for “expediting delivery of approximately 2.0 billion previous committed doses.. including by converting existing dose sharing pledges into near-term deliveries, swapping delivery dates to secure earlier delivery of doses to LIC/LMICs, and eliminating cross-border bottlenecks in the supply of vaccines and critical inputs.” But speaking at Tuesday’s press conference following two days of meetings in Geneva, African Union and African Centers for Disease officials stressed that the era of “pledges” for vaccine donations to Africa, needs to end and investments in African vaccine manufacturing to begin, as part of any ‘New Deal’ on pandemic response in low- and middle-income (LMICs) countries. “”We, as the African Union, are calling on a permanent structure,” said Masiyiwa, a billionaire entrepreneur and AU Special Envoy for COVID-19, “and this is something that we will be calling on to be put in place at this summit that President Biden is convening. “We strongly believe that the pledge architecture, where countries gathered together and made pledges…. has had its day. Let us now have a permanent structure. Vaccine sharing is good. But we shouldn’t have to be relying on vaccine sharing, when we can come to the table, put structures in place, and then say that we also want to buy.” Calls for new African vaccine facility Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank This should involve the creation of a new, and permanent African vaccine facility, supported by the African Union, World Bank and International Monetary Fund, said Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank. Afreximbank has provided financing for the continent’s purchase of some 400 million Johnson & Johnson vaccines – backed by the World Bank. But Benedict stressed this is only the beginning of a long road that will require the procurement of booster doses as well. And so a more permanent finance mechanism is needed for countries to manufacturer and purchase doses themselves – rather than being solely reliant on goodwill donations. While “thanking” COVAX for the role it has played in facilitating global COVID vaccine supplies, “going forward, we need the IMF to do the vaccine facility – to make it possible for countries to now access these vaccines through the structures put in place,” said Oramah. Those structures should include domestic manufacturing and procurement financed through African mechanisms, such as “Afreximbank, providing the initial financing, and then they refinance it in a way that makes it possible for the current accounts to carry all this – while the World Bank continues to provide institutional structures that are required to effectively administer vaccines.” Africa is region with lowest rates of vaccine coverage in the world Seth Berkley, CEO Gavi, The Vaccine Alliance Among all LMICs, Africa stands out for its particularly low vaccination rates so far – with under 3.5% of its population vaccinated – as compared to 60-70% in some high-income nations, African Union also said, speaking at a WHO press conference in Geneva. Of 5.2 billion doses delivered worldwide, only a tiny fraction have reached Africa, noted WHO Director General Dr Tedros Ahanom Ghebreyesus. And as things stand now, COVAX, the global vaccine facility, only has sufficient doses in the delivery pipeline to vaccinate roughly 20% of the population in the 91 lowest income countries by the end of the year, using some 1.4 billion purchased and donated doses, admitted Gavi CEO Seth Berkley at the WHO press conference. And it would hit 36% coverage by March, 2022. That falls far short of WHO’s target of 40% vaccination by December 2021 and 70% by March 2022. To reach those targets, “the world needs 2.4 billion additional doses to go into low income countries to get us to 40% by the end of this year,” Said Bruce Aylward, a special WHO advisor on the pandemic. “Those doses exist,” he said, citing recent pharma statements to the effect that there are now sufficient doses for everyone to go around – including high- and low-income countries. See related story Massive Increase in COVID-19 Vaccine Production May Mean Dose Surplus by Mid-2022, says IFPMA I think the question we ask is: where are those doses if there are enough for everybody?” Aylward asked. “And [the US Summit] next week is all about making sure there’s a clear path to ensuring they go to where they’re needed.” Barriers that have fouled vaccine access – both countries and manufacturers share blame Strive Masiyiwa, African Union COVID-19 envoy Speaking at the close of a two-day Geneva meeting, which also included Dr John Nkengasong, Africa CDC director and African Regional Director Matshidiso Moeti, the WHO and AU officials said that in they had reviewed in painstaking detail the various obstacles in the way of African vaccine access – and ways to overcome them. The challenges have included export bans, including the interruption of supplies from India in March 2020 when the subcontinent experienced its own COVID surge, but also barriers on the exports of vaccines and their inputs to a complex supply chain, they noted. But the African officials also repeated longstanding complaints against rich countries for vaccine hoarding, as well as against pharma for preferential sales to high income countries of huge vaccine quantities – in excess of actual population needs. “We want to buy from the same manufacturers,” said Masiyiwa. “But to be fair, those manufacturers know very well that they never gave us proper access. They gave access on a very different basis. “When they knew that supplies were restricted at the beginning, there was no production… they [pharma manufacturers] had a moral responsibility to ensure that others also had access,” he said. “And we find this very sad. It’s very sad. We could have addressed this very differently. We as Africa will now address this through setting up our own manufacturing capabilities.” Countries’ export restrictions also holding up distribution But countries’ export restrictions on vaccines as well as the many vaccine manufacturing inputs also continue to foul deliveries – and these are poorly understood, Masiyiwa said. . “My principal job is to negotiate with suppliers, and the suppliers have over the last 8-9 months, made it clear that the biggest challenge that they face are export restrictions, export restrictions are being operated right across the board. So, if those export restrictions aren’t there, where are the vaccines, because the production is happening? “We’re not seeing the vaccines, and we are being told by the suppliers, they are facing export restrictions. He added that without resolving, “this issue around the movement of the various ingredients that drive production… we will not even be able to get manufacturing effectively set up.” “We need to get these restrictions removed, and we had a very constructive discussion around this issue with the WTO yesterday,” he said. AU leaders call on India to remove its ban on AstraZeneca vaccine exports – now that domestic COVID surge has subsided WHO Director General Dr Tedros Adhanom Ghebreyesus Masiyiwa also appealed to India to resume its deliveries of AstraZeneca vaccines, produced by the Serum Institute of India – noting that the countries’ embargo on the export of vaccines, remains the most outstanding example of restrictions fouling distribution plans. The SII vaccines were a centerpiece of COVAX and African countries – until exports were abruptly cancelled in March. “We understood that at the time why they were put in place, it was because there was that massive surge in India, and we were incredibly, incredibly sympathetic. But we do now urge our colleagues to show sympathy to us, because we are the ones facing difficulty now. We need to see some of those vaccines begin to come through.” Finally, both African Union and WHO officials repeated their call to countries to support a waiver on intellectual property on COVID vaccines and therapeutics, currently being negotiated by the World Trade Organization – saying that this would help jump-start more manufacturing in developing regions. “American taxpayers, European taxpayers financed some of this intellectual property, and so it should be for the common good,” said Masiyiwa. “So we ask for this IP to be made available. It was a great miracle to have these vaccines, now let this miracle be available to all mankind”. Added WHO’s Tedros: “If it [a waiver] cannot be used now during this unprecedented condition or situation, then when is there a time when it can be used.” Image Credits: @WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Finding Sustainable Solutions to WHO’s Financial Woes 16/09/2021 Pokuaa Oduro-Bonsrah Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health and chair of the WHO Working Group on Sustainable Finance. For a long time, the World Health Organization (WHO) has experienced immense financial stress resulting in numerous debates on how to remedy its economic woes. A working group set up earlier this year has been tasked with finding long-term solutions. Each year the representatives of some 194 countries make demands on what work should be carried out by the WHO, but the money needed to carry out the requests is severely lacking. Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health, and chair of WHO’s Working Group on Sustainable Funding, recalls explaining the situation to his daughter who asks what the money problem is. “The family decides to have breakfast with lots of friends. We need to buy 20 buns from the bakery, and there’s a plan in place because we know our guests want different buns. I send my daughter to the bakery to buy 20 different buns but only give her enough money for two,” he says. Without enough money, Kümmel’s daughter would have to beg for money on the way to the store. Some generous passersby might give her some change, but on the condition that she spends it on specific types of buns. She might be able to bring back home all 20 buns but to a large extent they will not be the ones ordered. “It sounds absurd when we put it this way but the member states of the WHO, in the same way, do not provide the finances to fund their own priorities agreed to by these countries,” Kümmel told Geneva Solutions. Increasingly, individual donors have been providing funding money for these “buns”, but often face criticism for financing projects that personally interest them. Meanwhile, the funds needed to execute the activities of the ever-broadening agenda set by the World Health Assembly (WHA) are lacking. COVID-19 has revealed major discrepancies between the expectations of the WHO and its de facto ability. “The pandemic has shown that we need a strong WHO, now more than ever, and it is clear that it is not strong enough,” Kümmel said. Sustainability lens For years discussions have circled around WHO’s funding, prompting its Director-General, Dr Tedros Adhanom Ghebreyesus, to reflect on how these conversations have “remained rather abstract” in a report delivered to the Executive Board. As a result, the WHO created the Working Group on Sustainable Financing (WGSF), which is tasked with finding long-term solutions to the body’s financial troubles. Kümmel notes that although finances remain a popular topic amongst the organisation’s members, this is the first time a “sustainability” lens is being adopted. He adds that everyone shares the view that a stronger WHO is needed, which requires more stable sources of long-term funding. The alternative, continuing with the status quo, poses a threat to global health security and the achievement of the Sustainable Development Goals. “There needs to be a completely new approach to ensure the WHO has the right finances in place in order to fulfil the world’s expectations,” he says. The WSFG is working on a proposal that will “enable WHO to have the robust structures and capacities needed to fulfil its core functions,” as highlighted in the meeting report. The final report and recommendations will be taken forward to the WHO’s executive board in January 2022. Concluding their third and most recent meeting in June, the group has already explored different financing models, including other global health actors’ funding structures that could help recharge the WHO’s coffers, drawing on lessons from other health actors. Adopting the Global Fund’s so-called replenishment model, for example, would mean raising funds in multi-year cycles. Kümmel says the WHO budget could at least be partially funded this way. Dr Tedros addressing the WHO’s 149th Executive Board meeting Since taking office in 2017, Ghebreyesus has made broadening the WHO’s funding base one of the organisation’s main priorities. In 2019, he announced plans to establish the WHO Foundation to secure funds from the public, individual major donors and corporate partners. The launch of the independent grant-making body came amid controversy over former US President Donald Trump’s decision to halt funding from the US, the WHO’s single largest donor. The move was later reversed by current President Joe Biden but it had already exposed the health organisation’s heavy dependence on a few major donors. Approved for 2020-2021, the budget is $5.8 billion, which reflects a $1.4bn increase from the previous biennium, mostly needed for the Covid-19 response. About 16 per cent of this figure stems from mandatory payments known as assessed contributions, paid by its members, which over the last two decades or so, have remained flat at one billion US dollars. The other way is through voluntary contributions, secured from governments, other UN agencies and the private sector, which make up the majority of the budget. In recent years the top voluntary contributors, in addition to the US, have included the United Kingdom, Germany and the Bill and Melinda Gates Foundation. Yet, private players such as the Gates Foundation have come under fire for having some of the most powerful and influential voices in global health, raising questions about the WHO’s independence. Praise for ‘Big Philanthropy’ donors Kümmel, however, believes “these voluntary generous donors should be praised because they provide the needed funding in the absence of member states”. The vast majority of funds coming from the private sector go to the Polio Eradication Initiative, he points out. “If the WHO didn’t receive these resources, we wouldn’t even be close to an eradication of polio because many member states just don’t put the money on the table,” he adds. In the last 10 years, the UN health agency has depended heavily on voluntary contributions, which can include both flexible funds untied to specified causes as well as money that can only be spent on activities decided by the donor. Still, in 2018/2019, almost 70 % of the overall budget was financed by funds allocated for specific purposes. The working group has considered whether the core mandate of the WHO should be fully funded by “un-earmarked” flexible contributions, which favours the organisation’s aspired ways of working, whilst also exploring the importance of expanding the WHO’s donor base. Following the recommendations of the Independent Panel for Pandemic Preparedness and Response (IPPPR), who share the view that two thirds of assessed contributions should be dues paid by member states, the working group are toying with the idea of whether this figure should be at least 50 per cent, a proposal that has been put forward to the regional committees, which Kümmel expressed had been received constructively and positively. In addition, the group has put forward to the regional committees whether member states would support and agree to the proposal on increasing assessed contributions as well as adopt an incremental implementation schedule at next May’s 75th WHA. Contributions from all member states For Kümmel, all member states should contribute regardless of their economic status. However, he agrees that some countries experience severe financial challenges, thus the current mechanisms in place ensure financial possibilities are accounted for. At the moment each country is assigned a share of the assessed budget through the WHO’s scale of assessments proportional to the size of its economy, but ultimately it is up to member states to fork out the money, particularly if it is un-earmarked funding. Coordinated efforts across regions are vital, especially when faced with health crises such as the Covid-19 pandemic. If paired with the loss of funds from major contributors, the results can be devastating. In 2020, the US fell to the third largest donor position, providing about 8% of the overall budget in the first three quarters. Biden has since restored ties with the body and in February pledged $4bn to the WHO-backed COVAX initiative to boost the equitable distribution of COVID vaccines, however, the full effect of this is yet to be seen. Germany has similarly reinforced its support to WHO’s work and fight against COVID. Earlier this month the WHO launched its new Hub for Pandemic and Epidemic Intelligence in Berlin. Germany has said it will make an initial $100 million investment to prop up the facility. The Hub is said to focus on “collaborative intelligence”, where all 194 member states, scientific institutions and civil society could share information openly. As the coronavirus has demonstrated, the world is not ready to rapidly spot and tackle potential pandemics. The working group believes preparing the health body against such future challenges with the appropriate resources is crucial. “I think that it is quite clear that the strengthening of WHO post-COVID is a key priority for many countries including Germany. Member states who really want to strengthen WHO understand that ensuring sustainable financing to WHO is one of the key pillars of this,” Kümmel urged. “We are very supportive of constructive multilateralism in global health. WHO is the global health forum where everyone sits at the table, all 194 Member States, it has a broad global health mandate, and it is fully inclusive.” This article was first published by Geneva Solutions. Image Credits: WHO/ Violaine Martin, WHO. World Leaders Call on Future German Chancellor to Support TRIPS Waiver 15/09/2021 Kerry Cullinan German Health Minister Jens Spahn and German Chancellor Angela Merkel have staunchly opposed the TRIPS waiver. More than 140 former heads of state and Nobel laureates have called on the three candidates in line to be the next German chancellor to declare themselves in favour of waiving intellectual property on COVID-19 vaccines and transferring vaccine technologies. Germany is leading the European Commission’s refusal to accept the so-called TRIPS waiver proposal put forward by South Africa and India at the World Trade Organisation (WTO). However, German elections on 26 September could unseat Angela Merkel’s ruling Christian Democratic Union Party, which has steadfastly opposed the TRIPS waiver – apparently in support of BioNTech-Pfizer. In the letter, addressed to Annalena Baerbock, Olaf Scholz, and Armin Laschet, sent on Wednesday, the signatories stress that German support for waiving patents is vital to overcoming vaccine monopolies, transferring vaccine technology and scaling up vaccine manufacturing around the world to prevent millions more deaths from COVID-19. Signatories include former French President François Hollande, former UK Prime Minister Gordon Brown, former Colombian President Juan Manuel Santos, former Malawian President Joyce Banda and Helen Clark, New Zealand’s former prime minister. Nobel prize winners include Professor Joseph Stiglitz, Professor Francoise Barre-Sinoussi and Elfriede Jelinek. End the pandemic They express deep concern with Germany’s “continued opposition to a temporary waiver of the World Trade Organization’s (WTO) intellectual property rules”, at a time in which “the artificial restriction on manufacturing and supply is leading to thousands of unnecessary deaths from COVID-19 each day”. Less than 2% of adults are fully vaccinated in low-income countries compared to almost 50 % in high-income countries. The TRIPS waiver on COVID-19 vaccines, proposed by India and South Africa in October 2020, is supported by over 100 countries including the United States and France in doing so. “Having helped create the most successful vaccine technology against COVID-19, by overcoming pharmaceutical monopolies and insisting that the technology be shared, Germany has the ability to help end this pandemic,” according to the letter. It also calls on the next Chancellor to ensure that German pharmaceutical companies openly and rapidly share life-saving mRNA vaccine technology with qualified producers around the world. Commenting on the letter, New Zealand’s Clark stressed: “Germany’s support for a TRIPS waiver in the exceptional circumstances presented by COVID-19 would send a clear signal that all peoples should be able to benefit speedily from available vaccines and therapeutics. Widespread vaccination now and further scaling up of vaccine production will play a significant role in curbing the pandemic.” Extraordinary power Meanwhile, Nobel laureate Joseph Stiglitz, said that the new Chancellor of Germany will “hold extraordinary power to turn the tide on this horrific pandemic”. “Intellectual property rules are today locking out people across the world from the benefits of life-saving science – it is time for Germany to ensure the transfer of vaccine technologies and join the rest of the world in backing a temporary waiver at the WTO,” he added. Earlier in the week, Belgian Green Sarah Matthieu, a Member of the European Parliament, said that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. The letter was coordinated by the People’s Vaccine Alliance, a coalition of more than 70 organizations including Club de Madrid, Global Justice Now and UNAIDS. Image Credits: Clemens Bilan. Much More Needs to be Done About Unhealthy Impact of Meat 15/09/2021 Madeleine Hoecklin To address the climate impacts of livestock production, people need to halve their meat-eating, says the Meat Atlas 2021. Twenty multinational meat and dairy conglomerates emit more greenhouse gases than Germany, Britain, or France, according to the Meat Atlas which was launched recently by Friends of the Earth and the Heinrich Böll Stiftung. A range of health issues associated with meat-heavy diets also require attention in the push toward more sustainable practices, according to the World Health Organization (WHO), ahead of next week’s UN Food Systems Summit scheduled for 23 September and the Glasgow Climate Summit, COP 26, which opens 31 October. Around 840,000 deaths annually are attributable to diets high in processed meats, and some 40,000 deaths are linked to diets high in red meats, according to the WHO’s Dr Maria Neira, Director of the Department of Environment, Climate Change and Health, in an interview with Health Policy Watch. Millions more premature deaths have been associated with people eating diets high in saturated fats from meat, and not eating enough fruits, vegetables, fibre, legumes, and other plant-based foods. The consequences of this are malnutrition, hypertension, heart disease and other chronic disease ailments. “[We need to focus on] reducing the consumption of meat and increasing the consumption of plant-based foods, and at the same time [developing] more sustainable food systems, a better recovery from COVID-19, a strategy to tackle climate change, and promoting health,” Neira told Health Policy Watch. For decades, the WHO has recommended replacing high saturated-fat, high-calorie meats and processed foods with unprocessed foods, fibre-rich foods, fresh fruits and vegetables. Health and climate synergies The health and climate synergies are elaborated on in WHO’s recent Compendium of guidance on health and the environment, which covers issues from air pollution to biodiversity, clean water and sanitation. “Current patterns of food production and consumption use much of the world’s resources on land and water and contribute significantly to climate and ecosystem change through for example deforestation, loss of biodiversity and GHG emissions,” according to the compendium. “This is aggravated by the fact that about one third of food produced for human consumption is wasted,” it adds. “The expansion of industrial agriculture at the expense of nature puts our global health at risk,” according to the Meat Atlas. It calls on countries to “develop an action plan to promote less and better consumption and production of meat, dairy and eggs, to shift away from industrial farming, and to support better animal farming and healthy, plant-rich diets.” Meanwhile, the WHO’s compendium provides over 400 interventions and recommendations for action to address the overconsumption of red and processed meat. Neira argues that the world has to move to decarbonisation ”with a high level of ambition and speed”. This can be done through more regulation of meat producers, raising awareness about the health implications of high meat consumption, and shifting consumption decisions in favor of sustainability and health. Impact on water and land Livestock production produces 14.5% of the world’s greenhouse gas emissions, but also uses vast amounts of water. Agriculture uses some 92% of the global water footprint and 29% of this is used in animal production. Agriculture uses three times as much available fresh water than 50 years ago. Three-quarters of all agricultural land is used to raise livestock and to grow the crops to feed them – but livestock corporations also drive water pollution, deforestation, pesticide use, and biodiversity loss. While climate campaigners push for reducing meat consumption, the demand for meat is forecasted to continue to grow over the next decade, warns the Meat Atlas. To meet this demand, meat production is becoming more industrialised, marginalising smaller meat and milk producers that represent more sustainable food production models. Antimicrobial resistance Industrial livestock production also increases the risk of zoonotic disease transmission and antimicrobial resistance (AMR), through inappropriate and largely unregulated agricultural practices. Some 73% of the antibiotics sold worldwide are used on animals and the proportion of industrial animal agriculture that routinely uses antibiotics is rising. Antibiotics are used as growth stimulants in animals and can compensate for shortcomings in hygiene, management, and the care of animals in livestock production. But the overuse or misuse of antibiotics in food-producing animals can lead to AMR in humans that cause longer illnesses, more frequent hospitalizations, and treatment failures. According to the ‘Meat Atlas’, half the chicken samples from major poultry producers in five European Union countries were contaminated with antibiotic-resistant pathogens. “Antimicrobial resistance linked to the excessive and inappropriate use of antibiotics in animal and human healthcare leads to an estimated 33,000 human deaths in the EU every year,” said the Meat Atlas. Zoonotic diseases Freshly slaughtered animals and processed meat in a market in Wuhan, Hubei, China Certain wild animals – including rodents, bats, carnivores and monkeys – are among those most likely to harbour zoonotic diseases that are harmful to humans, according to the Meat Atlas. The coronavirus, which originates in bat populations, is an example. One of the most favoured hypotheses put forward by the WHO scientists investigating the origins of the SARS-C0V2 virus causing the current pandemic is that it came from wild animals. Approximately 60% of all infectious diseases in humans are zoonotic and almost three-quarters of known zoonoses can be traced to wildlife, for example by people eating the meat of wild animals. The industrialized production of wild animals or domesticated livestock often serve as a bridge for transmission, thus posing a “dire threat to global human health,” said the Meat Atlas. Emerging pathogens are crossing the animal-human barrier with increased frequency or greater impact. The crowded conditions used to house animals in industrialised livestock production systems allow infections to easily mutate and jump to human hosts. In addition, the destruction of ecosystems to cultivate land for agricultural production is bringing people into closer contact with wild animals. As consumption patterns shift towards more meat, the risk of contracting zoonotic diseases will increase. Shifting to plant-based foods Trends in meat production (Meat Atlas 2021) Shifting diets towards plant-based foods could help reduce diet-related non-communicable disease risks and global disease burdens of obesity, cardiovascular disease, and diabetes – and slow the rise in methane emissions associated with livestock production. Plant-based and minimally processed foods “must be made available, accessible, affordable, safe, culturally acceptable and desirable to the whole population including the most vulnerable,” says the WHO’s compendium report. The world will need tailored approaches to curbing meat consumption, said Neira. “For more industrialised countries, we can move into stimulating the reduction of meat consumption and promoting healthy diets…[with] plant-based or unprocessed food,” Neira said. “A policymaker in a developed country…can go with more ambition on promoting [a plant-based diet], while in developing countries…we need to have a holistic view of their protein intake…and ensure that people will have access to foods that meet their protein needs every day,” she said. Interventions from health policymakers will require advocacy campaigns with clear arguments to “promote the importance of reducing meat consumption and increasing consumption of plant-based foods for the health of the people,” said Neira. “WHO will go to COP26 with a very strong report called the ‘Health Argument for Climate Action’ and we will put the focus on the health benefits that can be obtained be mitigating the causes of climate change and promoting a more sustainable food system from the beginning to the end,” said Neira. Image Credits: Friends of the Earth and the Heinrich Böll Stiftung, Arend Kuester/Flickr, Meat Atlas 2021. Pressure Builds on Biden to End TRIPS Waiver Impasse, Enable Equitable Access to COVID Vaccines 15/09/2021 Kerry Cullinan President Joe Biden speaking in Germany after a G7 meeting. Pressure is mounting on US President Joe Biden to provide global leadership to ensure equitable access to COVID-19 vaccines in the face of the European Commission’s refusal to support a waiver on intellectual property rights. Biden is expected to host a global leaders’ summit on COVID-19 alongside the United Nations General Assembly next week, and US officials are lobbying countries to support targets to end the pandemic centred on how to get 70% of people vaccinated by late 2022. African leaders hope that Biden’s COVID-19 summit will lead to more equitable access to vaccines: WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response Negotiations over the suspension of intellectual property rights for COVID-19 vaccines, therapeutics and diagnostics, the TRIPS waiver, have stalled at the World Trade Organization (WTO) in the face of opposition from the European Union. But if the US put forward a text on waiver, this would reinvigorate the talks, appealed South African trade ministry advisor Zane Dangor on Tuesday. South Africa and India are co-sponsors of the waiver. “Action by the US will be particularly potent to shift the needle in the negotiations and make people come around the table and discuss these issues,” said Dangor, one of the key officials involved in the WTO TRIPS waiver negotiations. In May, Biden took the world by surprise when he announced US support for the waiver proposal – although only in relation to COVID-19 vaccines. But the European Commission, particularly Germany, has refused to budget. “The European Union would like to kick the discussions further down the road,” said Dangor, adding that the EU had made it known this week that it was not in favour of a decision on the TRIPS waiver being made at the upcoming WTO Ministerial on 30 November. Zane Dangor, Special Adviser to South Africa’s Trade Minister. “We need commitment on a text from the US that can be tabled and negotiated with South Africa, India and other co-sponsors so that we can have an outcome and move to get to the business of actually ensuring that we get jabs in arms of those who need most and have equitable access,” Dangor told a press briefing organised by Public Citizen. “Not only do we need to get the WTO waiver done, but we require vaccine recipes to be shared via broad tech transfer to speed expansion of COVID medicine supplies,” added Dangor. In July, the World Health Organization (WHO) announced that it had established a “tech transfer hub” in South Africa to enable African companies produce mRNA vaccines – but the mRNA manufacturers, Pfizer-BioNTech and Moderna, have refused to join the hub. Last week, in response to a recent Health Policy Watch question, Pfizer CEO Albert Bourla said: “I’m not sure what is the point of transferring technology that it is going to take years to transfer. And, by the way, this is what we do. I’m not sure I understand what they want, to give it someone else to do?” European Commission counter-proposal is ‘big air’ Belgian Green Sarah Matthieu, a Member of the European Parliament, believes that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. Matthieu said that the German elections on 26 September may shift the power balance it that country and change the position of Germany on the waiver. US Congressman Ro Khanna said that Biden had shown “strong leadership on the TRIPS waiver” but he now had to “convince our European allies, who are often fond of lecturing the United States about moral responsibility, to live up to theirs”. Khanna added that the US had been “instrumental in the development of these vaccines”, including by “funding some of the critical research” and “providing purchase agreements that mitigated the risk for pharmaceutical companies”. Although the US government has indicated it would only support a waiver for vaccines, Khanna told the MSF briefing that this should extend to therapeutics. “More broadly, we need to have a better system for how we incentivize the production and distribution of drugs to the poor and for issues of that really affect large numbers of population,” said Khanna. “A purely for-profit model of developing medicines may lead to an over-investment in acne treatment and an under-investment of treatment on some of the biggest diseases. “Not only do we need a TRIPS waiver, but we need to think about how can we incentivize the development and the production of medicine that actually are affecting the urgent needs of many people in the United States and around the world.” Waiver debate is about pharma profit, says Stiglitz Professor Joseph Stiglitz Nobel laureate and Columbia University economist Professor Joseph Stiglitz described the waiver debate as being about the ability of the drug companies to exercise monopoly power to get substantial profits, rather than a reasonable return on their investment. “Drug companies’ concern is maximising profits. That’s their business model. And maximising profits means restricting supply because by restricting supply, you increase price, and by increasing price you increase profits,” he stressed. Referring to Pfizer’s recent talk about selling its vaccine for $175 a dose, Stiglitz said this was based on the belief that there was going to be a vaccine shortage, which would enable the company to extract a monopoly price. Like Khanna, Stiglitz stressed that the development of the COVID-19 vaccines was an international effort that had involved significant investment from various governments as well as scientists from around the world. “Germany’s particular view on this is especially peculiar because the German company, BioNTech, has already sold its international rights to Pfizer so the waiver is not even going to affect its profits,” he said, describing the EU’s opposition to the waiver as “objectionable” and “unconscionable”. Confusion about TRIPS waiver Stiglitz stressed that there was also confusion about the TRIPS waiver. “First, this is not the abolition of property rights. [Pharmaceutical companies] still get compensated for using their intellectual property rights. So, it’s not taking away their property rights. Its just saying we are in an emergency, and in this emergency, intellectual property rights have to be available more widely,” Stiglitz told the MSF briefing. “Secondly, it’s not even a change in the intellectual framework because, since the beginning of the WTO, we’ve recognised the principle of compulsory licenses. This is effectively just a compulsory license… to lower transaction costs. Lower transaction costs in the midst of the pandemic, where there’s a kind of urgency that we don’t normally have, is absolutely essential,” he added. “We’ve enacted voluntary licenses. The world has debated this. It debated it when the WTO TRIPS initially adopted it. It was really debated that in the context of HIV/AIDS, which reaffirmed the principle of compulsory licenses.” “We are in the midst of what some people call the new cold war. On the one hand, there are authoritarian governments like Russia and China, and then, on the other hand, there are democracies. We would like the democracies to win, but we’re not putting a good face on democracy when we say our democracies put profits over lives. “Russia has been very actively engaged in vaccine diplomacy. It’s made its vaccine available, say in a country like Argentina. But not only has it made its vaccine available, it’s actually actively engaged in transferring technology and enabling countries to build plants to produce the vaccine. And I’m afraid we’re losing this particular battle.” Civil society groups demonstrate outside embassies of countries that oppose a temporary WTO patent waiver on COVID-19 health products. Image Credits: CNBC, Munich Security Conference, Tadeau Andre/MSF . WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response 14/09/2021 Elaine Ruth Fletcher Left-right: Strive Masiyiwa, AU COVID envoy, Dr Tedros Adhanom Ghebreyesus, WHO Director General, Dr John Nkengasong, Africa CDC diector After months of frustrated efforts to unlock global vaccine supplies for the African continent, WHO and African Union leaders are now pinning their hopes on US President Joe Biden’s reported plan to call heads of state to a “Global Pandemic Summit” on the sidelines of the United Nations General Assembly, which opened today, as a way out of the current deadlock. Biden reportedly is circulating a plan to hold the summit on 22 September – with the aim of reaching a joint commitment to the vaccination of 70% of the world’s population by the GA session in September 2022, ensuring that “additional doses and adequate supplies are available to all countries”, according to a set of targets circulating among embassies, and obtained by the Washington Post. To achieve that, the Biden plan for the Global COVID-19 Summit also calls for “expediting delivery of approximately 2.0 billion previous committed doses.. including by converting existing dose sharing pledges into near-term deliveries, swapping delivery dates to secure earlier delivery of doses to LIC/LMICs, and eliminating cross-border bottlenecks in the supply of vaccines and critical inputs.” But speaking at Tuesday’s press conference following two days of meetings in Geneva, African Union and African Centers for Disease officials stressed that the era of “pledges” for vaccine donations to Africa, needs to end and investments in African vaccine manufacturing to begin, as part of any ‘New Deal’ on pandemic response in low- and middle-income (LMICs) countries. “”We, as the African Union, are calling on a permanent structure,” said Masiyiwa, a billionaire entrepreneur and AU Special Envoy for COVID-19, “and this is something that we will be calling on to be put in place at this summit that President Biden is convening. “We strongly believe that the pledge architecture, where countries gathered together and made pledges…. has had its day. Let us now have a permanent structure. Vaccine sharing is good. But we shouldn’t have to be relying on vaccine sharing, when we can come to the table, put structures in place, and then say that we also want to buy.” Calls for new African vaccine facility Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank This should involve the creation of a new, and permanent African vaccine facility, supported by the African Union, World Bank and International Monetary Fund, said Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank. Afreximbank has provided financing for the continent’s purchase of some 400 million Johnson & Johnson vaccines – backed by the World Bank. But Benedict stressed this is only the beginning of a long road that will require the procurement of booster doses as well. And so a more permanent finance mechanism is needed for countries to manufacturer and purchase doses themselves – rather than being solely reliant on goodwill donations. While “thanking” COVAX for the role it has played in facilitating global COVID vaccine supplies, “going forward, we need the IMF to do the vaccine facility – to make it possible for countries to now access these vaccines through the structures put in place,” said Oramah. Those structures should include domestic manufacturing and procurement financed through African mechanisms, such as “Afreximbank, providing the initial financing, and then they refinance it in a way that makes it possible for the current accounts to carry all this – while the World Bank continues to provide institutional structures that are required to effectively administer vaccines.” Africa is region with lowest rates of vaccine coverage in the world Seth Berkley, CEO Gavi, The Vaccine Alliance Among all LMICs, Africa stands out for its particularly low vaccination rates so far – with under 3.5% of its population vaccinated – as compared to 60-70% in some high-income nations, African Union also said, speaking at a WHO press conference in Geneva. Of 5.2 billion doses delivered worldwide, only a tiny fraction have reached Africa, noted WHO Director General Dr Tedros Ahanom Ghebreyesus. And as things stand now, COVAX, the global vaccine facility, only has sufficient doses in the delivery pipeline to vaccinate roughly 20% of the population in the 91 lowest income countries by the end of the year, using some 1.4 billion purchased and donated doses, admitted Gavi CEO Seth Berkley at the WHO press conference. And it would hit 36% coverage by March, 2022. That falls far short of WHO’s target of 40% vaccination by December 2021 and 70% by March 2022. To reach those targets, “the world needs 2.4 billion additional doses to go into low income countries to get us to 40% by the end of this year,” Said Bruce Aylward, a special WHO advisor on the pandemic. “Those doses exist,” he said, citing recent pharma statements to the effect that there are now sufficient doses for everyone to go around – including high- and low-income countries. See related story Massive Increase in COVID-19 Vaccine Production May Mean Dose Surplus by Mid-2022, says IFPMA I think the question we ask is: where are those doses if there are enough for everybody?” Aylward asked. “And [the US Summit] next week is all about making sure there’s a clear path to ensuring they go to where they’re needed.” Barriers that have fouled vaccine access – both countries and manufacturers share blame Strive Masiyiwa, African Union COVID-19 envoy Speaking at the close of a two-day Geneva meeting, which also included Dr John Nkengasong, Africa CDC director and African Regional Director Matshidiso Moeti, the WHO and AU officials said that in they had reviewed in painstaking detail the various obstacles in the way of African vaccine access – and ways to overcome them. The challenges have included export bans, including the interruption of supplies from India in March 2020 when the subcontinent experienced its own COVID surge, but also barriers on the exports of vaccines and their inputs to a complex supply chain, they noted. But the African officials also repeated longstanding complaints against rich countries for vaccine hoarding, as well as against pharma for preferential sales to high income countries of huge vaccine quantities – in excess of actual population needs. “We want to buy from the same manufacturers,” said Masiyiwa. “But to be fair, those manufacturers know very well that they never gave us proper access. They gave access on a very different basis. “When they knew that supplies were restricted at the beginning, there was no production… they [pharma manufacturers] had a moral responsibility to ensure that others also had access,” he said. “And we find this very sad. It’s very sad. We could have addressed this very differently. We as Africa will now address this through setting up our own manufacturing capabilities.” Countries’ export restrictions also holding up distribution But countries’ export restrictions on vaccines as well as the many vaccine manufacturing inputs also continue to foul deliveries – and these are poorly understood, Masiyiwa said. . “My principal job is to negotiate with suppliers, and the suppliers have over the last 8-9 months, made it clear that the biggest challenge that they face are export restrictions, export restrictions are being operated right across the board. So, if those export restrictions aren’t there, where are the vaccines, because the production is happening? “We’re not seeing the vaccines, and we are being told by the suppliers, they are facing export restrictions. He added that without resolving, “this issue around the movement of the various ingredients that drive production… we will not even be able to get manufacturing effectively set up.” “We need to get these restrictions removed, and we had a very constructive discussion around this issue with the WTO yesterday,” he said. AU leaders call on India to remove its ban on AstraZeneca vaccine exports – now that domestic COVID surge has subsided WHO Director General Dr Tedros Adhanom Ghebreyesus Masiyiwa also appealed to India to resume its deliveries of AstraZeneca vaccines, produced by the Serum Institute of India – noting that the countries’ embargo on the export of vaccines, remains the most outstanding example of restrictions fouling distribution plans. The SII vaccines were a centerpiece of COVAX and African countries – until exports were abruptly cancelled in March. “We understood that at the time why they were put in place, it was because there was that massive surge in India, and we were incredibly, incredibly sympathetic. But we do now urge our colleagues to show sympathy to us, because we are the ones facing difficulty now. We need to see some of those vaccines begin to come through.” Finally, both African Union and WHO officials repeated their call to countries to support a waiver on intellectual property on COVID vaccines and therapeutics, currently being negotiated by the World Trade Organization – saying that this would help jump-start more manufacturing in developing regions. “American taxpayers, European taxpayers financed some of this intellectual property, and so it should be for the common good,” said Masiyiwa. “So we ask for this IP to be made available. It was a great miracle to have these vaccines, now let this miracle be available to all mankind”. Added WHO’s Tedros: “If it [a waiver] cannot be used now during this unprecedented condition or situation, then when is there a time when it can be used.” Image Credits: @WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
World Leaders Call on Future German Chancellor to Support TRIPS Waiver 15/09/2021 Kerry Cullinan German Health Minister Jens Spahn and German Chancellor Angela Merkel have staunchly opposed the TRIPS waiver. More than 140 former heads of state and Nobel laureates have called on the three candidates in line to be the next German chancellor to declare themselves in favour of waiving intellectual property on COVID-19 vaccines and transferring vaccine technologies. Germany is leading the European Commission’s refusal to accept the so-called TRIPS waiver proposal put forward by South Africa and India at the World Trade Organisation (WTO). However, German elections on 26 September could unseat Angela Merkel’s ruling Christian Democratic Union Party, which has steadfastly opposed the TRIPS waiver – apparently in support of BioNTech-Pfizer. In the letter, addressed to Annalena Baerbock, Olaf Scholz, and Armin Laschet, sent on Wednesday, the signatories stress that German support for waiving patents is vital to overcoming vaccine monopolies, transferring vaccine technology and scaling up vaccine manufacturing around the world to prevent millions more deaths from COVID-19. Signatories include former French President François Hollande, former UK Prime Minister Gordon Brown, former Colombian President Juan Manuel Santos, former Malawian President Joyce Banda and Helen Clark, New Zealand’s former prime minister. Nobel prize winners include Professor Joseph Stiglitz, Professor Francoise Barre-Sinoussi and Elfriede Jelinek. End the pandemic They express deep concern with Germany’s “continued opposition to a temporary waiver of the World Trade Organization’s (WTO) intellectual property rules”, at a time in which “the artificial restriction on manufacturing and supply is leading to thousands of unnecessary deaths from COVID-19 each day”. Less than 2% of adults are fully vaccinated in low-income countries compared to almost 50 % in high-income countries. The TRIPS waiver on COVID-19 vaccines, proposed by India and South Africa in October 2020, is supported by over 100 countries including the United States and France in doing so. “Having helped create the most successful vaccine technology against COVID-19, by overcoming pharmaceutical monopolies and insisting that the technology be shared, Germany has the ability to help end this pandemic,” according to the letter. It also calls on the next Chancellor to ensure that German pharmaceutical companies openly and rapidly share life-saving mRNA vaccine technology with qualified producers around the world. Commenting on the letter, New Zealand’s Clark stressed: “Germany’s support for a TRIPS waiver in the exceptional circumstances presented by COVID-19 would send a clear signal that all peoples should be able to benefit speedily from available vaccines and therapeutics. Widespread vaccination now and further scaling up of vaccine production will play a significant role in curbing the pandemic.” Extraordinary power Meanwhile, Nobel laureate Joseph Stiglitz, said that the new Chancellor of Germany will “hold extraordinary power to turn the tide on this horrific pandemic”. “Intellectual property rules are today locking out people across the world from the benefits of life-saving science – it is time for Germany to ensure the transfer of vaccine technologies and join the rest of the world in backing a temporary waiver at the WTO,” he added. Earlier in the week, Belgian Green Sarah Matthieu, a Member of the European Parliament, said that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. The letter was coordinated by the People’s Vaccine Alliance, a coalition of more than 70 organizations including Club de Madrid, Global Justice Now and UNAIDS. Image Credits: Clemens Bilan. Much More Needs to be Done About Unhealthy Impact of Meat 15/09/2021 Madeleine Hoecklin To address the climate impacts of livestock production, people need to halve their meat-eating, says the Meat Atlas 2021. Twenty multinational meat and dairy conglomerates emit more greenhouse gases than Germany, Britain, or France, according to the Meat Atlas which was launched recently by Friends of the Earth and the Heinrich Böll Stiftung. A range of health issues associated with meat-heavy diets also require attention in the push toward more sustainable practices, according to the World Health Organization (WHO), ahead of next week’s UN Food Systems Summit scheduled for 23 September and the Glasgow Climate Summit, COP 26, which opens 31 October. Around 840,000 deaths annually are attributable to diets high in processed meats, and some 40,000 deaths are linked to diets high in red meats, according to the WHO’s Dr Maria Neira, Director of the Department of Environment, Climate Change and Health, in an interview with Health Policy Watch. Millions more premature deaths have been associated with people eating diets high in saturated fats from meat, and not eating enough fruits, vegetables, fibre, legumes, and other plant-based foods. The consequences of this are malnutrition, hypertension, heart disease and other chronic disease ailments. “[We need to focus on] reducing the consumption of meat and increasing the consumption of plant-based foods, and at the same time [developing] more sustainable food systems, a better recovery from COVID-19, a strategy to tackle climate change, and promoting health,” Neira told Health Policy Watch. For decades, the WHO has recommended replacing high saturated-fat, high-calorie meats and processed foods with unprocessed foods, fibre-rich foods, fresh fruits and vegetables. Health and climate synergies The health and climate synergies are elaborated on in WHO’s recent Compendium of guidance on health and the environment, which covers issues from air pollution to biodiversity, clean water and sanitation. “Current patterns of food production and consumption use much of the world’s resources on land and water and contribute significantly to climate and ecosystem change through for example deforestation, loss of biodiversity and GHG emissions,” according to the compendium. “This is aggravated by the fact that about one third of food produced for human consumption is wasted,” it adds. “The expansion of industrial agriculture at the expense of nature puts our global health at risk,” according to the Meat Atlas. It calls on countries to “develop an action plan to promote less and better consumption and production of meat, dairy and eggs, to shift away from industrial farming, and to support better animal farming and healthy, plant-rich diets.” Meanwhile, the WHO’s compendium provides over 400 interventions and recommendations for action to address the overconsumption of red and processed meat. Neira argues that the world has to move to decarbonisation ”with a high level of ambition and speed”. This can be done through more regulation of meat producers, raising awareness about the health implications of high meat consumption, and shifting consumption decisions in favor of sustainability and health. Impact on water and land Livestock production produces 14.5% of the world’s greenhouse gas emissions, but also uses vast amounts of water. Agriculture uses some 92% of the global water footprint and 29% of this is used in animal production. Agriculture uses three times as much available fresh water than 50 years ago. Three-quarters of all agricultural land is used to raise livestock and to grow the crops to feed them – but livestock corporations also drive water pollution, deforestation, pesticide use, and biodiversity loss. While climate campaigners push for reducing meat consumption, the demand for meat is forecasted to continue to grow over the next decade, warns the Meat Atlas. To meet this demand, meat production is becoming more industrialised, marginalising smaller meat and milk producers that represent more sustainable food production models. Antimicrobial resistance Industrial livestock production also increases the risk of zoonotic disease transmission and antimicrobial resistance (AMR), through inappropriate and largely unregulated agricultural practices. Some 73% of the antibiotics sold worldwide are used on animals and the proportion of industrial animal agriculture that routinely uses antibiotics is rising. Antibiotics are used as growth stimulants in animals and can compensate for shortcomings in hygiene, management, and the care of animals in livestock production. But the overuse or misuse of antibiotics in food-producing animals can lead to AMR in humans that cause longer illnesses, more frequent hospitalizations, and treatment failures. According to the ‘Meat Atlas’, half the chicken samples from major poultry producers in five European Union countries were contaminated with antibiotic-resistant pathogens. “Antimicrobial resistance linked to the excessive and inappropriate use of antibiotics in animal and human healthcare leads to an estimated 33,000 human deaths in the EU every year,” said the Meat Atlas. Zoonotic diseases Freshly slaughtered animals and processed meat in a market in Wuhan, Hubei, China Certain wild animals – including rodents, bats, carnivores and monkeys – are among those most likely to harbour zoonotic diseases that are harmful to humans, according to the Meat Atlas. The coronavirus, which originates in bat populations, is an example. One of the most favoured hypotheses put forward by the WHO scientists investigating the origins of the SARS-C0V2 virus causing the current pandemic is that it came from wild animals. Approximately 60% of all infectious diseases in humans are zoonotic and almost three-quarters of known zoonoses can be traced to wildlife, for example by people eating the meat of wild animals. The industrialized production of wild animals or domesticated livestock often serve as a bridge for transmission, thus posing a “dire threat to global human health,” said the Meat Atlas. Emerging pathogens are crossing the animal-human barrier with increased frequency or greater impact. The crowded conditions used to house animals in industrialised livestock production systems allow infections to easily mutate and jump to human hosts. In addition, the destruction of ecosystems to cultivate land for agricultural production is bringing people into closer contact with wild animals. As consumption patterns shift towards more meat, the risk of contracting zoonotic diseases will increase. Shifting to plant-based foods Trends in meat production (Meat Atlas 2021) Shifting diets towards plant-based foods could help reduce diet-related non-communicable disease risks and global disease burdens of obesity, cardiovascular disease, and diabetes – and slow the rise in methane emissions associated with livestock production. Plant-based and minimally processed foods “must be made available, accessible, affordable, safe, culturally acceptable and desirable to the whole population including the most vulnerable,” says the WHO’s compendium report. The world will need tailored approaches to curbing meat consumption, said Neira. “For more industrialised countries, we can move into stimulating the reduction of meat consumption and promoting healthy diets…[with] plant-based or unprocessed food,” Neira said. “A policymaker in a developed country…can go with more ambition on promoting [a plant-based diet], while in developing countries…we need to have a holistic view of their protein intake…and ensure that people will have access to foods that meet their protein needs every day,” she said. Interventions from health policymakers will require advocacy campaigns with clear arguments to “promote the importance of reducing meat consumption and increasing consumption of plant-based foods for the health of the people,” said Neira. “WHO will go to COP26 with a very strong report called the ‘Health Argument for Climate Action’ and we will put the focus on the health benefits that can be obtained be mitigating the causes of climate change and promoting a more sustainable food system from the beginning to the end,” said Neira. Image Credits: Friends of the Earth and the Heinrich Böll Stiftung, Arend Kuester/Flickr, Meat Atlas 2021. Pressure Builds on Biden to End TRIPS Waiver Impasse, Enable Equitable Access to COVID Vaccines 15/09/2021 Kerry Cullinan President Joe Biden speaking in Germany after a G7 meeting. Pressure is mounting on US President Joe Biden to provide global leadership to ensure equitable access to COVID-19 vaccines in the face of the European Commission’s refusal to support a waiver on intellectual property rights. Biden is expected to host a global leaders’ summit on COVID-19 alongside the United Nations General Assembly next week, and US officials are lobbying countries to support targets to end the pandemic centred on how to get 70% of people vaccinated by late 2022. African leaders hope that Biden’s COVID-19 summit will lead to more equitable access to vaccines: WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response Negotiations over the suspension of intellectual property rights for COVID-19 vaccines, therapeutics and diagnostics, the TRIPS waiver, have stalled at the World Trade Organization (WTO) in the face of opposition from the European Union. But if the US put forward a text on waiver, this would reinvigorate the talks, appealed South African trade ministry advisor Zane Dangor on Tuesday. South Africa and India are co-sponsors of the waiver. “Action by the US will be particularly potent to shift the needle in the negotiations and make people come around the table and discuss these issues,” said Dangor, one of the key officials involved in the WTO TRIPS waiver negotiations. In May, Biden took the world by surprise when he announced US support for the waiver proposal – although only in relation to COVID-19 vaccines. But the European Commission, particularly Germany, has refused to budget. “The European Union would like to kick the discussions further down the road,” said Dangor, adding that the EU had made it known this week that it was not in favour of a decision on the TRIPS waiver being made at the upcoming WTO Ministerial on 30 November. Zane Dangor, Special Adviser to South Africa’s Trade Minister. “We need commitment on a text from the US that can be tabled and negotiated with South Africa, India and other co-sponsors so that we can have an outcome and move to get to the business of actually ensuring that we get jabs in arms of those who need most and have equitable access,” Dangor told a press briefing organised by Public Citizen. “Not only do we need to get the WTO waiver done, but we require vaccine recipes to be shared via broad tech transfer to speed expansion of COVID medicine supplies,” added Dangor. In July, the World Health Organization (WHO) announced that it had established a “tech transfer hub” in South Africa to enable African companies produce mRNA vaccines – but the mRNA manufacturers, Pfizer-BioNTech and Moderna, have refused to join the hub. Last week, in response to a recent Health Policy Watch question, Pfizer CEO Albert Bourla said: “I’m not sure what is the point of transferring technology that it is going to take years to transfer. And, by the way, this is what we do. I’m not sure I understand what they want, to give it someone else to do?” European Commission counter-proposal is ‘big air’ Belgian Green Sarah Matthieu, a Member of the European Parliament, believes that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. Matthieu said that the German elections on 26 September may shift the power balance it that country and change the position of Germany on the waiver. US Congressman Ro Khanna said that Biden had shown “strong leadership on the TRIPS waiver” but he now had to “convince our European allies, who are often fond of lecturing the United States about moral responsibility, to live up to theirs”. Khanna added that the US had been “instrumental in the development of these vaccines”, including by “funding some of the critical research” and “providing purchase agreements that mitigated the risk for pharmaceutical companies”. Although the US government has indicated it would only support a waiver for vaccines, Khanna told the MSF briefing that this should extend to therapeutics. “More broadly, we need to have a better system for how we incentivize the production and distribution of drugs to the poor and for issues of that really affect large numbers of population,” said Khanna. “A purely for-profit model of developing medicines may lead to an over-investment in acne treatment and an under-investment of treatment on some of the biggest diseases. “Not only do we need a TRIPS waiver, but we need to think about how can we incentivize the development and the production of medicine that actually are affecting the urgent needs of many people in the United States and around the world.” Waiver debate is about pharma profit, says Stiglitz Professor Joseph Stiglitz Nobel laureate and Columbia University economist Professor Joseph Stiglitz described the waiver debate as being about the ability of the drug companies to exercise monopoly power to get substantial profits, rather than a reasonable return on their investment. “Drug companies’ concern is maximising profits. That’s their business model. And maximising profits means restricting supply because by restricting supply, you increase price, and by increasing price you increase profits,” he stressed. Referring to Pfizer’s recent talk about selling its vaccine for $175 a dose, Stiglitz said this was based on the belief that there was going to be a vaccine shortage, which would enable the company to extract a monopoly price. Like Khanna, Stiglitz stressed that the development of the COVID-19 vaccines was an international effort that had involved significant investment from various governments as well as scientists from around the world. “Germany’s particular view on this is especially peculiar because the German company, BioNTech, has already sold its international rights to Pfizer so the waiver is not even going to affect its profits,” he said, describing the EU’s opposition to the waiver as “objectionable” and “unconscionable”. Confusion about TRIPS waiver Stiglitz stressed that there was also confusion about the TRIPS waiver. “First, this is not the abolition of property rights. [Pharmaceutical companies] still get compensated for using their intellectual property rights. So, it’s not taking away their property rights. Its just saying we are in an emergency, and in this emergency, intellectual property rights have to be available more widely,” Stiglitz told the MSF briefing. “Secondly, it’s not even a change in the intellectual framework because, since the beginning of the WTO, we’ve recognised the principle of compulsory licenses. This is effectively just a compulsory license… to lower transaction costs. Lower transaction costs in the midst of the pandemic, where there’s a kind of urgency that we don’t normally have, is absolutely essential,” he added. “We’ve enacted voluntary licenses. The world has debated this. It debated it when the WTO TRIPS initially adopted it. It was really debated that in the context of HIV/AIDS, which reaffirmed the principle of compulsory licenses.” “We are in the midst of what some people call the new cold war. On the one hand, there are authoritarian governments like Russia and China, and then, on the other hand, there are democracies. We would like the democracies to win, but we’re not putting a good face on democracy when we say our democracies put profits over lives. “Russia has been very actively engaged in vaccine diplomacy. It’s made its vaccine available, say in a country like Argentina. But not only has it made its vaccine available, it’s actually actively engaged in transferring technology and enabling countries to build plants to produce the vaccine. And I’m afraid we’re losing this particular battle.” Civil society groups demonstrate outside embassies of countries that oppose a temporary WTO patent waiver on COVID-19 health products. Image Credits: CNBC, Munich Security Conference, Tadeau Andre/MSF . WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response 14/09/2021 Elaine Ruth Fletcher Left-right: Strive Masiyiwa, AU COVID envoy, Dr Tedros Adhanom Ghebreyesus, WHO Director General, Dr John Nkengasong, Africa CDC diector After months of frustrated efforts to unlock global vaccine supplies for the African continent, WHO and African Union leaders are now pinning their hopes on US President Joe Biden’s reported plan to call heads of state to a “Global Pandemic Summit” on the sidelines of the United Nations General Assembly, which opened today, as a way out of the current deadlock. Biden reportedly is circulating a plan to hold the summit on 22 September – with the aim of reaching a joint commitment to the vaccination of 70% of the world’s population by the GA session in September 2022, ensuring that “additional doses and adequate supplies are available to all countries”, according to a set of targets circulating among embassies, and obtained by the Washington Post. To achieve that, the Biden plan for the Global COVID-19 Summit also calls for “expediting delivery of approximately 2.0 billion previous committed doses.. including by converting existing dose sharing pledges into near-term deliveries, swapping delivery dates to secure earlier delivery of doses to LIC/LMICs, and eliminating cross-border bottlenecks in the supply of vaccines and critical inputs.” But speaking at Tuesday’s press conference following two days of meetings in Geneva, African Union and African Centers for Disease officials stressed that the era of “pledges” for vaccine donations to Africa, needs to end and investments in African vaccine manufacturing to begin, as part of any ‘New Deal’ on pandemic response in low- and middle-income (LMICs) countries. “”We, as the African Union, are calling on a permanent structure,” said Masiyiwa, a billionaire entrepreneur and AU Special Envoy for COVID-19, “and this is something that we will be calling on to be put in place at this summit that President Biden is convening. “We strongly believe that the pledge architecture, where countries gathered together and made pledges…. has had its day. Let us now have a permanent structure. Vaccine sharing is good. But we shouldn’t have to be relying on vaccine sharing, when we can come to the table, put structures in place, and then say that we also want to buy.” Calls for new African vaccine facility Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank This should involve the creation of a new, and permanent African vaccine facility, supported by the African Union, World Bank and International Monetary Fund, said Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank. Afreximbank has provided financing for the continent’s purchase of some 400 million Johnson & Johnson vaccines – backed by the World Bank. But Benedict stressed this is only the beginning of a long road that will require the procurement of booster doses as well. And so a more permanent finance mechanism is needed for countries to manufacturer and purchase doses themselves – rather than being solely reliant on goodwill donations. While “thanking” COVAX for the role it has played in facilitating global COVID vaccine supplies, “going forward, we need the IMF to do the vaccine facility – to make it possible for countries to now access these vaccines through the structures put in place,” said Oramah. Those structures should include domestic manufacturing and procurement financed through African mechanisms, such as “Afreximbank, providing the initial financing, and then they refinance it in a way that makes it possible for the current accounts to carry all this – while the World Bank continues to provide institutional structures that are required to effectively administer vaccines.” Africa is region with lowest rates of vaccine coverage in the world Seth Berkley, CEO Gavi, The Vaccine Alliance Among all LMICs, Africa stands out for its particularly low vaccination rates so far – with under 3.5% of its population vaccinated – as compared to 60-70% in some high-income nations, African Union also said, speaking at a WHO press conference in Geneva. Of 5.2 billion doses delivered worldwide, only a tiny fraction have reached Africa, noted WHO Director General Dr Tedros Ahanom Ghebreyesus. And as things stand now, COVAX, the global vaccine facility, only has sufficient doses in the delivery pipeline to vaccinate roughly 20% of the population in the 91 lowest income countries by the end of the year, using some 1.4 billion purchased and donated doses, admitted Gavi CEO Seth Berkley at the WHO press conference. And it would hit 36% coverage by March, 2022. That falls far short of WHO’s target of 40% vaccination by December 2021 and 70% by March 2022. To reach those targets, “the world needs 2.4 billion additional doses to go into low income countries to get us to 40% by the end of this year,” Said Bruce Aylward, a special WHO advisor on the pandemic. “Those doses exist,” he said, citing recent pharma statements to the effect that there are now sufficient doses for everyone to go around – including high- and low-income countries. See related story Massive Increase in COVID-19 Vaccine Production May Mean Dose Surplus by Mid-2022, says IFPMA I think the question we ask is: where are those doses if there are enough for everybody?” Aylward asked. “And [the US Summit] next week is all about making sure there’s a clear path to ensuring they go to where they’re needed.” Barriers that have fouled vaccine access – both countries and manufacturers share blame Strive Masiyiwa, African Union COVID-19 envoy Speaking at the close of a two-day Geneva meeting, which also included Dr John Nkengasong, Africa CDC director and African Regional Director Matshidiso Moeti, the WHO and AU officials said that in they had reviewed in painstaking detail the various obstacles in the way of African vaccine access – and ways to overcome them. The challenges have included export bans, including the interruption of supplies from India in March 2020 when the subcontinent experienced its own COVID surge, but also barriers on the exports of vaccines and their inputs to a complex supply chain, they noted. But the African officials also repeated longstanding complaints against rich countries for vaccine hoarding, as well as against pharma for preferential sales to high income countries of huge vaccine quantities – in excess of actual population needs. “We want to buy from the same manufacturers,” said Masiyiwa. “But to be fair, those manufacturers know very well that they never gave us proper access. They gave access on a very different basis. “When they knew that supplies were restricted at the beginning, there was no production… they [pharma manufacturers] had a moral responsibility to ensure that others also had access,” he said. “And we find this very sad. It’s very sad. We could have addressed this very differently. We as Africa will now address this through setting up our own manufacturing capabilities.” Countries’ export restrictions also holding up distribution But countries’ export restrictions on vaccines as well as the many vaccine manufacturing inputs also continue to foul deliveries – and these are poorly understood, Masiyiwa said. . “My principal job is to negotiate with suppliers, and the suppliers have over the last 8-9 months, made it clear that the biggest challenge that they face are export restrictions, export restrictions are being operated right across the board. So, if those export restrictions aren’t there, where are the vaccines, because the production is happening? “We’re not seeing the vaccines, and we are being told by the suppliers, they are facing export restrictions. He added that without resolving, “this issue around the movement of the various ingredients that drive production… we will not even be able to get manufacturing effectively set up.” “We need to get these restrictions removed, and we had a very constructive discussion around this issue with the WTO yesterday,” he said. AU leaders call on India to remove its ban on AstraZeneca vaccine exports – now that domestic COVID surge has subsided WHO Director General Dr Tedros Adhanom Ghebreyesus Masiyiwa also appealed to India to resume its deliveries of AstraZeneca vaccines, produced by the Serum Institute of India – noting that the countries’ embargo on the export of vaccines, remains the most outstanding example of restrictions fouling distribution plans. The SII vaccines were a centerpiece of COVAX and African countries – until exports were abruptly cancelled in March. “We understood that at the time why they were put in place, it was because there was that massive surge in India, and we were incredibly, incredibly sympathetic. But we do now urge our colleagues to show sympathy to us, because we are the ones facing difficulty now. We need to see some of those vaccines begin to come through.” Finally, both African Union and WHO officials repeated their call to countries to support a waiver on intellectual property on COVID vaccines and therapeutics, currently being negotiated by the World Trade Organization – saying that this would help jump-start more manufacturing in developing regions. “American taxpayers, European taxpayers financed some of this intellectual property, and so it should be for the common good,” said Masiyiwa. “So we ask for this IP to be made available. It was a great miracle to have these vaccines, now let this miracle be available to all mankind”. Added WHO’s Tedros: “If it [a waiver] cannot be used now during this unprecedented condition or situation, then when is there a time when it can be used.” Image Credits: @WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Much More Needs to be Done About Unhealthy Impact of Meat 15/09/2021 Madeleine Hoecklin To address the climate impacts of livestock production, people need to halve their meat-eating, says the Meat Atlas 2021. Twenty multinational meat and dairy conglomerates emit more greenhouse gases than Germany, Britain, or France, according to the Meat Atlas which was launched recently by Friends of the Earth and the Heinrich Böll Stiftung. A range of health issues associated with meat-heavy diets also require attention in the push toward more sustainable practices, according to the World Health Organization (WHO), ahead of next week’s UN Food Systems Summit scheduled for 23 September and the Glasgow Climate Summit, COP 26, which opens 31 October. Around 840,000 deaths annually are attributable to diets high in processed meats, and some 40,000 deaths are linked to diets high in red meats, according to the WHO’s Dr Maria Neira, Director of the Department of Environment, Climate Change and Health, in an interview with Health Policy Watch. Millions more premature deaths have been associated with people eating diets high in saturated fats from meat, and not eating enough fruits, vegetables, fibre, legumes, and other plant-based foods. The consequences of this are malnutrition, hypertension, heart disease and other chronic disease ailments. “[We need to focus on] reducing the consumption of meat and increasing the consumption of plant-based foods, and at the same time [developing] more sustainable food systems, a better recovery from COVID-19, a strategy to tackle climate change, and promoting health,” Neira told Health Policy Watch. For decades, the WHO has recommended replacing high saturated-fat, high-calorie meats and processed foods with unprocessed foods, fibre-rich foods, fresh fruits and vegetables. Health and climate synergies The health and climate synergies are elaborated on in WHO’s recent Compendium of guidance on health and the environment, which covers issues from air pollution to biodiversity, clean water and sanitation. “Current patterns of food production and consumption use much of the world’s resources on land and water and contribute significantly to climate and ecosystem change through for example deforestation, loss of biodiversity and GHG emissions,” according to the compendium. “This is aggravated by the fact that about one third of food produced for human consumption is wasted,” it adds. “The expansion of industrial agriculture at the expense of nature puts our global health at risk,” according to the Meat Atlas. It calls on countries to “develop an action plan to promote less and better consumption and production of meat, dairy and eggs, to shift away from industrial farming, and to support better animal farming and healthy, plant-rich diets.” Meanwhile, the WHO’s compendium provides over 400 interventions and recommendations for action to address the overconsumption of red and processed meat. Neira argues that the world has to move to decarbonisation ”with a high level of ambition and speed”. This can be done through more regulation of meat producers, raising awareness about the health implications of high meat consumption, and shifting consumption decisions in favor of sustainability and health. Impact on water and land Livestock production produces 14.5% of the world’s greenhouse gas emissions, but also uses vast amounts of water. Agriculture uses some 92% of the global water footprint and 29% of this is used in animal production. Agriculture uses three times as much available fresh water than 50 years ago. Three-quarters of all agricultural land is used to raise livestock and to grow the crops to feed them – but livestock corporations also drive water pollution, deforestation, pesticide use, and biodiversity loss. While climate campaigners push for reducing meat consumption, the demand for meat is forecasted to continue to grow over the next decade, warns the Meat Atlas. To meet this demand, meat production is becoming more industrialised, marginalising smaller meat and milk producers that represent more sustainable food production models. Antimicrobial resistance Industrial livestock production also increases the risk of zoonotic disease transmission and antimicrobial resistance (AMR), through inappropriate and largely unregulated agricultural practices. Some 73% of the antibiotics sold worldwide are used on animals and the proportion of industrial animal agriculture that routinely uses antibiotics is rising. Antibiotics are used as growth stimulants in animals and can compensate for shortcomings in hygiene, management, and the care of animals in livestock production. But the overuse or misuse of antibiotics in food-producing animals can lead to AMR in humans that cause longer illnesses, more frequent hospitalizations, and treatment failures. According to the ‘Meat Atlas’, half the chicken samples from major poultry producers in five European Union countries were contaminated with antibiotic-resistant pathogens. “Antimicrobial resistance linked to the excessive and inappropriate use of antibiotics in animal and human healthcare leads to an estimated 33,000 human deaths in the EU every year,” said the Meat Atlas. Zoonotic diseases Freshly slaughtered animals and processed meat in a market in Wuhan, Hubei, China Certain wild animals – including rodents, bats, carnivores and monkeys – are among those most likely to harbour zoonotic diseases that are harmful to humans, according to the Meat Atlas. The coronavirus, which originates in bat populations, is an example. One of the most favoured hypotheses put forward by the WHO scientists investigating the origins of the SARS-C0V2 virus causing the current pandemic is that it came from wild animals. Approximately 60% of all infectious diseases in humans are zoonotic and almost three-quarters of known zoonoses can be traced to wildlife, for example by people eating the meat of wild animals. The industrialized production of wild animals or domesticated livestock often serve as a bridge for transmission, thus posing a “dire threat to global human health,” said the Meat Atlas. Emerging pathogens are crossing the animal-human barrier with increased frequency or greater impact. The crowded conditions used to house animals in industrialised livestock production systems allow infections to easily mutate and jump to human hosts. In addition, the destruction of ecosystems to cultivate land for agricultural production is bringing people into closer contact with wild animals. As consumption patterns shift towards more meat, the risk of contracting zoonotic diseases will increase. Shifting to plant-based foods Trends in meat production (Meat Atlas 2021) Shifting diets towards plant-based foods could help reduce diet-related non-communicable disease risks and global disease burdens of obesity, cardiovascular disease, and diabetes – and slow the rise in methane emissions associated with livestock production. Plant-based and minimally processed foods “must be made available, accessible, affordable, safe, culturally acceptable and desirable to the whole population including the most vulnerable,” says the WHO’s compendium report. The world will need tailored approaches to curbing meat consumption, said Neira. “For more industrialised countries, we can move into stimulating the reduction of meat consumption and promoting healthy diets…[with] plant-based or unprocessed food,” Neira said. “A policymaker in a developed country…can go with more ambition on promoting [a plant-based diet], while in developing countries…we need to have a holistic view of their protein intake…and ensure that people will have access to foods that meet their protein needs every day,” she said. Interventions from health policymakers will require advocacy campaigns with clear arguments to “promote the importance of reducing meat consumption and increasing consumption of plant-based foods for the health of the people,” said Neira. “WHO will go to COP26 with a very strong report called the ‘Health Argument for Climate Action’ and we will put the focus on the health benefits that can be obtained be mitigating the causes of climate change and promoting a more sustainable food system from the beginning to the end,” said Neira. Image Credits: Friends of the Earth and the Heinrich Böll Stiftung, Arend Kuester/Flickr, Meat Atlas 2021. Pressure Builds on Biden to End TRIPS Waiver Impasse, Enable Equitable Access to COVID Vaccines 15/09/2021 Kerry Cullinan President Joe Biden speaking in Germany after a G7 meeting. Pressure is mounting on US President Joe Biden to provide global leadership to ensure equitable access to COVID-19 vaccines in the face of the European Commission’s refusal to support a waiver on intellectual property rights. Biden is expected to host a global leaders’ summit on COVID-19 alongside the United Nations General Assembly next week, and US officials are lobbying countries to support targets to end the pandemic centred on how to get 70% of people vaccinated by late 2022. African leaders hope that Biden’s COVID-19 summit will lead to more equitable access to vaccines: WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response Negotiations over the suspension of intellectual property rights for COVID-19 vaccines, therapeutics and diagnostics, the TRIPS waiver, have stalled at the World Trade Organization (WTO) in the face of opposition from the European Union. But if the US put forward a text on waiver, this would reinvigorate the talks, appealed South African trade ministry advisor Zane Dangor on Tuesday. South Africa and India are co-sponsors of the waiver. “Action by the US will be particularly potent to shift the needle in the negotiations and make people come around the table and discuss these issues,” said Dangor, one of the key officials involved in the WTO TRIPS waiver negotiations. In May, Biden took the world by surprise when he announced US support for the waiver proposal – although only in relation to COVID-19 vaccines. But the European Commission, particularly Germany, has refused to budget. “The European Union would like to kick the discussions further down the road,” said Dangor, adding that the EU had made it known this week that it was not in favour of a decision on the TRIPS waiver being made at the upcoming WTO Ministerial on 30 November. Zane Dangor, Special Adviser to South Africa’s Trade Minister. “We need commitment on a text from the US that can be tabled and negotiated with South Africa, India and other co-sponsors so that we can have an outcome and move to get to the business of actually ensuring that we get jabs in arms of those who need most and have equitable access,” Dangor told a press briefing organised by Public Citizen. “Not only do we need to get the WTO waiver done, but we require vaccine recipes to be shared via broad tech transfer to speed expansion of COVID medicine supplies,” added Dangor. In July, the World Health Organization (WHO) announced that it had established a “tech transfer hub” in South Africa to enable African companies produce mRNA vaccines – but the mRNA manufacturers, Pfizer-BioNTech and Moderna, have refused to join the hub. Last week, in response to a recent Health Policy Watch question, Pfizer CEO Albert Bourla said: “I’m not sure what is the point of transferring technology that it is going to take years to transfer. And, by the way, this is what we do. I’m not sure I understand what they want, to give it someone else to do?” European Commission counter-proposal is ‘big air’ Belgian Green Sarah Matthieu, a Member of the European Parliament, believes that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. Matthieu said that the German elections on 26 September may shift the power balance it that country and change the position of Germany on the waiver. US Congressman Ro Khanna said that Biden had shown “strong leadership on the TRIPS waiver” but he now had to “convince our European allies, who are often fond of lecturing the United States about moral responsibility, to live up to theirs”. Khanna added that the US had been “instrumental in the development of these vaccines”, including by “funding some of the critical research” and “providing purchase agreements that mitigated the risk for pharmaceutical companies”. Although the US government has indicated it would only support a waiver for vaccines, Khanna told the MSF briefing that this should extend to therapeutics. “More broadly, we need to have a better system for how we incentivize the production and distribution of drugs to the poor and for issues of that really affect large numbers of population,” said Khanna. “A purely for-profit model of developing medicines may lead to an over-investment in acne treatment and an under-investment of treatment on some of the biggest diseases. “Not only do we need a TRIPS waiver, but we need to think about how can we incentivize the development and the production of medicine that actually are affecting the urgent needs of many people in the United States and around the world.” Waiver debate is about pharma profit, says Stiglitz Professor Joseph Stiglitz Nobel laureate and Columbia University economist Professor Joseph Stiglitz described the waiver debate as being about the ability of the drug companies to exercise monopoly power to get substantial profits, rather than a reasonable return on their investment. “Drug companies’ concern is maximising profits. That’s their business model. And maximising profits means restricting supply because by restricting supply, you increase price, and by increasing price you increase profits,” he stressed. Referring to Pfizer’s recent talk about selling its vaccine for $175 a dose, Stiglitz said this was based on the belief that there was going to be a vaccine shortage, which would enable the company to extract a monopoly price. Like Khanna, Stiglitz stressed that the development of the COVID-19 vaccines was an international effort that had involved significant investment from various governments as well as scientists from around the world. “Germany’s particular view on this is especially peculiar because the German company, BioNTech, has already sold its international rights to Pfizer so the waiver is not even going to affect its profits,” he said, describing the EU’s opposition to the waiver as “objectionable” and “unconscionable”. Confusion about TRIPS waiver Stiglitz stressed that there was also confusion about the TRIPS waiver. “First, this is not the abolition of property rights. [Pharmaceutical companies] still get compensated for using their intellectual property rights. So, it’s not taking away their property rights. Its just saying we are in an emergency, and in this emergency, intellectual property rights have to be available more widely,” Stiglitz told the MSF briefing. “Secondly, it’s not even a change in the intellectual framework because, since the beginning of the WTO, we’ve recognised the principle of compulsory licenses. This is effectively just a compulsory license… to lower transaction costs. Lower transaction costs in the midst of the pandemic, where there’s a kind of urgency that we don’t normally have, is absolutely essential,” he added. “We’ve enacted voluntary licenses. The world has debated this. It debated it when the WTO TRIPS initially adopted it. It was really debated that in the context of HIV/AIDS, which reaffirmed the principle of compulsory licenses.” “We are in the midst of what some people call the new cold war. On the one hand, there are authoritarian governments like Russia and China, and then, on the other hand, there are democracies. We would like the democracies to win, but we’re not putting a good face on democracy when we say our democracies put profits over lives. “Russia has been very actively engaged in vaccine diplomacy. It’s made its vaccine available, say in a country like Argentina. But not only has it made its vaccine available, it’s actually actively engaged in transferring technology and enabling countries to build plants to produce the vaccine. And I’m afraid we’re losing this particular battle.” Civil society groups demonstrate outside embassies of countries that oppose a temporary WTO patent waiver on COVID-19 health products. Image Credits: CNBC, Munich Security Conference, Tadeau Andre/MSF . WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response 14/09/2021 Elaine Ruth Fletcher Left-right: Strive Masiyiwa, AU COVID envoy, Dr Tedros Adhanom Ghebreyesus, WHO Director General, Dr John Nkengasong, Africa CDC diector After months of frustrated efforts to unlock global vaccine supplies for the African continent, WHO and African Union leaders are now pinning their hopes on US President Joe Biden’s reported plan to call heads of state to a “Global Pandemic Summit” on the sidelines of the United Nations General Assembly, which opened today, as a way out of the current deadlock. Biden reportedly is circulating a plan to hold the summit on 22 September – with the aim of reaching a joint commitment to the vaccination of 70% of the world’s population by the GA session in September 2022, ensuring that “additional doses and adequate supplies are available to all countries”, according to a set of targets circulating among embassies, and obtained by the Washington Post. To achieve that, the Biden plan for the Global COVID-19 Summit also calls for “expediting delivery of approximately 2.0 billion previous committed doses.. including by converting existing dose sharing pledges into near-term deliveries, swapping delivery dates to secure earlier delivery of doses to LIC/LMICs, and eliminating cross-border bottlenecks in the supply of vaccines and critical inputs.” But speaking at Tuesday’s press conference following two days of meetings in Geneva, African Union and African Centers for Disease officials stressed that the era of “pledges” for vaccine donations to Africa, needs to end and investments in African vaccine manufacturing to begin, as part of any ‘New Deal’ on pandemic response in low- and middle-income (LMICs) countries. “”We, as the African Union, are calling on a permanent structure,” said Masiyiwa, a billionaire entrepreneur and AU Special Envoy for COVID-19, “and this is something that we will be calling on to be put in place at this summit that President Biden is convening. “We strongly believe that the pledge architecture, where countries gathered together and made pledges…. has had its day. Let us now have a permanent structure. Vaccine sharing is good. But we shouldn’t have to be relying on vaccine sharing, when we can come to the table, put structures in place, and then say that we also want to buy.” Calls for new African vaccine facility Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank This should involve the creation of a new, and permanent African vaccine facility, supported by the African Union, World Bank and International Monetary Fund, said Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank. Afreximbank has provided financing for the continent’s purchase of some 400 million Johnson & Johnson vaccines – backed by the World Bank. But Benedict stressed this is only the beginning of a long road that will require the procurement of booster doses as well. And so a more permanent finance mechanism is needed for countries to manufacturer and purchase doses themselves – rather than being solely reliant on goodwill donations. While “thanking” COVAX for the role it has played in facilitating global COVID vaccine supplies, “going forward, we need the IMF to do the vaccine facility – to make it possible for countries to now access these vaccines through the structures put in place,” said Oramah. Those structures should include domestic manufacturing and procurement financed through African mechanisms, such as “Afreximbank, providing the initial financing, and then they refinance it in a way that makes it possible for the current accounts to carry all this – while the World Bank continues to provide institutional structures that are required to effectively administer vaccines.” Africa is region with lowest rates of vaccine coverage in the world Seth Berkley, CEO Gavi, The Vaccine Alliance Among all LMICs, Africa stands out for its particularly low vaccination rates so far – with under 3.5% of its population vaccinated – as compared to 60-70% in some high-income nations, African Union also said, speaking at a WHO press conference in Geneva. Of 5.2 billion doses delivered worldwide, only a tiny fraction have reached Africa, noted WHO Director General Dr Tedros Ahanom Ghebreyesus. And as things stand now, COVAX, the global vaccine facility, only has sufficient doses in the delivery pipeline to vaccinate roughly 20% of the population in the 91 lowest income countries by the end of the year, using some 1.4 billion purchased and donated doses, admitted Gavi CEO Seth Berkley at the WHO press conference. And it would hit 36% coverage by March, 2022. That falls far short of WHO’s target of 40% vaccination by December 2021 and 70% by March 2022. To reach those targets, “the world needs 2.4 billion additional doses to go into low income countries to get us to 40% by the end of this year,” Said Bruce Aylward, a special WHO advisor on the pandemic. “Those doses exist,” he said, citing recent pharma statements to the effect that there are now sufficient doses for everyone to go around – including high- and low-income countries. See related story Massive Increase in COVID-19 Vaccine Production May Mean Dose Surplus by Mid-2022, says IFPMA I think the question we ask is: where are those doses if there are enough for everybody?” Aylward asked. “And [the US Summit] next week is all about making sure there’s a clear path to ensuring they go to where they’re needed.” Barriers that have fouled vaccine access – both countries and manufacturers share blame Strive Masiyiwa, African Union COVID-19 envoy Speaking at the close of a two-day Geneva meeting, which also included Dr John Nkengasong, Africa CDC director and African Regional Director Matshidiso Moeti, the WHO and AU officials said that in they had reviewed in painstaking detail the various obstacles in the way of African vaccine access – and ways to overcome them. The challenges have included export bans, including the interruption of supplies from India in March 2020 when the subcontinent experienced its own COVID surge, but also barriers on the exports of vaccines and their inputs to a complex supply chain, they noted. But the African officials also repeated longstanding complaints against rich countries for vaccine hoarding, as well as against pharma for preferential sales to high income countries of huge vaccine quantities – in excess of actual population needs. “We want to buy from the same manufacturers,” said Masiyiwa. “But to be fair, those manufacturers know very well that they never gave us proper access. They gave access on a very different basis. “When they knew that supplies were restricted at the beginning, there was no production… they [pharma manufacturers] had a moral responsibility to ensure that others also had access,” he said. “And we find this very sad. It’s very sad. We could have addressed this very differently. We as Africa will now address this through setting up our own manufacturing capabilities.” Countries’ export restrictions also holding up distribution But countries’ export restrictions on vaccines as well as the many vaccine manufacturing inputs also continue to foul deliveries – and these are poorly understood, Masiyiwa said. . “My principal job is to negotiate with suppliers, and the suppliers have over the last 8-9 months, made it clear that the biggest challenge that they face are export restrictions, export restrictions are being operated right across the board. So, if those export restrictions aren’t there, where are the vaccines, because the production is happening? “We’re not seeing the vaccines, and we are being told by the suppliers, they are facing export restrictions. He added that without resolving, “this issue around the movement of the various ingredients that drive production… we will not even be able to get manufacturing effectively set up.” “We need to get these restrictions removed, and we had a very constructive discussion around this issue with the WTO yesterday,” he said. AU leaders call on India to remove its ban on AstraZeneca vaccine exports – now that domestic COVID surge has subsided WHO Director General Dr Tedros Adhanom Ghebreyesus Masiyiwa also appealed to India to resume its deliveries of AstraZeneca vaccines, produced by the Serum Institute of India – noting that the countries’ embargo on the export of vaccines, remains the most outstanding example of restrictions fouling distribution plans. The SII vaccines were a centerpiece of COVAX and African countries – until exports were abruptly cancelled in March. “We understood that at the time why they were put in place, it was because there was that massive surge in India, and we were incredibly, incredibly sympathetic. But we do now urge our colleagues to show sympathy to us, because we are the ones facing difficulty now. We need to see some of those vaccines begin to come through.” Finally, both African Union and WHO officials repeated their call to countries to support a waiver on intellectual property on COVID vaccines and therapeutics, currently being negotiated by the World Trade Organization – saying that this would help jump-start more manufacturing in developing regions. “American taxpayers, European taxpayers financed some of this intellectual property, and so it should be for the common good,” said Masiyiwa. “So we ask for this IP to be made available. It was a great miracle to have these vaccines, now let this miracle be available to all mankind”. Added WHO’s Tedros: “If it [a waiver] cannot be used now during this unprecedented condition or situation, then when is there a time when it can be used.” Image Credits: @WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pressure Builds on Biden to End TRIPS Waiver Impasse, Enable Equitable Access to COVID Vaccines 15/09/2021 Kerry Cullinan President Joe Biden speaking in Germany after a G7 meeting. Pressure is mounting on US President Joe Biden to provide global leadership to ensure equitable access to COVID-19 vaccines in the face of the European Commission’s refusal to support a waiver on intellectual property rights. Biden is expected to host a global leaders’ summit on COVID-19 alongside the United Nations General Assembly next week, and US officials are lobbying countries to support targets to end the pandemic centred on how to get 70% of people vaccinated by late 2022. African leaders hope that Biden’s COVID-19 summit will lead to more equitable access to vaccines: WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response Negotiations over the suspension of intellectual property rights for COVID-19 vaccines, therapeutics and diagnostics, the TRIPS waiver, have stalled at the World Trade Organization (WTO) in the face of opposition from the European Union. But if the US put forward a text on waiver, this would reinvigorate the talks, appealed South African trade ministry advisor Zane Dangor on Tuesday. South Africa and India are co-sponsors of the waiver. “Action by the US will be particularly potent to shift the needle in the negotiations and make people come around the table and discuss these issues,” said Dangor, one of the key officials involved in the WTO TRIPS waiver negotiations. In May, Biden took the world by surprise when he announced US support for the waiver proposal – although only in relation to COVID-19 vaccines. But the European Commission, particularly Germany, has refused to budget. “The European Union would like to kick the discussions further down the road,” said Dangor, adding that the EU had made it known this week that it was not in favour of a decision on the TRIPS waiver being made at the upcoming WTO Ministerial on 30 November. Zane Dangor, Special Adviser to South Africa’s Trade Minister. “We need commitment on a text from the US that can be tabled and negotiated with South Africa, India and other co-sponsors so that we can have an outcome and move to get to the business of actually ensuring that we get jabs in arms of those who need most and have equitable access,” Dangor told a press briefing organised by Public Citizen. “Not only do we need to get the WTO waiver done, but we require vaccine recipes to be shared via broad tech transfer to speed expansion of COVID medicine supplies,” added Dangor. In July, the World Health Organization (WHO) announced that it had established a “tech transfer hub” in South Africa to enable African companies produce mRNA vaccines – but the mRNA manufacturers, Pfizer-BioNTech and Moderna, have refused to join the hub. Last week, in response to a recent Health Policy Watch question, Pfizer CEO Albert Bourla said: “I’m not sure what is the point of transferring technology that it is going to take years to transfer. And, by the way, this is what we do. I’m not sure I understand what they want, to give it someone else to do?” European Commission counter-proposal is ‘big air’ Belgian Green Sarah Matthieu, a Member of the European Parliament, believes that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added. “We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network. Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added. Matthieu said that the German elections on 26 September may shift the power balance it that country and change the position of Germany on the waiver. US Congressman Ro Khanna said that Biden had shown “strong leadership on the TRIPS waiver” but he now had to “convince our European allies, who are often fond of lecturing the United States about moral responsibility, to live up to theirs”. Khanna added that the US had been “instrumental in the development of these vaccines”, including by “funding some of the critical research” and “providing purchase agreements that mitigated the risk for pharmaceutical companies”. Although the US government has indicated it would only support a waiver for vaccines, Khanna told the MSF briefing that this should extend to therapeutics. “More broadly, we need to have a better system for how we incentivize the production and distribution of drugs to the poor and for issues of that really affect large numbers of population,” said Khanna. “A purely for-profit model of developing medicines may lead to an over-investment in acne treatment and an under-investment of treatment on some of the biggest diseases. “Not only do we need a TRIPS waiver, but we need to think about how can we incentivize the development and the production of medicine that actually are affecting the urgent needs of many people in the United States and around the world.” Waiver debate is about pharma profit, says Stiglitz Professor Joseph Stiglitz Nobel laureate and Columbia University economist Professor Joseph Stiglitz described the waiver debate as being about the ability of the drug companies to exercise monopoly power to get substantial profits, rather than a reasonable return on their investment. “Drug companies’ concern is maximising profits. That’s their business model. And maximising profits means restricting supply because by restricting supply, you increase price, and by increasing price you increase profits,” he stressed. Referring to Pfizer’s recent talk about selling its vaccine for $175 a dose, Stiglitz said this was based on the belief that there was going to be a vaccine shortage, which would enable the company to extract a monopoly price. Like Khanna, Stiglitz stressed that the development of the COVID-19 vaccines was an international effort that had involved significant investment from various governments as well as scientists from around the world. “Germany’s particular view on this is especially peculiar because the German company, BioNTech, has already sold its international rights to Pfizer so the waiver is not even going to affect its profits,” he said, describing the EU’s opposition to the waiver as “objectionable” and “unconscionable”. Confusion about TRIPS waiver Stiglitz stressed that there was also confusion about the TRIPS waiver. “First, this is not the abolition of property rights. [Pharmaceutical companies] still get compensated for using their intellectual property rights. So, it’s not taking away their property rights. Its just saying we are in an emergency, and in this emergency, intellectual property rights have to be available more widely,” Stiglitz told the MSF briefing. “Secondly, it’s not even a change in the intellectual framework because, since the beginning of the WTO, we’ve recognised the principle of compulsory licenses. This is effectively just a compulsory license… to lower transaction costs. Lower transaction costs in the midst of the pandemic, where there’s a kind of urgency that we don’t normally have, is absolutely essential,” he added. “We’ve enacted voluntary licenses. The world has debated this. It debated it when the WTO TRIPS initially adopted it. It was really debated that in the context of HIV/AIDS, which reaffirmed the principle of compulsory licenses.” “We are in the midst of what some people call the new cold war. On the one hand, there are authoritarian governments like Russia and China, and then, on the other hand, there are democracies. We would like the democracies to win, but we’re not putting a good face on democracy when we say our democracies put profits over lives. “Russia has been very actively engaged in vaccine diplomacy. It’s made its vaccine available, say in a country like Argentina. But not only has it made its vaccine available, it’s actually actively engaged in transferring technology and enabling countries to build plants to produce the vaccine. And I’m afraid we’re losing this particular battle.” Civil society groups demonstrate outside embassies of countries that oppose a temporary WTO patent waiver on COVID-19 health products. Image Credits: CNBC, Munich Security Conference, Tadeau Andre/MSF . WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response 14/09/2021 Elaine Ruth Fletcher Left-right: Strive Masiyiwa, AU COVID envoy, Dr Tedros Adhanom Ghebreyesus, WHO Director General, Dr John Nkengasong, Africa CDC diector After months of frustrated efforts to unlock global vaccine supplies for the African continent, WHO and African Union leaders are now pinning their hopes on US President Joe Biden’s reported plan to call heads of state to a “Global Pandemic Summit” on the sidelines of the United Nations General Assembly, which opened today, as a way out of the current deadlock. Biden reportedly is circulating a plan to hold the summit on 22 September – with the aim of reaching a joint commitment to the vaccination of 70% of the world’s population by the GA session in September 2022, ensuring that “additional doses and adequate supplies are available to all countries”, according to a set of targets circulating among embassies, and obtained by the Washington Post. To achieve that, the Biden plan for the Global COVID-19 Summit also calls for “expediting delivery of approximately 2.0 billion previous committed doses.. including by converting existing dose sharing pledges into near-term deliveries, swapping delivery dates to secure earlier delivery of doses to LIC/LMICs, and eliminating cross-border bottlenecks in the supply of vaccines and critical inputs.” But speaking at Tuesday’s press conference following two days of meetings in Geneva, African Union and African Centers for Disease officials stressed that the era of “pledges” for vaccine donations to Africa, needs to end and investments in African vaccine manufacturing to begin, as part of any ‘New Deal’ on pandemic response in low- and middle-income (LMICs) countries. “”We, as the African Union, are calling on a permanent structure,” said Masiyiwa, a billionaire entrepreneur and AU Special Envoy for COVID-19, “and this is something that we will be calling on to be put in place at this summit that President Biden is convening. “We strongly believe that the pledge architecture, where countries gathered together and made pledges…. has had its day. Let us now have a permanent structure. Vaccine sharing is good. But we shouldn’t have to be relying on vaccine sharing, when we can come to the table, put structures in place, and then say that we also want to buy.” Calls for new African vaccine facility Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank This should involve the creation of a new, and permanent African vaccine facility, supported by the African Union, World Bank and International Monetary Fund, said Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank. Afreximbank has provided financing for the continent’s purchase of some 400 million Johnson & Johnson vaccines – backed by the World Bank. But Benedict stressed this is only the beginning of a long road that will require the procurement of booster doses as well. And so a more permanent finance mechanism is needed for countries to manufacturer and purchase doses themselves – rather than being solely reliant on goodwill donations. While “thanking” COVAX for the role it has played in facilitating global COVID vaccine supplies, “going forward, we need the IMF to do the vaccine facility – to make it possible for countries to now access these vaccines through the structures put in place,” said Oramah. Those structures should include domestic manufacturing and procurement financed through African mechanisms, such as “Afreximbank, providing the initial financing, and then they refinance it in a way that makes it possible for the current accounts to carry all this – while the World Bank continues to provide institutional structures that are required to effectively administer vaccines.” Africa is region with lowest rates of vaccine coverage in the world Seth Berkley, CEO Gavi, The Vaccine Alliance Among all LMICs, Africa stands out for its particularly low vaccination rates so far – with under 3.5% of its population vaccinated – as compared to 60-70% in some high-income nations, African Union also said, speaking at a WHO press conference in Geneva. Of 5.2 billion doses delivered worldwide, only a tiny fraction have reached Africa, noted WHO Director General Dr Tedros Ahanom Ghebreyesus. And as things stand now, COVAX, the global vaccine facility, only has sufficient doses in the delivery pipeline to vaccinate roughly 20% of the population in the 91 lowest income countries by the end of the year, using some 1.4 billion purchased and donated doses, admitted Gavi CEO Seth Berkley at the WHO press conference. And it would hit 36% coverage by March, 2022. That falls far short of WHO’s target of 40% vaccination by December 2021 and 70% by March 2022. To reach those targets, “the world needs 2.4 billion additional doses to go into low income countries to get us to 40% by the end of this year,” Said Bruce Aylward, a special WHO advisor on the pandemic. “Those doses exist,” he said, citing recent pharma statements to the effect that there are now sufficient doses for everyone to go around – including high- and low-income countries. See related story Massive Increase in COVID-19 Vaccine Production May Mean Dose Surplus by Mid-2022, says IFPMA I think the question we ask is: where are those doses if there are enough for everybody?” Aylward asked. “And [the US Summit] next week is all about making sure there’s a clear path to ensuring they go to where they’re needed.” Barriers that have fouled vaccine access – both countries and manufacturers share blame Strive Masiyiwa, African Union COVID-19 envoy Speaking at the close of a two-day Geneva meeting, which also included Dr John Nkengasong, Africa CDC director and African Regional Director Matshidiso Moeti, the WHO and AU officials said that in they had reviewed in painstaking detail the various obstacles in the way of African vaccine access – and ways to overcome them. The challenges have included export bans, including the interruption of supplies from India in March 2020 when the subcontinent experienced its own COVID surge, but also barriers on the exports of vaccines and their inputs to a complex supply chain, they noted. But the African officials also repeated longstanding complaints against rich countries for vaccine hoarding, as well as against pharma for preferential sales to high income countries of huge vaccine quantities – in excess of actual population needs. “We want to buy from the same manufacturers,” said Masiyiwa. “But to be fair, those manufacturers know very well that they never gave us proper access. They gave access on a very different basis. “When they knew that supplies were restricted at the beginning, there was no production… they [pharma manufacturers] had a moral responsibility to ensure that others also had access,” he said. “And we find this very sad. It’s very sad. We could have addressed this very differently. We as Africa will now address this through setting up our own manufacturing capabilities.” Countries’ export restrictions also holding up distribution But countries’ export restrictions on vaccines as well as the many vaccine manufacturing inputs also continue to foul deliveries – and these are poorly understood, Masiyiwa said. . “My principal job is to negotiate with suppliers, and the suppliers have over the last 8-9 months, made it clear that the biggest challenge that they face are export restrictions, export restrictions are being operated right across the board. So, if those export restrictions aren’t there, where are the vaccines, because the production is happening? “We’re not seeing the vaccines, and we are being told by the suppliers, they are facing export restrictions. He added that without resolving, “this issue around the movement of the various ingredients that drive production… we will not even be able to get manufacturing effectively set up.” “We need to get these restrictions removed, and we had a very constructive discussion around this issue with the WTO yesterday,” he said. AU leaders call on India to remove its ban on AstraZeneca vaccine exports – now that domestic COVID surge has subsided WHO Director General Dr Tedros Adhanom Ghebreyesus Masiyiwa also appealed to India to resume its deliveries of AstraZeneca vaccines, produced by the Serum Institute of India – noting that the countries’ embargo on the export of vaccines, remains the most outstanding example of restrictions fouling distribution plans. The SII vaccines were a centerpiece of COVAX and African countries – until exports were abruptly cancelled in March. “We understood that at the time why they were put in place, it was because there was that massive surge in India, and we were incredibly, incredibly sympathetic. But we do now urge our colleagues to show sympathy to us, because we are the ones facing difficulty now. We need to see some of those vaccines begin to come through.” Finally, both African Union and WHO officials repeated their call to countries to support a waiver on intellectual property on COVID vaccines and therapeutics, currently being negotiated by the World Trade Organization – saying that this would help jump-start more manufacturing in developing regions. “American taxpayers, European taxpayers financed some of this intellectual property, and so it should be for the common good,” said Masiyiwa. “So we ask for this IP to be made available. It was a great miracle to have these vaccines, now let this miracle be available to all mankind”. Added WHO’s Tedros: “If it [a waiver] cannot be used now during this unprecedented condition or situation, then when is there a time when it can be used.” Image Credits: @WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response 14/09/2021 Elaine Ruth Fletcher Left-right: Strive Masiyiwa, AU COVID envoy, Dr Tedros Adhanom Ghebreyesus, WHO Director General, Dr John Nkengasong, Africa CDC diector After months of frustrated efforts to unlock global vaccine supplies for the African continent, WHO and African Union leaders are now pinning their hopes on US President Joe Biden’s reported plan to call heads of state to a “Global Pandemic Summit” on the sidelines of the United Nations General Assembly, which opened today, as a way out of the current deadlock. Biden reportedly is circulating a plan to hold the summit on 22 September – with the aim of reaching a joint commitment to the vaccination of 70% of the world’s population by the GA session in September 2022, ensuring that “additional doses and adequate supplies are available to all countries”, according to a set of targets circulating among embassies, and obtained by the Washington Post. To achieve that, the Biden plan for the Global COVID-19 Summit also calls for “expediting delivery of approximately 2.0 billion previous committed doses.. including by converting existing dose sharing pledges into near-term deliveries, swapping delivery dates to secure earlier delivery of doses to LIC/LMICs, and eliminating cross-border bottlenecks in the supply of vaccines and critical inputs.” But speaking at Tuesday’s press conference following two days of meetings in Geneva, African Union and African Centers for Disease officials stressed that the era of “pledges” for vaccine donations to Africa, needs to end and investments in African vaccine manufacturing to begin, as part of any ‘New Deal’ on pandemic response in low- and middle-income (LMICs) countries. “”We, as the African Union, are calling on a permanent structure,” said Masiyiwa, a billionaire entrepreneur and AU Special Envoy for COVID-19, “and this is something that we will be calling on to be put in place at this summit that President Biden is convening. “We strongly believe that the pledge architecture, where countries gathered together and made pledges…. has had its day. Let us now have a permanent structure. Vaccine sharing is good. But we shouldn’t have to be relying on vaccine sharing, when we can come to the table, put structures in place, and then say that we also want to buy.” Calls for new African vaccine facility Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank This should involve the creation of a new, and permanent African vaccine facility, supported by the African Union, World Bank and International Monetary Fund, said Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank. Afreximbank has provided financing for the continent’s purchase of some 400 million Johnson & Johnson vaccines – backed by the World Bank. But Benedict stressed this is only the beginning of a long road that will require the procurement of booster doses as well. And so a more permanent finance mechanism is needed for countries to manufacturer and purchase doses themselves – rather than being solely reliant on goodwill donations. While “thanking” COVAX for the role it has played in facilitating global COVID vaccine supplies, “going forward, we need the IMF to do the vaccine facility – to make it possible for countries to now access these vaccines through the structures put in place,” said Oramah. Those structures should include domestic manufacturing and procurement financed through African mechanisms, such as “Afreximbank, providing the initial financing, and then they refinance it in a way that makes it possible for the current accounts to carry all this – while the World Bank continues to provide institutional structures that are required to effectively administer vaccines.” Africa is region with lowest rates of vaccine coverage in the world Seth Berkley, CEO Gavi, The Vaccine Alliance Among all LMICs, Africa stands out for its particularly low vaccination rates so far – with under 3.5% of its population vaccinated – as compared to 60-70% in some high-income nations, African Union also said, speaking at a WHO press conference in Geneva. Of 5.2 billion doses delivered worldwide, only a tiny fraction have reached Africa, noted WHO Director General Dr Tedros Ahanom Ghebreyesus. And as things stand now, COVAX, the global vaccine facility, only has sufficient doses in the delivery pipeline to vaccinate roughly 20% of the population in the 91 lowest income countries by the end of the year, using some 1.4 billion purchased and donated doses, admitted Gavi CEO Seth Berkley at the WHO press conference. And it would hit 36% coverage by March, 2022. That falls far short of WHO’s target of 40% vaccination by December 2021 and 70% by March 2022. To reach those targets, “the world needs 2.4 billion additional doses to go into low income countries to get us to 40% by the end of this year,” Said Bruce Aylward, a special WHO advisor on the pandemic. “Those doses exist,” he said, citing recent pharma statements to the effect that there are now sufficient doses for everyone to go around – including high- and low-income countries. See related story Massive Increase in COVID-19 Vaccine Production May Mean Dose Surplus by Mid-2022, says IFPMA I think the question we ask is: where are those doses if there are enough for everybody?” Aylward asked. “And [the US Summit] next week is all about making sure there’s a clear path to ensuring they go to where they’re needed.” Barriers that have fouled vaccine access – both countries and manufacturers share blame Strive Masiyiwa, African Union COVID-19 envoy Speaking at the close of a two-day Geneva meeting, which also included Dr John Nkengasong, Africa CDC director and African Regional Director Matshidiso Moeti, the WHO and AU officials said that in they had reviewed in painstaking detail the various obstacles in the way of African vaccine access – and ways to overcome them. The challenges have included export bans, including the interruption of supplies from India in March 2020 when the subcontinent experienced its own COVID surge, but also barriers on the exports of vaccines and their inputs to a complex supply chain, they noted. But the African officials also repeated longstanding complaints against rich countries for vaccine hoarding, as well as against pharma for preferential sales to high income countries of huge vaccine quantities – in excess of actual population needs. “We want to buy from the same manufacturers,” said Masiyiwa. “But to be fair, those manufacturers know very well that they never gave us proper access. They gave access on a very different basis. “When they knew that supplies were restricted at the beginning, there was no production… they [pharma manufacturers] had a moral responsibility to ensure that others also had access,” he said. “And we find this very sad. It’s very sad. We could have addressed this very differently. We as Africa will now address this through setting up our own manufacturing capabilities.” Countries’ export restrictions also holding up distribution But countries’ export restrictions on vaccines as well as the many vaccine manufacturing inputs also continue to foul deliveries – and these are poorly understood, Masiyiwa said. . “My principal job is to negotiate with suppliers, and the suppliers have over the last 8-9 months, made it clear that the biggest challenge that they face are export restrictions, export restrictions are being operated right across the board. So, if those export restrictions aren’t there, where are the vaccines, because the production is happening? “We’re not seeing the vaccines, and we are being told by the suppliers, they are facing export restrictions. He added that without resolving, “this issue around the movement of the various ingredients that drive production… we will not even be able to get manufacturing effectively set up.” “We need to get these restrictions removed, and we had a very constructive discussion around this issue with the WTO yesterday,” he said. AU leaders call on India to remove its ban on AstraZeneca vaccine exports – now that domestic COVID surge has subsided WHO Director General Dr Tedros Adhanom Ghebreyesus Masiyiwa also appealed to India to resume its deliveries of AstraZeneca vaccines, produced by the Serum Institute of India – noting that the countries’ embargo on the export of vaccines, remains the most outstanding example of restrictions fouling distribution plans. The SII vaccines were a centerpiece of COVAX and African countries – until exports were abruptly cancelled in March. “We understood that at the time why they were put in place, it was because there was that massive surge in India, and we were incredibly, incredibly sympathetic. But we do now urge our colleagues to show sympathy to us, because we are the ones facing difficulty now. We need to see some of those vaccines begin to come through.” Finally, both African Union and WHO officials repeated their call to countries to support a waiver on intellectual property on COVID vaccines and therapeutics, currently being negotiated by the World Trade Organization – saying that this would help jump-start more manufacturing in developing regions. “American taxpayers, European taxpayers financed some of this intellectual property, and so it should be for the common good,” said Masiyiwa. “So we ask for this IP to be made available. It was a great miracle to have these vaccines, now let this miracle be available to all mankind”. Added WHO’s Tedros: “If it [a waiver] cannot be used now during this unprecedented condition or situation, then when is there a time when it can be used.” Image Credits: @WHO. Posts navigation Older postsNewer posts